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ABSTRACT  
   
Extracellular vesicles (EVs) represent a heterogeneous population of small 
vesicles, consisting of a phospholipidic bilayer surrounding a soluble interior cargo. 
These vesicles play an important role in cellular communication by virtue of their protein, 
RNA, and lipid content, which can be transferred among cells. Peripheral blood is a rich 
source of circulating EVs. An analysis of EVs in peripheral blood could provide access to 
unparalleled amounts of biomarkers of great diagnostic, prognostic as well as therapeutic 
value. In the current study, a plasma EV enrichment method based on pluronic co-
polymer was first established and characterized. Plasma EVs from breast cancer patients 
were then enriched, profiled and compared to non-cancer controls. Proteins signatures 
that contributed to the prediction of cancer samples from non-cancer controls were 
created by a random-forest based cross-validation approach. We found that a large 
portion of these signatures were related to breast cancer aggression. To verify such 
findings, KIAA0100, one of the features identified, was chosen for in vitro molecular and 
cellular studies in the breast cancer cell line MDA-MB-231. We found that KIAA0100 
regulates cancer cell aggression in MDA-MB-231 in an anchorage-independent manner 
and is particularly associated with anoikis resistance through its interaction with 
HSPA1A. Lastly, plasma EVs contain not only individual proteins, but also numerous 
molecular complexes. In order to measure millions of proteins, isoforms, and complexes 
simultaneously, Adaptive Dynamic Artificial Poly-ligand Targeting (ADAPT) platform 
was applied. ADAPT employs an enriched library of single-stranded 
oligodeoxynucleotides to profile complex biological samples, thus achieving a deep 
coverage of system-wide, native biomolecules. Profiling of EVs from breast cancer 
  ii 
patients was able to obtain a prediction AUC performance of 0.73 when compared 
biopsy-positive cancer patient to healthy controls and 0.64 compared to biopsy-negative 
controls and such performance was not associated with the physical breast condition 
indicated by BIRAD scores. Taken together, current research demonstrated the potential 
of profiling plasma EVs in searching for therapeutic targets as well as diagnostic 
signatures.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Significance of Extracellular Vesicles 
Extracellular Vesicles (EVs)/exosomes are nanosized membrane vesicles released 
by fusion of an organelle of the endocytic pathway, the multi-vesicular body (MVB), 
with the plasma membrane. This process was discovered more than 30 years ago. During 
these years, EVs have gone from being considered cellular waste to a novel mechanism 
of mediating cell-to-cell communication1. The exponential interest in EVs during recent 
years is due to their important roles in health and disease as well as to their potential 
clinical applications for therapeutic and diagnostic1. 
EVs were first discovered by Peter Wolf, who referred these vesicles as “platelet 
dust”2 and later on were considered as “garbage cans”3 as well as “cellular waste”4-5. 
Since then, all biological fluids tested have been shown to contain vesicles. In vitro 
grown cell lines have been shown to release vesicles to different extents1, 6-7. Two major 
types of vesicles have been described based on their mechanisms of release and size: 
EVs/exosome (less than 150 nm in diameter) and microvesicle particles (MPs). MPs are 
released directly from the plasma membrane (PM), which include microvesicles (MVs), 
apoptotic bodies and apoptotic microparticles are typically small particles ranging from 
50nm to 3µm in diameter8. Secreted MPs derived from MVBs fused with the plasma 
membrane are termed EVs, while MPs released from the surface of plasma membranes 
are referred to as MVs, membrane particles,  apoptotic vesicles8.  Lately, EVs are to play 
a role not only in intercellular communication but also numerous physiological and 
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pathological functions1, 6, 9-10. EVs from cancer cells have been shown to promote 
angiogenesis, modulate the immune system and remodel the surrounding parenchymal 
tissue to support tumor progression. In particular, EVs have been shown to participate in 
the generation of the pre-metastatic niche11-13, suggesting they might contain critical 
information related to aggressive. 
EV biogenesis starts within the endosomal system. Figure 1.1.1 shows the 
schematic representation of the origin and release of EVs by eukaryotic cells14. EVs are 
formed as intraluminal vesicles (ILVs) by budding into early endosomes and MVBs. 
Several molecules are involved in the biogenesis of ILVs, such as the ESCRT machinery, 
lipids (e.g. ceramide) and tetraspanins proteins14. It is still unknown whether these 
mechanisms act simultaneously on the same MVB or on different MVBs. The fate of 
MVBs can be either fusion with lysosomes or fusion with the PM, which allows the 
release of their content into the extracellular milieu. Several RAB proteins (RAB11, 
RAB27 and RAB35) have been shown to be involved in the transport of MVBs to the PM 
and in EV secretion14. 
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Figure 1.1.1 Biogenesis of EVs14.    
Curr Opin Cell Biol 2014, 29, 116-25 
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EVs contain proteins, lipids and nucleic acids. Their compositions to some extent 
are cell-type dependent and can be influenced by different cellular conditions or 
treatments1. Moreover, EVs released by cell lines are quite heterogeneous1, 15, but less is 
known about how the cargos are sorted into the vesicles. Proteomic studies revealed that 
EVs may contain a specific subset of proteins from endosomes, the PM and the cytosol14. 
In contrast, proteins from intracellular organelles such as the nucleus, mitochondria, and 
Golgi are or under-represented in EVs14. Additionally, EVs contain DNA bound by 
nuclear proteins16; mitochondrial-derived vesicles (MDVs) are also able to fused with the 
MVBs17. Further, HSP60, a mitochondrial heat-shock protein, was found in tumor cell 
plasma membrane, EV membrane as well as in the Golgi apparatus18. These all suggest 
that though other cellular compartments that may not be directly involved in the EV 
biogenesis, the constant communication between these compartments and MVBs results 
in these proteins being found in MVBs or EVs. 
Observations of protein, RNA and lipid composition in numerous studies have 
been made accessible through the creation of the EV protein, RNA and lipid database 
ExoCarta19. Although EVs should be enriched in endosomal components, as compared to 
MPs, the two types of vesicles display a large overlap in composition, and it is not 
possible today to name universal (i.e. valid for any cell type) protein markers specific for 
EVs versus MPs1. 
Interestingly, emerging studies are now showing EV release may be a highly 
regulated process instead of a random process for the removal of unwanted internal 
cellular debris as originally thought20. MVBs can either be directed to lysosomes where 
their content is degraded, or transported to the plasma membrane for EV release1. The 
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molecular mechanisms and the cellular states that regulate this balance are yet to be 
elucidated. Transporting MVBs to the plasma membrane depends on their interaction 
with actin and the microtubule cytoskeleton1, 21-22. Knock-down or over-expression of the 
actin binding protein cortactin has been shown to decrease or increase EV release 
respectively23; live-cell imaging indicated that cortactin is involved in both trafficking 
and docking of MVBs to the plasma membrane23. Treatment with paclitaxel (PTX), a 
chemotherapy that stabilizes microtubules, of breast cancer cell MDA-MB-231, resulted 
in elevated amount of EVs that are highly enriched with the cell survival protein and 
cancer markers24, implying stabilization of microtubule network may be enhancing EV 
transportation and release. Moreover, Rab GTPases, the largest family of small 
GTPases25, regulate many steps of membrane trafficking, including vesicle budding, 
transport of vesicles along actin and tubulin, as well as membrane fusion. Interestingly, 
several Rab GTPases have been shown to play a role in EV secretion, although their 
precise mechanism of action in this process is not yet known1.  
EVs located in biological fluids attract enormous interest because of their 
potential use as a source of protein and nucleic acid biomarkers, or as a prospective 
delivery system for various therapeutic purposes26.  The study of EVs is opening new 
horizons for their potential application not only as therapeutic tools but also as clinical 
biomarkers for monitoring disease progression27. Increased levels of EVs have been 
detected in the body fluid relating to a varieties of diseases, including cardiovascular and 
inflammatory pathologies, obesity, atherosclerosis, diabetes, metabolic syndrome, 
neurodegenerative diseases and multiple sclerosis27. In term of cancer biology, one of the 
hallmarks of cancer cells is that they react to their micro-environment and can 
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communicate and exchange information to the host immune system. This occurs through 
the secretion of growth factors, cytokines, chemokines, small molecular mediators as well 
as EVs28, which may be a package of all the above. As cell-to-cell messenger mediators 
of communication, EVs could have profound effects on cancer development such as 
invasion, metastasis, angiogenesis, and responses to hypoxia as well as 
immunomodulation (Figure 1.1.2). Therefore, profiling the EVs from biological fluids 
might lead to identification of new target with both therapeutic and diagnostic potential. 
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Figure 1.1.2 EVs in Cancer Progression28. EV released from tumor cells affect the local 
tumor microenvironment and are critically involved in tumor initiation, growth, 
progression, and metastasis by transferring oncogenic proteins and nucleic acids. (A) EVs 
travel to distant sites to promote generation of the pre-metastatic niche; (B) Angiogenesis 
is increased and endothelial and stromal cell differentiation is induced, leading to a pro-
tumor environment; (C) EVs have immunosuppressive effects and assist cancers in 
immune evasion. Cytotoxic T cells induced apoptosis, while natural killer cell 
proliferation is impaired, and T-helper cells differentiate toward a T-regulatory cell 
phenotype; (D) Bone marrow-derived cells are recruited to tumor and pre-tumor tissue 
where they contribute to cancer development; (E) EVs are also responsible for the 
recruitment and activation of tumor-associated macrophages (TAMs) by promoting their 
polarization. TAMs support diverse phenotypes within the primary tumor, including 
growth, angiogenesis, and invasion, by secreting a plethora of pro-tumorigenic proteases, 
cytokines, and growth factors; (F) EVs can functionally modify fibroblasts by 
reprogramming these cells to cancer-associated fibroblasts (CAFs), which exhibit 
myofibroblastic differentiation. *Red arrows indicate a negative contribution or 
repression and green arrows indicate an activation or positive function. 
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Int J Mol Sci 2017, 18 (3) 
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1.2 Current EV Enrichment Methods 
 Varieties of EV enrichment methods are currently available, each with advantages 
and disadvantages. Importantly, it is currently technically challenging to obtain a pure EV 
fraction free from non-vesicular components for functional studies29. Therefore, each 
methology may only recover a subset of the EV population. The choice of which method 
to use is highly dependent on the expected abundance of EV, sample amount, scale of the 
study, EV purity requirments, potential contamination, as well as complexity of the 
protocol.  Restrictions and limitations imposed by these considerations could resulted in 
different profiles which may be observed in downstream applications.  
In cell line EV release studies, EVs have often been isolated by sequential 
centrifugation. This method includes 2–3 centrifugations at low speeds to remove cells, 
cell debris and MPs, followed by ultracentrifugation at approximately 100,000g for hours 
with multiple PBS washes1. The principle of this method implies a mixed EVs population 
will be collected since the size of EVs and MPs are partially overlapped. When combined 
with density gradient, it does provid the most pure EVs to date30-32. However, this comes 
with a cost of extremely low recovery efficiency and reproducibility30. In additon, it is 
relatively tedious procedures, time consuming and technique sensitive, requiring prior 
training and the availability of an ultracentrifuge30. However, when the purpose of the 
study is to enrich the EVs generated by cell lines, this may be acceptable because the 
source is almost unlimited and the purity requirement of such EVs is critical for the 
follow-up functional studies. In contrast, UC  for large scale clinical studies on body fluid 
EVs, where sample amount and source limited. In this case, reproducibility and of the 
procedure priority, and minor contamination be acceptable. 
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The term “EVs” is used to refer to the pellet obtained after 100,000g 
ultracentrifugation1. Although this pellet is enriched in EVs, it also contains small MPs as 
well as protein aggregates. In fact, it was recently suggested that this pellet should be 
referred to as small EVs (sEVs) instead of EVs, as it has been shown to contain different 
vesicle populations1, 15. Therefore, this pellet not only reflects changes in EV release, but 
also in small MPs or other similar density elements. Another concern that is associated 
with UC is that particle size distribution curves from UC EV preparations shifted slightly 
to the right (larger) as compared to the other commercial kits. The cause could be the 
centrifugation at such high speeds potentially led to fusion of the particles with 
contaminants and other proteins, therefore affecting the physical properties of the EVs 
and impacting the sensitivity of proteomic analysis30, 33-35. 
Immunoisolation of EVs based on specific proteins at the EV membrane is 
another method that results a in relatively pure EV sub-populations1, 15, 36. However, it 
requires that the selected membrane protein is present in the EVs and that the 
immunoisolation protocol is optimized. A list of identified cell line EV surface markers is  
shown in Table 1.2.11 and the protein families presented in EVs from different cell types 
is shown in Table 1.2.237. The most common proteins that could be found in EVs 
includes tetraspanin proteins (CD9, CD63, CD81). In the case of tumor, epithelial cell 
adhesion molecules (EpCAM), IGF-1R α units (α-IGF-1R), CA125, CD41b, and E-
cadherin38 are also found in EVs.  
Unfortunately, immunisolation methods have not been very successful due to the 
the heterogeneity of the EVs popultation.  EVs released by a cell line are already quite 
heterogeneous15. Many studies have described the proteins, lipids and RNA cargos of 
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EVs, but have not shown how the cargos are sorted into the vesicles1. The proteins in 
Table 1.2.1 and Table 1.2.2 are rather a list of potential indicators for particular sub-
population than univeral EV markers. Though varieties of proteins markers have been 
shown associated with EV, none of these proteins are universal maker for any EV 
populations. Thus the immunoisolation method may only be suitable in the situation 
where the EVs pupulation is closely related to the souce cells with known surface 
markers. For samples like plasma, EVs may be derived from diverse sources, suggesting 
that immunoisolation would only recover a small portion from all the potential EVs, and 
may not suitable for the study of the whole EV populations. 
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Table 1.2.1 Cell line EV Surface Markers1 
  
PMC full text: Cell Mol Life Sci. 2018; 75(2): 193–208.
Published online 2017 Jul 21. doi:  10.1007/s00018­017­2595­9
Copyright/License ► Request permission to reuse
Table 1
Molecules shown to be involved in exosome biogenesis and/or release
Protein/lipid/modification Cell line Secretion quantified by References
Hrs DCs, HEK293, SCC61, SCC25­H1047R HNSCC, HeLa Ubiquitinated proteins, TSG101, VPS4B, Evi, Wnt3A (WB), NTA, CD81/HLA­DR (FC), MHC II, HSC70,
CD63 (WB)
[31–34]
STAM1 HeLa CD81/HLA­DR (FC), MHC II, HSC70, CD63 (WB) [31]
TSG101 HeLa CD81/HLA­DR (FC), MHC II, HSC70, CD63 (WB) [31]
CHMP4C HeLa CD81/HLA­DR (FC) [31]
ALIX HeLa, DCs, MCF­7 CD81/HLA­DR (FC), CD63, HSP70, syndecan (WB), NTA [31, 35]
VTA1 HeLa CD81/HLA­DR (FC) [31]
VPS4 HeLa CD81/HLA­DR (FC), MHC II, HSC70, CD63 (WB) [31]
Syntenin MCF­7 CD63, HSP70, syndecan (WB), NTA [35]
Syndecan MCF­7 CD63, HSP70, ALIX, syntenin (WB), NTA [35]
CD9 HEK293, BMDCs β­Catenin, flotillin­1 (WB) [40]
CD82 HEK293 β­Catenin (WB) [40]
CD63 HEK293 NTA [42]
LMP1 HEK293 NTA, acetylcholinesterase activity, Alix, HSC70, CD63, and TSG101 (WB) [43]
Tspan8 Adenocarcinoma cells mRNA microarray, RT­qPCR, proteomics, WB [41]
Synaptotagmin­7 SCC61, SCC25­H1047R HNSCC NTA [34]
VAMP7 K562 Acetylcholinesterase activity [94]
YKT6 HEK293 and A549 TSG101, WNT3A and VPS26/35 (WB) [33, 95]
Syntaxin 1A Drosophila S2 Evi (WB) [82]
PKM2 A549, HeLa NTA [96]
SNAP­23 A549 NTA [96]
RalA and RalB 4T1 EM, ALIX, CD63, HSC70 and TSG101 (WB) [97]
Rab2b HeLa HLA­DR (FACS­assay) [83]
Rab5a HeLa HLA­DR (FACS­assay) [83]
Rab9a HeLa HLA­DR (FACS­assay) [83]
Rab7 MCF­7, HUVEC CD63, syntenin and syndecan (WB), miR­143 (qPCR) [35, 89]
Rab11 K562, Drosophila S2 Transferrin receptor, Lyn, HSC70 and Evi (WB) [81, 82]
Rab27a HeLa, 4T1, TS/A, B­16­F­10, SK­Mel­28, SCC61, SCC25­H1047R
HNSCC, Du145
HLA­DR (FACS­assay), total protein, HLA­DR, HSC70, TSG101, CD63, ALIX and LAMP2 (WB), NTA,
CD9 (ELISA)
[14, 34, 83, 86,
87]
Rab27b HeLa, HUVEC HLA­DR (FACS­assay), total protein, HLA­DR, HSC70 and TSG101 (WB), miR­143 (qPCR) [83, 89]
Rab35 Oli­neu PLP (WB) [84, 85]
Citron kinase HeLa, 293T HSC70, CD82, Lamp­1 (WB) [91]
Cortactin SCC61 NTA, TSG101, CD63 and flotillin­1 (WB) [79]
ISGylation Jurkat T and HEK293 CD63, CD81, TSG101 and flotillin (WB), NTA [77]
SIMPLE COS Fluorescence of LactC2­RFP, NTA, CD63, ALIX (WB) [44]
nSMase2 Oli­neu, PC­3, HEK293, J77 PLP, EGFP­CD63 (WB), miR­16, miR­146a (qPCR), total protein, CD81 (WB) [47–49]
DGKα J­HM1­2.2 CD63, Lamp­1, FasL, (WB) [55]
PLD2 RBL­2H3, MCF­7 Bodipy­ceramide label (FACS), syntenin, ALIX, CD63 (WB) [52, 53]
ARF6 MCF­7 Syntenin, ALIX, CD63, SDC1CTF (WB) [53]
Cholesterol Oli­neu, PC­3 Flotillin­2, ALIX, EGFP­CD63, PLP­myc, caveolin­1, Lamp­1 (WB) [100, 101]
Ether lipid (hexadecylglycerol) PC­3 NTA, total protein [98]
V­ATPase HeLa EM, CD63, ALIX, TSG101 (WB) [105]
Tetherin HeLa EM, CD63, ALIX, TSG101 (WB) [105]
Hypoxia MCF­7, SKBR3, MDA­MB 231 NTA, CD63 (WB) [110]
Irradiation LNCaP, 22Rv1, PBMC Vybrant DiI (fluorescent staining), B7­H3 (WB), NTA, total protein [107, 108]
Cisplatin A549 Total protein [109]
PIKfyve PC­3 NTA, total protein, MS­proteomics [10]
ER stress (tunicamycin) MEFs qNano [111]
Autophagy (starvation) K562 Acetylcholinesterase activity, HSC70 (WB) [113]
ATG12­ATG3 MEFs Total protein, ALIX, TSG101, GAPDH, HSC70 (WB) [116]
Autophagy (ATG7) DCs GAPDH (WB) [114]
Intracellular calcium (monensin, A23187,
ionomycin)
K562, oligodendrocytes HSC70 (WB), acetylcholinesterase activity, PLP (WB) [102, 103]
The methods that were used for exosome quantification in each study are listed
CELLULAR AND MOLECULAR LIFE SCIENCES
Cell Mol Life Sci 2018, 75 (2), 193-208 
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Table 1.2.2 EV Surface Marker from Different Cell Types37 
  
Nat Rev Immunol 2002, 2 (8), 569-79 
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Recently, commercial kits have been made available for EV isolation using 
precipitation via PEG polymer, including Exoquick and Total Exosome Isolation (TEI). 
PEG has been used in a range of protein applications utilizing volume exclusion 
mechansim39. Once the sample is mixed with the reagent, the solubility of the proteins is 
lowered and results in the precipitation of EVs. Using these kits, EVs can be separated at 
a low g force and with higher yield as well as improved reproducibility relative to UC38. 
The precipitation is not dependent on EV sub-populations is a simpler procedure, has 
better yield and reproducibility, which makes made this method attractive for EV studies 
of  complex samples like plasma.  
However, PEG, especially PEG8000, which is included in these commercial kits, 
is well-known for precipitating IgG, fibrinogens, and components of complement system 
in the plasma, and thus has limited selectivity40-41. Moreover, the use of linear, long PEG 
polymer results in much high viscosity41, which compromise some downstream 
applications, such as electro-microscopy, mass spectrometry and flow cytometry unless 
tedious procedures are adopted to remove the polymer after the precipitation.  
Other than the UC, immunoisolation and precipitation based EV enrichment 
methods, other techniques, such a membrane filtration, and size exlusion chromatography  
are available. A comparison of advantages and disadvantages of different methods is 
summarized in Table 1.2.3 (https://www.labome.com/method/Exosomes-isolation-and-
characterization-methods-and-specific-markers.html). Previous studies have already 
compared the reproducibility and efficiency of enriching plasma-derived EVs between 
UC and PEG-based methods30-32. Though results might vary from study to study, the 
conclusion in general was that UC may obtain EV with relatively better purity but with 
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very low efficiency. In contrast, PEG-based method offers higher efficiency and better 
reproducibility, but at a cost of significant contamination of high abundant plasma 
proteins. Therefore, though EV enrichment method based on precipitation is more 
preferred for the body fluid study like plasma, increasing the precipitation specificity and 
reducing the recovery of high abundant plasma proteins may be necessary to improve its 
reliability.   
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Table 1.2.3 Advantages and Disadvantages of Different EV Isolation Methods 
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1.3 Breast Cancer and Breast Cancer Aggression 
Breast cancer is the most common noncutaneous cancer in U.S. women, with an 
estimated 61,000 cases of in situ disease and 246,660 cases of invasive disease in 2016. 
One out of six women diagnosed with breast cancer is estimated to die of the disease.  
Population studies from the United States and the United Kingdom also demonstrated an 
increase in DCIS and invasive breast cancer incidence since the 1970s, attributable to the 
widespread adoption of both postmenopausal hormone therapy and screening 
mammography (https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032676/).  
Breast cancer is a heterogeneous disease and several biologic subtypes have been 
identified as conventional clinical factors such as tumor grade, size, lymph node 
involvement, and surgical margins are no longer sufficient as sole prognostic factors42. 
Most (80%) breast cancers are invasive, or infiltrating, which means they have broken 
through the walls of the glands or ducts where they originated and grown into 
surrounding breast tissue. Although breast cancer generally has been referred to as a 
single disease, there are up to 21 distinct histological subtypes and at least four different 
molecular subtypes that differ in terms of risk factors, presentation, response to treatment, 
and outcomes43. Breast cancers are generally divided into subtypes according to the status 
of their estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth 
factor receptor 2 (HER2) as well as the origins of cancer epithelail cells, including 
luminal epithelial (types A and B, non-basal like) and basal epithelial (basal-like)44. 
Luminal A is the most common breast cancer subtype and is characterized by ER+ and/or 
PR+/HER2- status, low grade tumors, and good prognosis45-47. Luminal B subtype 
accounts for roughly 10% of all breast cancer and is distinguished by ER+ and/or 
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PR+/HER2+ status42. Breast cancer subtypes with negative ER, PR, and HER2 status are 
typically called “triple negative” breast cancers and approximate the basal-like 
category42.  
 The prognosis of invasive breast cancer is strongly influenced by the stage of the 
disease – that is, the extent or spread of the cancer when it is first diagnosed43. There are 
two main staging systems for cancer43. The TNM classification of tumors uses 
information on tumor size and how far it has spread within the breast and to adjacent 
tissues (T), the extent of spread to the nearby lymph nodes (N), and the presence or 
absence of distant metastases (spread to distant organs) (M). Once the T, N, and M are 
determined, a stage of 0, I, II, III, or IV is assigned43, 48, with stage 0 being in situ 
(abnormal cells have not penetrated the ducts or glands from which they originated), 
stage I being early-stage cancer, and stage IV being the most advanced disease. The 
overall 5-year relative survival rate is 99% for localized disease, 85% for regional 
disease, and 27% for distant-stage disease43. Therefore, understanding how breast cancer 
cells are able to acquire metastasis capability might be able to increase the survival rate 
for the disease. 
 Many factors may contribute to the risk of transforming locally contained breast 
cancer cells to a more invasive form, such as age, tumor types/subtypes as well as genetic 
disposition. For example, among women under age 50, incidence of having invasive 
breast cancer rates have slowly increased (0.2% per year) since the mid-1990s43; lobular 
carcinoma in situ (LCIS), whose cancer cells were developed in milk producing glands 
poses an increased risk for developing invasive cancer compared to the ductal carcinoma 
in situ (DCIS) that arised in epithelial cells lining the breast ducts49-50; women with 
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HER2-enriched as well luminal B tumors (HR 1.96, 95% CI: 1.08-3.54) had roughly a 
two-fold increased adjusted risk of breast cancer mortality42. Breast cancers in BRCA1 
mutation carriers are associated with more aggressive tumor characteristics compared to 
BRCA2 and are more difficult to detect using mammography51.  
Escalation of invasive carcinoma begins with the epithelial mesenchymal 
transition (EMT), a physiological process that allows epithelial cells to remodel the 
cytoskeleton, release the linkage with vicinal cells and acquire a motile phenotype52-53. 
This phenomenon is usually activated during wound healing, inflammation or 
embryogenesis. In cancers, EMT has long been associated with the acquisition of 
malignant cell traits, such as motility, invasiveness and a heightened resistance to various 
cytotoxic therapies for cancer cells53, allowing cancer cells to detach from neighboring 
cells, overcome anoikis and to move from their primary location to invade others 
tissues52. During EMT cancer cells activate epigenetic pathways that lead to the down-
regulation of cell–cell adhesion molecules, such as E-cadherins and γ-catenin. At the 
same time, the expression of mesenchymal markers such as vimentin, fibronectin, α-
smooth muscle actin (SMA), N-cadherin, as well as to the activation of MMPs, were 
increased52, 54. It is known that the ability to overcome anoikis is correlated with the 
acquisition of the mesenchymal phenotype52. Otherwise, detaching from the extracellular 
matrix (ECM) would triggers the apoptotic process for normal epithelial cells54. Such 
ability of cancer  cells to survive in the absence of normal matrix components represents 
an important property for cells undergoing EMT54. As shown in Figure 1.3.1, during 
EMT, cancer cells started to break through the local growth barrier. Once they have 
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acquired the capability to circumvent anoikis, cancer cells are able to migrate outside of 
the orignal tumor location52.  
Since EVs from tumor cells resies in the micro enviroment around the tumor, 
there is a increased likelihood of secretion into the plasma. Though invasive behavior of 
breast cancer may be observed in stage II, it is more frequently found in stage III/IV 
(https://www.cancer.net/cancer-types/breast-cancer/stages). Thus, the likelihood of 
detecting EVs that contains information related to the cancer in the plasma, could be 
higher, profiling of plasma EVs at that stages may lead to discovery of molecules with 
diagnostic/therapeutic information. 
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Figure 1.3.1 Cancer Epithelial-Mesenchymal Transition52. Hypoxia, stromal cells, 
oncogene activation, ROS as well as kinase activation drive the cancer cells to a more 
aggressive, invasive mode. During EMT, under these conditions, cells started to break the 
local growth barrier, once anoikis resistance is acquired, cancer cells are able to migrate 
outside of the primary tumor location. 
  
Biochim Biophys Acta 2013, 1833 (12), 3481-3498 
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1.4 Current Breast Cancer Diagnosis and Limitation 
 Breast imaging, including mammography, ultrasound and magnetic resonance 
imaging (MRI) are the most common breast cancer diagnosis tools. Mammography is 
currently the most common method of early breast cancer detection since it can often 
identify cancer several years before physical symptoms develop. MRI and ultrasound 
detection were also reported in conjunction with mammography to improved the 
detection performance55-57.  
The American Cancer Society (ACS) recommendations for the early detection of 
breast cancer screening vary depending on a woman’s age and include mammography, as 
well as MRI for women at high risk. In 2015, the American Cancer Society updated its 
breast cancer screening guideline for average-risk women58. Screening mammography in 
women aged 40 to 69 years was associated with a reduction in breast cancer deaths across 
a range of study designs, and inferential evidence supported breast cancer screening for 
women 70 years and older who were in good health58. The ACS recommendation58 for 
women with an average risk of breast cancer is that regular screening mammography 
should be started at age 45 years (strong recommendation); Women aged 45 to 54 years 
should be screened annually (qualified recommendation); Women 55 years and older 
should transition to biennial screening or have the opportunity to continue screening 
annually (qualified recommendation); Women should have the opportunity to begin 
annual screening between the ages of 40 and 44 years (qualified recommendation). 
Women should continue screening mammography as long as their overall health is good 
and they have a life expectancy of 10 years or longer (qualified recommendation)58.  
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 An expert panel convened by the ACS published recommendations for the use of 
MRI for screening women at increased risk for breast cancer in 200756. The panel 
recommended annual MRI screening in addition to mammography for women at high 
lifetime risk (~20%-25% or greater) beginning at 30 years of age56. Breast MRI is not 
recommended as a routine screening tool for all women. However, it is recommended for 
screening women who are at high risk for breast cancer, usually due to a strong family 
history and/or a mutation in genes such as BRCA1 or BRCA2. 
 Ultrasound is an imaging test that sends high-frequency sound waves through the 
breast and converts them into images on a viewing screen. Ultrasound is an attractive 
supplement to mammography because it is widely available, relatively inexpensive and 
well-tolerated by patients59. Ultrasound images the tissue to the chest wall and is a cross-
sectional technique, displaying tissue without overlap involved59. Under age of 30, the 
doctor may recommend ultrasound before mammography to evaluate a palpable breast 
lump (a breast lump that can be felt through the skin) because mammograms can be 
difficult to interpret in young women because their breasts tend to be dense and full of 
milk glands (http://www.breastcancer.org/symptoms/testing/types/ultrasound). Breast 
cancer detection doubled from 23 to 46 in 6,425 subjects using automated whole breast 
ultrasound (AWBU) with mammography, resulting in an increase in diagnostic yield 
from 3.6 per 1,000 with mammography alone to 7.2 per 1,000 by adding AWBU59. 
  Despite the sensitivity of these technologies based on advanced imaging systems, 
there are fundamental limitations that exist. For mammography, there is a high false-
positive rate, leading to over-diagnosis and includes radiation exposure. Mammography 
often results in false positive  leading to biopsies, when there is no cancer60. When 
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screening begins at age 40, the cumulative probability of a woman receiving at least one 
false-positive result after 10 years was 61.3% (95% CI, 59.4% to 63.1%) with annual and 
41.6% (CI, 40.6% to 42.5%) with biennial screening60. On average, 1 in 9 women are 
recalled from each screening examination for further testing, but most (95%) do not have 
cancer61. In addition, over the course of 10 screening examinations, about one-half of 
women experience a false positive, and about 19% undergo biopsy but do not have 
cancer55. Mammography also likely results in some over-diagnosis, the diagnosis of 
cancer that would not cause a woman any harm in her lifetime and that would not have 
progressed or otherwise been detected in the absence of screening43. Estimates of the 
prevalence of over-diagnosis are highly variable, ranging from <5% to more than 30%62-
66. Additionally, repeated exposure to radiation from mammography could increase the 
risk of radiation-induced cancer, especially for the BRCA mutation carriers that are 
recommended to start mammographic screening for breast cancer as early as age 25-30 
years67. A relative risk model suggested that there would be no net benefit from annual 
mammographic screening of BRCA mutation carriers at age 25-29 years, the net benefit 
would be zero or small at age 30-34 years, but there should be some net benefit at age 35 
or older67. Exposure of the breast to ionizing radiation was predicted to cause breast 
cancer and cancer related death though the percentage is relatively low (~0.1%)68; 
Moreover, not all early breast cancer will be detected by mammogram, and some cancers 
that are screen-detected still have poor prognosis. Most women will never be diagnosed 
with breast cancer, but will undergo regular screening and may experience one or more 
“false alarms.”43. 
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On the other hand, breast MRI is also not a perfect tool. Although it is generally 
considered more sensitive for picking up breast cancer than mammography, it also can 
miss some cancers that would be detected by mammography. MRI screening is not 
recommended for women whose lifetime risk of breast cancer is less than 15%. Studies 
indicated that although MRI is underutilized among high-risk women, it is often used in 
women who are not at high risk for breast cancer43, 69, which may be the reason why 
breast MRI is recommended only in combination with other tests, such as mammogram 
or ultrasound. 
Ultrasound is not used on its own as a screening test for breast cancer. Rather, it is 
used to complement other screening tests. The performance of detecting breast cancer in 
ultrasound is comparable with mammography, with a greater proportion of invasive and 
node-negative cancers57. However, similar to mammography, false positive rates are 
more common using ultrasound detection. If an abnormality is seen on mammography or 
felt by physical exam, ultrasound is the best way to find out if the abnormality is solid 
(such as a benign fibroadenoma or cancer) or fluid-filled57 (such as a benign cyst). It 
cannot determine whether a solid lump is cancerous, nor can it detect calcifications. 
Therefore, in addition to the currently available breast imaging tools, a non-invasive test 
could be desired in the detection of breast cancer and the overall screening performance 
could be improved. In contrast to the high-cost equipment required by the breast imaging, 
blood/plasma is routinely collected in most clinical setting. Therefore, a blood-based 
detecting approach for breast cancer based on the patient's biochemical changes would be 
able to increase the confidence in clinical decisions and decreases the stress and anxiety 
that every woman faces.  
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1.5 Aptamer-Based Profiling of Biological Samples 
Aptamers are artificial nucleic acid ligands that can be generated against amino 
acids, drugs, proteins and other molecules. They are isolated from complex libraries of 
synthetic nucleic acid by an iterative process of adsorption, recovery and re-
amplification. They have potential applications in analytical devices, including 
biosensors, and as therapeutic agents70. 
Systematic Evolution of Ligands by EXponential enrichment (SELEX) is an 
experimental procedure that allows extraction, from an initially random pool of 
oligonucleotides, of the oligomers with a desired binding affinity for a given molecular 
target71. The procedure can be used to infer the strongest binders for a given DNA or 
RNA binding protein, and the highest affinity binding sequences isolated through SELEX 
can have both diagnostic and therapeutic applications. For example, nucleic acid ligands 
against important targets in infectious, malignant and vascular diseases are continually 
being discovered by the process of in vitro evolution. Promising methods are being 
developed for the exploitation of these aptamers in biosensors and other diagnostic 
devices72-76.  
 A large variety of molecules can be targets in SELEX experiments. When the 
library consists of dsDNA, targets are typically proteins that interact with DNA as a part 
of their natural function77. In the case of single stranded oligonucleotides, a wide range of 
proteins and small molecules have been used as targets in SELEX experiments71. The 
initial library of oligonucleotides typically consists of a large number (1015-1016) of 
random sequences. In principle, larger libraries of up to 1020 oligonucleotides are 
technically feasible78, but are rarely used in practice. Each oligonucleotide consists of a 
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central region of random sequence, which is flanked by two regions of fixed sequence 
that enable amplification. The length of the random region is typically between 20 and 30 
bp, while each flanking region is typically 15-25 bp long. 
 Figure 1.5.1 shows the standard SELEX procedure79. As indicated, SELEX 
generally started from a synthetic library, a more diversity-rich pool is first generated by 
PCR; the library is then mixed and incubated with the desired target; after wash, the 
aptamers that remain on the target are eluted and new library is regenerated by PCR 
amplification; the selection is then repeated 6-20 times, during which the enriched library 
could be characterized and individual aptamer could be chosen for further evaluation.  
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Figure 1.5.1 Standard SELEX Procedure.  
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With the latest developments and the increasing capacity of Next Generation 
Sequencing (NGS), instead of ranking the aptamer by random cloning, the enriched 
library can be sequenced as a whole with output as many as 300 million reads. The 
relative abundance of the individual aptamers could then be evaluated and ranked as 
shown in Figure 1.5.2. The advantage of SELEX-NGS combination is that limitation of 
quantification with traditional SELEX cloning procedure is overcome, which leads to the 
possibility of more accurate statistical analysis. 
 Interestingly, recent studies have also shown that cell-based SELEX and in vivo 
SELEX are both able to obtain specific aptamers which target the tumor cell surface80-84, 
and even have identified brain-penetrating aptamers85, implying that SELEX procedure 
might not necessarily to be restricted to single, pure targets. Instead, more complex, 
multi-targets sample could also be used, such as enriched plasma EVs from cancer 
patients.  
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Figure 1.5.2 SELEX-NGS Pipeline  
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1.6 Summary 
 EV analysis presents several advantages over the traditional analyses of soluble 
molecules in blood, such as hormones and cytokines86. One significant advantage is the 
inherent protection of the EV cargo of proteins and RNA from degradation. Otherwise, 
they would be rapidly degraded in blood87-88. Moreover, EVs have a relatively long half-
life in blood88. Therefore, EVs can be transported from any location of the body to the 
bloodstream, making them easily accessible for analysis compared to biopsies86. This 
also has a significant advantage for the patient because the collection of a blood sample is 
a minimally invasive procedure associated with much less discomfort than a biopsy. It 
can often become an issue to detect relevant biomarkers because these diagnostic 
molecules frequently constitute a small part of the total amount of molecules in a blood 
sample86. With appropriate enrichment method, EV-associated proteins, which 
represented by only 0.01% of the plasma proteome86, 89, can be identified. The EV cargos, 
biomarkers of otherwise undetectable amounts in the plasma, can now be analyzed and 
interpreted into clinically relevant information. Furthermore, EV cargo content can 
seemingly change according to the progression of a disease89-93. Therefore, EVs from a 
blood sample may render a sophisticated fingerprint of a disease of diagnostic and 
prognostic value.  
 This work is intended to examine whether enriched plasma EVs could be used for 
diagnostic application. Here we established and compared a nova plasma EV 
precipitation method based on pluronic block copolymer to the commercially available 
precipitation methods. The proteomic profiles of enriched plasma EVs from high grade 
breast cancer patients and the non-cancer patients were then compared and features 
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selected to generate a classifier between breast cancer patient and non-cancer controls. 
Cross-validation was used to validate the findings. To further validate our finding that EV 
associated proteins related to breast cancer was discovered from the cancer vs non-cancer 
study, one feature that significantly contributed to the model was chosen for further in 
vitro studies. In parallel, we also examined the possibility of differentiating breast cancer 
patients from controls by profiling the enriched plasma EVs through a SELEX-based 
profiling platform.      
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CHAPTER 2 
MOLECULAR PROFILING PLASMA EXTRACELLULAR VESICLE UNVEILS 
FEATURES ASSOCIATED WITH BREAST CANCER AGGRESSION, 
METASTASIS AND INVASION 
 
Abstract 
Extracellular vesicle (EV) based liquid biopsies have been proposed to be a 
readily obtainable biological substrate recently for both profiling and diagnostics 
purposes. Development of a fast and reliable preparation protocol to enrich such small 
particles could accelerate the discovery of informative, disease-related biomarkers. 
Though multiple EV enrichment protocols are available, in terms of efficiency, 
reproducibility and simplicity, precipitation-based methods are most amenable to studies 
with large numbers of subjects. However, the selectivity of the precipitation becomes 
critical. Here we present a simple plasma EV enrichment protocol based on pluronic 
block copolymer. The enriched plasma EVs were verified by multiple platforms. Our 
results showed that the particles enriched from plasma by the copolymer were EV size 
vesicles with membrane structure. Proteomic profiling showed that EV related proteins 
were significantly enriched, while high abundant plasma proteins were significantly 
reduced in comparison to other precipitation-based enrichment methods. Next generation 
sequencing confirmed the existence of various RNA species that was found in EVs from 
previous studies. Small RNA sequencing also showed enriched miR species compared to 
the corresponding plasma. Moreover, plasma EVs enriched from 20 advanced breast 
cancer patients and 20 age-matched non-cancer controls were profiled by semi-
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quantitative mass spectrometry. Protein features were further screened by EV proteomic 
profiles generated from four breast cancer cell lines, and then selected in random forest-
based cross-validation models. In total 60 protein features that highly contributed in 
model prediction were identified. Interestingly, a large portion of these features were 
found to be associated with breast cancer aggression, metastasis as well as invasion, 
consistent with the patients advanced clinical stage status. In summary, we have 
developed a plasma EV enrichment method with improved precipitation selectivity and it 
might be suitable for larger scale discovery studies. 
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Introduction 
Extracellular vesicles (EVs) or exosomes, are small, spherical vesicles with a 
diameter of ~40-100nm that are secreted into the extracellular milieu by many cell types 
upon fusing the membrane of multi-vesicular bodies (MVBs) with the plasma membrane. 
In contrast, micro-particles (MPs), which include not only EVs, but also microvesicles 
(MVs), apoptotic bodies and apoptotic micro-particles are typically small particles 
ranging from 50nm to 3µm in diameter. Secreted MPs derived from MVBs fused with the 
plasma membrane are termed EVs, while MPs released from the surface of plasma 
membranes are referred to as microvesicles, membrane particles, as well as apoptotic 
vesicles8. Recent studies are now showing EV release may be a highly regulated process 
instead of a random process for the removing unwanted internal cellular debris as 
originally thought 20. EVs located in biological fluids attract enormous interest because of 
their potential uses as a source of protein and nucleic acid biomarkers or as a prospective 
delivery system for various therapeutic purposes 26. A simple and efficient method to 
enrich EVs from complex bio fluids, such as plasma samples, that addresses the many 
pitfalls of currently used methods would be useful in the research, clinical, and 
commercial setting. 
Blood samples frequently contain large quantities of soluble proteins, aggregates 
and contaminants from other organelles that restrict the accuracy of EV analysis. 
Limitations of the current methods of EV enrichment from complex biological fluids 
include sample volume requirements, carryover of undesired high abundance proteins, 
and interference of downstream analysis due to leftover of method-based reagents. 
Differential ultracentrifugation (UC) was the gold standard to separate EVs94, which aids 
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in the removal of most of the plasma contaminants. However, time consuming steps and 
large sample volume requirement leads to poor reproducibility, which restricts its utility 
for large scale studies. Immunoprecipitation (IP), while providing a faster process, is 
restricted only to certain EV subpopulation with known surface proteins, which limits its 
value to identify novel biomarkers. More recently, polymer based enrichment techniques 
by, for example PEG8000, have been used to enrich EVs95.  
Previous studies have already compared the reproducibility and efficiency in 
enriching plasma-derived EVs between UC and PEG-based methods30-32. Though results 
might vary from study to study, the conclusion, in general, was that UC-based methods 
may obtain EV with relatively better purity, but with very low efficiency. In contrast, 
PEG-based method offers higher efficiency and better reproducibility, but at the cost of 
huge contamination of high abundant plasma proteins. In addition, high viscosity and 
carryover of PEG also might affect the compatibility of the enriched sample with 
downstream applications, such as electro-microscopy (EM), mass spectrometry (MS) and 
flow cytometry (FL). Procedures that used for the removal of the polymer are often 
tedious and incomplete. 
Pluronic block copolymers consist of ethylene oxide (EO) and propylene oxide 
(PO) blocks arranged in a triblock structure: EOx–POy–EOx. This arrangement results in 
an amphiphilic copolymer, in which the hydrophilicity and hydrophobicity could be 
altered by varying the size of the hydrophilic EO(x) and hydrophobic PO(y) units96.  
Pluronic block copolymers F68 and related F127 have been demonstrated to have broad 
utilities and biological properties. Copolymers with higher hydrophilic/lipophilic balance 
(HLB) (e.g., F-68, HLB0.80) were shown capable of being inserted into lipid bilayer 
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membranes and restoring the integrity of damaged membranes97-100; F68 was also shown 
to be capable of inhibiting protein aggregation101. The biological properties of pluronic 
block copolymers are different from PEG and offer the potential to increase the 
selectivity of EV precipitation from complex bio fluids, such as plasma. 
An ideal method of enriching EVs from plasma might be a balance between high 
efficiency, low contamination and simplicity. We describe here a plasma EV enrichment 
method based on the pluronic block copolymer F68, which might be a balance between 
these three requirements. The enrichment method described here was proven to be more 
selective for plasma EV fraction with high efficiency, while much less contamination 
from high abundant plasma proteins, making it ideal for larger scale plasma EV 
biomarker studies. To demonstrate its potential utility, plasma EVs from 20 high-grade 
(stage III and IV) breast cancer patients and age-matched non-cancer controls were 
profiled and compared in the current study to identify features in the EVs that might be 
related to breast cancer aggression, metastasis and invasion.  
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Material and Methods 
Cell line EV Preparation 
Cell line used in this study in includes: Vcap, MCF7, T47D, MDA-MB-231, and 
MDA-MB-468. Cell culture: FBS (20% in respective medium) was depleted of bovine 
EV by centrifugation at 100,000g for 16 h at 4°C. Vcap cells were cultured in DMEM, 
MCF7 cells were culture in EMEM, T47D cells were cultured in RMPI1640, MDA-MB-
231/468 were cultured in L15 medium, all supplemented with 10% depleted FBS, 2 mM 
L-glutamine, 1 U/mL penicillin, and 1 μg/mL streptomycin at 37°C and 5% CO2. Cell 
line generated EVs were isolated from cell cultures supernatant by sucrose density 
centrifugation. Briefly, supernatant was cleared of cells and cellular debris by sequential 
centrifugation at 400g for 10 min and 2000g for 20 min at 4°C. Cleared supernatant was 
concentrated by centrifugal filtration (Centricon Plus-70, 100 kDa NMWL), layered on a 
30% sucrose cushion and centrifuged at 100,000g for 75 min at 4°C. Supernatant was 
removed and discarded without disrupting the cushion interface, which was then 
collected, diluted 6-fold with PBS and centrifuged at 100,000g for 70 min at 4°C. The 
resulting EV pellet was re-suspended in PBS by pipetting and incubation overnight at 
4°C, and then stored at -80°C. 
 
Breast Cancer / non-cancer Plasma Samples and Processing 
Breast cancer and non-cancer samples were from Caris biorepository, age-match 
samples (average of 55 years old) were chosen (Figure 2.5). Breast cancer samples were 
all from advanced clinical stage III or IV. All information regarding to age and stage of 
the patients were list in Table 2.1. Plasma specimens utilized in this experiment were 
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obtained under an IRB-approved Biorepository Protocol. All subjects were consented 
with an IRB approved consent form and per 21 CFR 50.20 guidelines. Blood was 
collected using standard venipuncture to EDTA tubes and plasma was collected by 
standardized protocol. Blood were then spun in the Labofuge 200 for 10 minutes at 5300 
RPM to remove cell debris. The clear layer of the plasma was aliquoted and transferred 
into cryovials and store at -80qC until use. Before the EV enrichment described below, 
the plasma was quickly thawed in water at room temperature (RT) and centrifuged at 
4000g for 15min at RT to remove any potential protein aggregation/cell debris. The clear 
supernatant of the plasma was then used for the EV enrichment. Plasma aliquots for the 
EV enrichment below were all freeze-thawed only one-time. 
 
EV Enrichment from Plasma 
Pluronic block copolymer F68 was obtained from Amresco in a powder format, 
the block copolymer was dissolved in PBS to make a 15% stock solution. The stock 
solution is further diluted in PBS in a way that when adding 100ul of plasma to 900ul of 
such solution, the final F68 concentration for enrichment is 2%; the mixture was then 
incubated at room temperature for 30min; followed by centrifuge at 20000g for 30min at 
4qC. The pellets were then washed with 1% F68 by vortexing following by centrifuge for 
10min at 4qC at 20000g; Supernatant was then removed and appropriate amount of PBS 
were added to re-suspend the fraction. For cell line EV spiked-in sample, 1ug of the Vcap 
generated EV prepared as shown above, was spiked into 100ul plasma. Plasma EV 
extraction by Exoquick (System Biosciences, Inc.) and Total Exosome Isolation kit 
(ThermoFisher, TEI) instructions for 100ul of plasma were followed. Protein 
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quantification was performed by microBCA kit from Thermoscientific according to the 
instruction from the product. 
 
DLS, ELISA and Western blot  
Particle size distributions were measured with DynaPro Plate Reader II (Wyatt 
Technology Corporation, Santa Barbara, CA), in three replicates, 5 acquisitions of 5 
seconds each at 25°C. PBS buffer and UC-isolated cell line EV were used as control. 
Direct CD9 ELISA was performed as follow: 1ug of the protein from neat plasma, 
plasma with cell line EV (Vcap) precipitated by F68 and plasma alone precipitated by 
F68 were coated on the 96 well ELISA plate overnight at 4qC, the plate were blocked by 
1% BSA in PBS for 1 hour; biotinylated anti-CD9 monoclonal antibody (Abcam, 
ab34161) was added as detection antibody followed by streptavidin-HRP; 100ul of Ultra 
ELISA substrate (Pierce) were used and OD450 were recorded by the BioTek plate 
reader. For western blots, protein samples were separated on 4-12% Bis Tris protein gel 
and transferred to a PDVF membrane. Primary antibodies include mouse anti-CD9 
(Abcam), mouse anti-β actin antibody (Abcam), mouse anti-HSP70 antibody (Abcam), 
rabbit anti-Von Willebrand Factor antibody (Abcam), rabbit anti-human serum albumin 
antibody (Abcam), mouse anti-alpha2 macroglobulin antibody (Abcam) and rabbit anti 
human IgG antibody (Abcam). Chemiluminescent signals were captured by imager (PXi, 
Syngene). 
 
  41 
RNA analysis, RNA sequencing, small RNA (smRNA) Sequencing and miR assay 
To extract total RNA and smRNA, trizol LS reagent was used (ThermoFisher). 
RNA, including total RNA and smRNA, was purified through the miRNeasy column 
(Qiagen) according to the instructions from manufacturer. All samples were eluted in 
20ul of RNase-free water. 1ul of these samples were used for bioanalyzer analysis 
(Agilent). Density analysis of the small RNA bands was performed in ImageJ software 
package102. To prepare total RNA Next Gen Sequencing (NGS) library, SMARTer 
Stranded Total RNA-Seq Kit (Clontech) was used and were sequenced on the Illumina 
Miseq instrument according to the instruction from the manufacturer. The data were 
analyzed by a customized Tophat/cufflinks pipeline103 against the ensemble-GRCh38 
human genome and further categorized according to their biotypes from Ensemble 
GRCh38.85 RNA annotation. For smRNA sequencing, the library preparation was 
performed according to the instruction of Clean-Tag smRNA kit from Trilink Biotech. 
Data were then analyzed by customized smRNA pipeline, reads were normalized to RPM 
(reads per million mapped read) for comparison; smRNA recovery also examined by let-
7a Taqman probe assay (ThermoFisher). The same amount of eluted sample was used. 
When comparing recovery rate of let-7a from cell line EV-spiked plasma and cell line EV 
alone, directly Ct comparison was used with normalization to the input sample volume 
(all samples were processed the same way, eluted by same volume). To comparing 
enrichment of let-7a from plasma enriched EVs to plasma alone, relative abundance was 
analyzed by ''Ct method with miR-451a as reference miR (one of the most abundant 
miR found in plasma104). 
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Transmission Electron Microscopy (TEM)  
TEM and immuno-TEM analysis of EVs were performed as described 
previously94 with modifications. Specifically, the vesicles were re-suspended in 1x PBS 
and deposited onto a formvar coated slide of copper mesh EM grids (FF300-Cu-50, 
Electron Microscopy Sciences). The vesicle-coated grids were washed, stained with 1% 
UO2(CH3COO)2 and then viewed by the transmission EM (TEM) using a Philips CM12 
with Gatan model 791 camera. For the immuno-gold labelling with antibodies, blocked 
grids coated with EVs were briefly fixed by ice-cold 1:1 ethanol/methanol for 5min 
followed by washing with PBS. The grids were then transferred to a drop of the anti-CD9 
antibody (Abcam) in PBS with 1% BSA, 0.01% tween20 and incubated for 30 min. The 
grids were then washed, incubated with gold-labeled secondary antibody (Sigma). The 
grids were stained with 0.5% UO2 (CH3COO) 2 and then imaged by TEM. 
 
Flow Cytometry Analysis  
The isolated EVs were labelled with a cocktail of mouse anti-CD9-PE (BD), anti-
CD63-PE (BD) and mouse anti-CD81 PE (BD) or mouse IgG1 kappa PE as isotype 
antibody control (eBioscience). PBS, antibody isotype control, anti-tetraspanin cocktail 
diluent as well as samples without staining were processed as controls. PE fluorescence 
intensity associated with particle events was measured by flow cytometry (A50-Micro, 
Apogee Flow Systems). Data analysis was performed in R3.2.2 environment with 
customized script.  
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Mass Spectrometry Analysis 
In-solution trypsin digestion was performed according to the manufacturer 
instruction (ThermoFisher). Samples were analyzed by nanoflow reverse phase liquid 
chromatography using a Dionex Ultimate 3000 RSLCnano System (ThermoFisher) 
coupled in-line to a Q Exactive HF mass spectrometer (ThermoFisher). The nano LC 
system included an Acclaim PepMap 100 C18 5μm 100A 300μm×5mm trap column and 
an EASY-Spray C18 2μm 100A 50μm×150mm analytical column (ThermoFisher). 
Peptide samples were eluted with a two-step gradient of 2% to 30% B in 28 min then 
30% to 45% B in 5 min, where B consisted of acetonitrile containing 0.1% formic acid.  
Blank samples consisting of 0.1% formic acid in water were injected between each 
sample and eluted with the same gradient profile and times as the samples.  The LC 
system was interfaced with the mass spectrometry using an EASY-Spray electrospray ion 
source (ThermoFisher) and the samples were analyzed using positive ion spray voltage 
set to 2 kV, S-lens RF level at 65, and heated capillary at 285°C. The Q Exactive HF was 
operated in the data-dependent acquisition mode for fragmentation. MS1 survey scans 
(m/z 400–1400) were acquired in the Orbitrap analyzer with a resolution of 120,000 at 
m/z 200, an accumulation target of 3×106, and maximum fill time of 50ms. MS2 scans 
were collected using a resolution of 30,000 at m/z 200, an accumulation target of 1×105, 
and maximum fill time of 100ms, with an isolation window of 1.5 m/z, normalized 
collision energy of 28, and charged state recognition between 2 and 7. 
ProteoWizard105 was used for peak-picking, filtering out peaks with intensity less 
the 100 and converting the file to mzML format. Protein search and identifications were 
performed using MS-GF+106 search engine on Homo sapiens (Uniprot TaxID=9606). For 
  44 
semi-quantification analysis, an algorithm was established according to the previous 
normalized spectra index (SIN) algorithm107-108 with modifications: sum of intensity from 
each peptide MS2 scan were normalized by the parent peptide charge, the normalized 
intensity for the same peptide from different MS2 scans were then summed together. The 
sum of the normalized intensity for the same peptide was then further normalized by the 
experimental molecular weight of the peptide, as a unit of normalized intensity per 
Dalton (mass). Normalized intensity per mass between different peptides of the same 
protein detected in the same sample was then averaged to obtain the final spectrum index 
(SI). For relative abundance, the SI was further normalized by the average total MS2 
intensity among all samples. 
 
Protein GO Categorization 
To categorize the proteins for their relevance to EVs, individual GO terms were 
query for GO definition of extracellular exosome (0070062), cytoskeleton (0005856), cell 
surface receptor (0007166), endosome (0005768), Golgi apparatus (0044431), blood 
microparticles (0072562), endoplasmic reticulum (0044432), mitochondrion (0044429) 
and nucleosome (0000788). ExoCarta database version 5 was obtained from 
www.exocarta.org. For the second categorization, all proteins that could be found with 
GO terms of extracellular exosome, cytoskeleton, cell surface receptor, endosome as well 
as the ones that could be found in ExoCarta database were regarded as “Potential EV”; 
proteins with GO terms of blood microparticles, endoplasmic reticulum, mitochondrion 
as well as nucleosome were regarded as “Potential Contaminants” and proteins with both 
potential EV and potential contaminant terms, are regarded as “Undetermined”. 
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Statistical Models 
All the analysis was performed on R 3.2.2 environment. Leave-One-Out (LOO) 
cross-validation model was built based on random forest: Briefly, to predict each test 
sample (1), the rest of the samples (39) were used as training set to build the model. In 
order to select the most important features to maximizing the removal of trivial features, 
a second layer of LOO models was built within the 39 training set samples. In the second 
layer LOO models, features occur in at least 90% of the individual second layer models 
were extracted and used to build the final prediction model for that training set, this 
model (from 39 samples) was then used to predict the test sample. The predicted 
probabilities for individual samples from the LOO cross-validation model were then used 
to plot the AUC curve. The final set of selected features was then collected by combining 
all the features retained in the individual training models and used for the un-supervised 
cluster heatmap. 
Permutation prediction were performed by permuting the sample label 
(cancer/non-cancer) 10000 times, same models as described above was applied to 
calculate the AUC for each permutation. Statistical significance p value was given by the 
percentage of permutation AUC that are equal or higher to the AUC performance from 
the correct label.  
All other statistical analysis, include mean, SD, and t test were calculated either in 
Excel or in R environment, as were the graphs. 
  
  46 
Results 
Pluronic Block Copolymer F68 as a Reagent to Enrich EVs from Plasma 
In order to examine whether the pluronic copolymer could be used as a reagent to 
enrich EVs from plasma, we first examined if the enriched fraction from plasma contains 
EV size particles. Plasma EVs was first enriched by F68 copolymer as described in the 
methods. Same procedures were also applied to samples spiked UC purified cell line EVs 
with or without plasma as controls. Dynamic Light Scatter (DLS) and transmission 
electron microscopy (TEM) were used to determine the size distributions as well as 
morphology of the plasma particles recovered respectively.  
As shown in Figure 2.1Aa, cell line EVs were at size around 100nm and range 
between 30nm to 300nm, consistent with the EV sizes reported previously20. Size 
distributions in the cell line EVs precipitated by F68 in the absence/presence of plasma 
showed patterns consistent with the cell line EV alone (Figure 2.1Ab/c). Size 
distributions for plasma EV enriched by F68 was ranged between 20nm-100nm (Figure 
2.1Ad), which matches exactly the size of EV described previously20. In contrast, 
particles in PBS buffer control were at around 10nm (Figure 2.1Ae), which is far below 
the expected EV size range, indicating the particles in the buffer solution would not 
interfere the analysis. Besides the major population at around 100nm, a small 
subpopulation of particles with a size distribution around ~1000nm were found in both 
cell line EVs from UC and the plasma particles enriched by F68 (Figure 2.1Aa/b/c/d). 
This small subpopulation may consist of particles made up of microvesicles, apoptotic 
bodies, or from potential EV aggregates.   
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Transmission electron microscopy (TEM) was used to capture the morphological 
detail of the enriched particles. UC purified cell line EVs, alone or recovered by F68 
precipitation (in presence or absence of plasma) showed intact round shape vesicles with 
membrane structure (Figure 2.1B a, b, c), similar to the shape of EV that described in 
previous study20. The native plasma particles recovered by F68 precipitation also show 
similar shape with membrane structure and size (around 100nm) (Figure 2.1Bd), which is 
consistent to the DLS results, indicating the particles recovered from the plasma by the 
copolymer are in EV size range membrane structures.  
To find out if the particles could be associated with tetraspanin, a common EV 
indicator, the enriched plasma EVs were labeled with immune-gold by anti-CD9 
antibody29. For these scans, a modified protocol with ethanol/methanol fixation procedure 
was adopted. As a result, shapes of the EVs appeared to be more condensed and with 
lighter contrast compared to the regular protocol above. TEM scans shows cell line EVs 
alone or precipitated by F68 were able to be labeled with gold particles against CD9 
marker as expected (Figure 2.1Ca/b), indicating the presence of CD9 on their surface. 
Anti-CD9 gold labeled particles were also found from native plasma EVs enriched by 
F68 copolymer (Figure 2.1Cc), indicating tetraspanin CD9, as a EV indicator, were also 
associated with the native plasma EVs enriched by F68. 
To confirm whether the CD9 EV indicator was indeed enriched, the levels of CD9 
presence in the samples were further examined by a direct CD9 ELISA. As shown in 
Figure 2.1D, EVs enriched by F68 copolymer from plasma sample with the cell-line EVs 
spike showed significant higher signal compared to the same amount of plasma protein 
without enrichment (p<0.05). Similarly, plasma EVs enriched by the copolymer also 
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showed significant higher CD9 signals compared to the plasma control (p<0.05), 
indicating EV marker CD9 was indeed enriched in the F68 precipitated population.   
The EV recovery efficiency by the copolymer was also evaluated by the EV small 
RNA recovery from the precipitation of plasma samples with cell line generated EVs. 
Three distinct smRNA patterns (~140bp, ~90bp and ~60bp) could be detected from Vcap 
cell line generated EVs (Figure 2.1Ea). Such smRNA signature could be used to evaluate 
the recovery rate of EVs by densitometry analysis. We hypothesized that if the precipitate 
reagent is harmful to the EVs, for example disrupting the membrane structure, internal 
material including the RNAs, would be degraded or removed during the washing steps 
and would be reflected on the intensities of the smRNA signature bands. As shown in 
Figure 2.1Ea patterns and intensity of the cell line EV in PBS precipitated by F68 were 
very comparable to the direct RNA extraction from same amount of cell line EVs.  At the 
same time, EV enriched by F68 from plasma sample with cell line EVs show same 
smRNA pattern as the cell line EV alone, the intensities of those signature bands were 
also not significantly different from the cell line EV controls.  
To further evaluate the cell line EV smRNA recovery rate more quantitatively, 
densitometry analysis was performed for all three individual smRNA bands and 
summarized in Figure 2.1Eb. As shown, no significant difference was observed from 
analyzing respective smRNA bands between cell line EV, cell line EV precipitated by 
F68 and cell line EV in plasma precipitated by F68 samples (p>0.05), nor by the 
combined density of all three signature bands between those three samples (p>0.05). The 
recovery rate of each individual band for cell line EVs in PBS precipitated with F68 were 
ranged from 93% to 100% with final combined rate of 97% in reference to the cell line 
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EV control. Recovery rate of each individual band for cell line EVs in plasma enriched 
by F68 also ranged from 97% to 102% with final combined rate of 98%. The average 
recovery rate in sample with cell line EVs in plasma was slightly more than the cell line 
EV in PBS alone, which may be caused by the small amount small RNA recovered from 
plasma native EVs. High recovery rate of the spiked-in EVs smRNA suggested high 
recovery efficiency for spiked-in cell line EVs in presence of plasma, in turn implies high 
recovery rate for the native plasma EVs.  
miR let-7a has been reported to reside inside EVs109-111 and it was highly 
expressed in our cell line generated EVs (Vcap). In addition to the evaluation of 
efficiency by the smRNA pattern and densitometry from images, let-7a recovery rate was 
also examined by qPCR. As expected, no significant difference was observed in let-7a 
level between cell-line EV spiked plasma precipitated by F68 and the same amount of 
cell line EV alone (Ct 22.3±0.08 vs Ct 22.8±0.06, p>0.05), indicating the level of let-7a 
recovered by F68 was very comparable, from the same amount of original cell line EVs, 
consistent to the smRNA analysis that showed high recovery rate of EV smRNA from the 
F68 enrichment.  
Let-7a level from native plasma EVs precipitated by F68 were also compared to 
the let-7a level from whole plasma extraction. There was no significant difference in 
recovered let-7a level in the plasma EVs enriched by F68 compared to same amount of 
plasma RNA extraction (Ct 31.6±0.3 vs Ct 31.4±0.7, p>0.05), indicating the precipitation 
was able to fully recover most of the circulating plasma let-7a microRNAs. Meanwhile, 
relative enrichment of let-7a in comparison to the original plasma was also evaluated by 
''Ct analysis by normalizing let-7a levels to miR-451a, one of the most abundant 
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plasma miR104. As show in Figure 2.1F, let-7a level in the plasma EVs fraction 
precipitated by F68 enriched more than 20 folds from the corresponding neat plasma, 
mostly because the significant reduction in recovery of miR-451a (Ct 26.4±0.5 vs Ct 
22±0.7, p<0.05). The results indicate that EV related miR like let-7a was enriched by the 
F68 precipitation, while plasma related miR was significantly reduced, suggesting the 
high recovery of native plasma EVs could be obtained by the copolymer precipitation. 
Additionally, EV recovery efficiency was analyzed in term of protein recovery 
rate. Cell line EVs in PBS were precipitated by F68 according to the above protocol. 
Protein amounts from before and after the precipitation were measured and the protein 
recovery rate was then calculated. As shown in the Figure 2.1G, about 80% of the cell 
line EV proteins (before: total protein amount is 9991±1156 ng, after: 7852±852 ng, 4 
replicates for each sample) was recovered after the precipitation. The result is largely in 
agreement with the above result that showed >90% recovery by smRNA density analysis 
and let-7a qPCR analysis. 
To further verify the EV identity of the particles recovered from F68 precipitation 
and the sample’s compatibility to downstream application, flow cytometry (FL) analysis 
was employed. EVs enriched by F68 precipitation were labeled with a fluorescence anti-
tetraspanin (CD9/63/81) antibody cocktail. Figure 2.1H(abc) shows FL analysis of the 
EVs enriched by F68 from plasma sample with cell line EVs by the light scatter signals: 
when the enriched particles were not labeled with any antibody, majority of the particles 
distributed horizontally along the SALS-area axis with very narrow LALS-area range 
(Figure 2.1H a); similar pattern was also found for the same particles labeled with isotype 
antibody control (Figure 2.1H b); In contrast, when the particles were labeled with anti-
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tetraspanin antibody cocktail, a more condensed population, with an correlated LALS-
area/SALS-area signal appeared on the plot with an angle against the horizontal minor 
population(Figure 2.1Hc). This population was clearly distinct from the noise particles 
found in sample labeled with isotype antibody, as well as non-labeled particles, 
suggesting a positive binding on the EV size particles by the tetraspanin antibody might 
have an effect on the integrated light scatter signals, indicating the population of 
antibody-labeled EVs could be isolated based on such light scatter pattern. 
Based on this finding, native plasma EVs enriched by F68 copolymer were also 
analyzed by the same scheme. A similar pattern was found as shown in Figure 2.1H (def). 
Native EVs enriched from plasma, when labeled with tetraspanin antibody, show two 
distinct populations (Figure 2.1H f), one aligned to the distribution from non-staining 
controls (Figure 2.1H d) and the samples stained with isotype antibody control (Figure 
2.1H e), the other population showed signal range similar to the positive control in Figure 
2.1H c. Minimal and maximal threshold were then determined manually (Figure 2.1Ha-f, 
green and red lines, two-step gating see Appendix-A) to select the particles events for 
fluorescence signal analysis. The selected populations were summarized in a distribution 
histogram according to their PE fluorescence signals. EVs enriched from a plasma 
sample spiked with cell-line EVs showed that the majority of the selected populations 
were tetraspanin positive (green) while the none-specific events that associated with 
isotype-antibody-PE labeling in the selected population were minimal (blue, almost not 
visible) (Figure 2.1H g). For the native plasma EVs enriched by F68, a similar pattern 
was also observed, with more tetraspanin positive events compared to the non-specific 
signal from isotype-PE labeling (Figure 2.1H h). The PE signal range in the selected 
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population was very similar to that from cell line EV spiked plasma positive control in 
Figure 2.1H g. This result further confirms that there is a subpopulation from native 
plasma EVs enriched by F68 method could be identified with the tetraspanin expression 
pattern when compared to the cell line generated EVs. (More detail description of the 
analysis and more controls see Appendix-A) 
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Figure 2.1 Characterizations of the EVs Enriched by Pluronic Copolymer F68. A) DLS 
characterization of the particle size: a) cell line EV, b) cell line EV in PBS precipitated by 
F68, c) cell line EV in plasma enriched by F68, d) native plasma EV enriched by F68, e) 
PBS buffer control; B) TEM image of EVs from: a) the cell line EVs, b) cell line EV in 
PBS precipitated by F68, c) plasma with cell line EV spike-in precipitated by F68, d) 
native plasma EVs enriched by F68 with arrow point to the label of the EV size. All scale 
in the images are 100nm as shown by the scale bar on lower left corner of the images; C) 
CD9 Immuno-gold TEM, EVs from a) cell line EVs, b) plasma spiked with cell line EVs 
and precipitated by F68, and c) native plasma EV enriched by F68, were labeled with 
anti-CD9 antibody followed by secondary antibody with gold particle; D) Direct CD9 
ELISA, 1ug of proteins from each sample were used, two replicate per sample 
(*significantly higher than corresponding plasma sample, p<0.05); E) smRNA recovery 
analysis: a) gel image from bioanalyzer for comparing smRNA recovery efficiency, all 
samples were processed in the same way, equal volume of the eluted sample (1ul) were 
analyzed. Arrow point to the three most concentrated bands for density analysis; b) 
density analysis of three distinct cell-line EV smRNA bands (140bp, 90bp and 60bp). 
Plots comparing including in density from individual band and combined density from all 
three bands are shown; F) Relative abundance (ΔΔCt analysis) of let-7a microRNA from 
EV fraction enriched by F68 method compared to original plasma, 5 replicate for each 
sample (plasma as reference sample, miR-451 as reference miR; *significantly higher 
than corresponding plasma sample, p<0.05); G) Protein recovery by F68 precipitation 
with cell line EVs in PBS. H) Flow Cytometry: a-g) EVs enriched by F68 from plasma 
spiked with cell line EV; d-h) Native plasma EVs enriched by F68; a, d) samples without 
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labeling with antibody; b, e) samples labeled with isotype antibody-PE antibody; c, f) 
samples were labeled with tetraspanin antibody-PE cocktail (CD9/63/81). Green line and 
red lines are the minimal/maximal thresholds for SALS-area and LALS-area respectively 
to gate the particle population. The extracted particle events were then projected in the 
event distribution histogram according to their PE fluorescence signal strength. g) Event 
distribution histogram for EV enriched from plasma sample spiked with cell line EVs and 
f) Event distribution histogram for native plasma EVs enriched by F68. (Tet+: tetraspanin 
CD9/63/81 antibody-PE positive population; isotype+: isotype antibody-PE positive 
population)   
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Proteomic Profiling of Plasma EVs Enriched by Pluronic Copolymer  
Our results have shown that the plasma particles enriched by F68 precipitation 
were EV-size membrane structures, contained RNA/miRNA, part of them contained EV 
marker tetraspanin proteins. While tetraspanins (CD9/63/81) are frequently used as 
potential EV markers, they are certainly not universal markers for any EV populations 
from varieties of cell types29, especially in plasma. To evaluate what EV-related proteins 
could be detected and enriched by the copolymer method, shotgun semi-quantitative mass 
spectrometry (MS) analysis was adopted. In addition, in order to evaluate the purity of 
the plasma EV recovered by the proposed method, two PEG-based EV enrichment 
methods commercially available (Exoquick and TEI) were also used as comparison.  
The EV fractions from same plasma were enriched from three different protocols: 
F68, Exoquick and TEI Kit. After precipitation according to respective protocols, protein 
recoveries were first measured and compared: total protein recovery was 0.46% for F68 
protocol, 16% from Exoquick protocol and 4.6% for TEI kit. As >99% of the protein 
mass in plasma were from high abundant plasma proteins112,  protein mass related to EV 
was not expected to be high. In contrast, higher yield might imply high abundant plasma 
protein contamination.    
Both high abundant plasma proteins (including ALB, A2M and IgG) and the EV 
related proteins (including ACTB, HSP70 and VWF) were examined by western blot and 
semi-quantitative MS analysis. ALB and IgG are the two most abundant plasma proteins, 
and A2M is also one of the high ranking proteins in the plasma112. High amount of ALB 
not only implies plasma protein contamination, but also might reduce the sensitivity of 
the MS by narrowing its dynamic range of analysis. On the other hand, CD9, ACTB, 
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HSP70 and VWF were used as an indicator of plasma EV enrichment. ACTB is a 
cytoskeleton protein while HSP70 is cytosolic proteins and both were reported to be 
enriched in EVs37, 113-114. VWF has been reported to be one of the protein markers found 
in platelet derived EVs113-114, which accounts for 70%-90% of the EVs in the plasma. 
Protocols that could enrich plasma EV should be most likely to include this protein. 
Western blots were first used to examine these general EV protein indicators. As 
shown in Figure 2.2A, the relative abundance of ALB in the neat plasma was obviously 
the highest of all, Exoquick and TEI kit was able to reduce that slightly but not very 
significant based on the density of the images. Level of ALB in plasma EV enriched by 
F68 dropped dramatically as shown by the blot. In comparison of A2M and IgG levels, 
EVs enriched by F68 methods consistently showed lowest contamination of these two 
proteins compared to other two methods. In contrast, Exoquick showed highly 
enrichment of A2M and IgG, while TEI kit showed slightly reduced in A2M but almost 
same level of IgG compared to neat plasma.  
On the other hand, tetraspanin CD9 and ACTB were detected in plasma EVs 
enriched by F68 and TEI kit only, but not detected in EVs enriched by Exoquick as well 
as neat plasma; HSP70 was enriched in all three methods compared to the neat plasma 
with highest level in EVs enriched by TEI kit, followed by EVs from F68 and Exoquick 
respectively. VWF was significantly enriched in plasma EVs enriched by F68, which is 
also higher than those from samples enriched by Exoquick and TEI kit respectively. 
Semi-quantitative MS analyses of the same proteins as above are shown in Figure 
2.2B. As expected, the plasma contained highest level of ALB. Plasma EVs enriched by 
Exoquick and TEI reduced ALB by about 70%, but both were still more than 400% 
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higher than that from F68 method. A2M protein was significantly reduced by 65% in 
plasma EVs enriched by TEI kit compared to neat plasma (p<0.05), but it was completely 
removed from the plasma EVs enriched by F68. In contrast, sample enriched by 
Exoquick showed significant higher level of A2M compared to others (p<0.05). Plasma 
enriched EVs by F68 method significantly reduced the recovery of IgG proteins to about 
35% compared to the neat plasma (p<0.05), while sample processed by Exoquick again 
significantly enriched more IgG than the other two methods (p<0.05).  
Relative abundance of ACTB was enriched in plasma EV from both F68 and TEI 
protocols compared to the neat plasma (p<0.05), while the enrichment of ACTB in 
Exoquick was significantly lower than the other two methods (p<0.05); HSP70 levels 
was also shown to be enriched by all three methods compared to neat plasma, with 
highest by TEI and comparable level enrichment between Exoquick and F68. Most 
significantly, relative abundance of VWF showed to be highly enriched in EV fraction by 
F68 protocol compared to others (p<0.05), which was more than 16 folds higher than that 
from TEI Kit protocol and over 4 folds higher than that from Exoquick protocol.  
The results between western blot and the semi-quantitative MS analysis were 
highly consistent, which gives us the confidence of using such semi-quantitative method 
for global comparisons. Though CD9 was readily detected on the western blot, it and 
other tetraspanins were very difficult to be detected in MS, partially due to high 
hydrophobicity115. However, the western blot of CD9 confirmed the enrichment of the 
tetraspanin protein in the plasma particles enriched by F68 precipitation, consistent to the 
result from the above ELISA, TEM and FL analysis.  
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Figure 2.2 Comparing Different Plasma EV Enrichment Methods. A) Western blot 
comparison of plasma high abundant protein and EV-related protein among three 
precipitations reagents used.  Plasma high abundant proteins include ALB, A2M, and 
IgG. Plasma EV-related proteins include CD9, ACTB, HSP70 and VWF; B) Same 
comparison of the plasma high abundant proteins and EV-related proteins by semi-
quantitative shotgun proteomic analysis. (Exoq: Exoquick; TEI: Total Exosome Isolation 
Kit, 4 replicates per sample; *significantly lower compared to original plasma (p<0.05); 
**significantly lower compared to Exoquick/TEI methods (p<0.05); ***significantly 
enriched compared to original plasma; ****significantly enriched compared to 
Exoquick/TEI methods.  
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In Figure 2.3A, shotgun proteomics showed that among the >5000 proteins 
identified from all three methods, over half of those proteins (2648) were shared features 
for all methods as well as in the corresponding plasma. 93 unique proteins were identified 
from EVs enriched by F68 compared to others, which is quite similar to that from 
Exoquick (88) and slightly more than TEI kit (76). Comparing to Exoquick and TEI kit, 
the unique protein numbers are quite even in either comparison (F68 vs Exoquick: 629 vs 
614; F68 vs TEI Kit: 587 vs 595). 
To find out what proteins were enriched in the precipitates recovered by different 
enrichment methods semi-quantitatively, features were first filtered by none-zero data 
points from individual methods as well as in the neat plasma, then the average relative 
abundance (from 4 technical replicates) were compared between individual method to the 
corresponding neat plasma; fold changes of all valid features in reference to the neat 
plasma were then obtained, while at the same time t-tests were also performed to gain 
statistical significance. The highly enriched features were defined as those features where 
the average relative abundance was 10-fold higher (p<0.05 by t-test) than the 
corresponding neat plasma. Therefore, sets of features with valid quantitative enrichment 
of equal or above 10 folds compared to that from neat plasma were obtained. These 
features from different methods were then used in the Venn diagram of Figure 2.3B. 
Among the 592 shared protein features identified from all three EV enrichment methods 
with significant enrichment level from plasma by different methods, 170 are unique to 
F68 protocol, 140 proteins are unique to Exoquick protocol, and 146 proteins from TEI 
kit.  
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To explore what kind of cellular functions that these enriched proteins (both 
unique features in Figure 2.3A and 2.3B) could be involved, the identified proteins were 
then categorized according to their GO terms. Proteins were first categorized by their 
association with EV, cytoskeleton, cell surface, endosome, blood macromolecule, 
endoplasmic reticulum (ER), mitochondrial, Golgi apparatus and nucleosome (Figure 
2.3Cace). Cytoskeleton, cell surface and endosome related proteins are ubiquitous, and 
they are most likely involved in the biogenesis of EV29. Proteins were also queried 
against the EV protein database ExoCarta19 to match the EV proteins that have been 
identified from previous studies. These proteins were then categorized as “Potential EV” 
proteins. In contrast, blood macromolecules, ER, mitochondrial, Golgi and nucleosome 
related proteins are less unlikely to be present in EVs29 due to their different biological 
pathway. They were then all categorized as “Potential Contaminant”. Meanwhile, 
proteins could be identified either as “Potential EV” or “Potential Contaminant” 
categories were regarded as “Undetermined” (Figure 2.3Cbdf). 
In highly enriched proteins from plasma EVs recovered by F68 (including the 
unique features for individual methods in both Figure 3A and 3B), 40 highly enriched 
proteins were identified as potential EV proteins, 22 as cytoskeleton proteins, 12 as cell 
surface proteins, 15 as endosome related proteins and 93 proteins were found matched in 
ExoCarta EV protein database (Figure 2.3Ca). When categorized only by the three groups 
(“Potential EV”, “Potential Contaminant”, and “Undetermined”), there are 85 “Potential 
EV” proteins, 31 proteins are “Undetermined” proteins, and only 20 are “Potential 
Contaminant” proteins (Figure 2.3Cb). Same analysis was also applied to the samples 
from Exoquick and TEI kit preparations (Figure 2.3Ccdef). The EV related proteins from 
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F68 method showed 50% more than Exoquick (40 to 26) and over 2 folds more than TEI 
kit (40 to 18). Similarly, the number of highly enriched “Potential EV” proteins in F68 
protocol is about 50% more than corresponding Exoquick and TEI kit protocol (85 vs 57 
and 60 respectively). As the previous results showed the F68 method significantly 
reduced the high abundant plasma protein recovery in the enriched EVs fraction, we 
further showed that the F68 enrichment method was able to enrich more “Potential EV” 
protein features compared to the other two precipitation-based protocol while 
dramatically reduce the plasma high abundant protein contaminations.  
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Figure 2.3 Categorization of Plasma EVs Proteins Enriched from Different Enrichment 
Method. A) Venn Diagram of unique and shared identified proteins in MS analysis from 
F68, Exoquick, TEI kit as well as the corresponding plasma; B) Venn Diagram of unique 
and shared proteins identified from the semi-quantitative MS analysis from different EV 
enrichment protocols that are significantly higher than original plasma (p<0.05 and >= 10 
folds higher); C) a/b: protein categorization for plasma EV enriched by F68, c/d: protein 
categorization for plasma EV enriched by Exoquick, e/f: protein categorization for 
plasma EV enriched by TEI. *unique proteins identified in A as well as the unique 
proteins that show significantly higher than plasma from individual protocol were 
categorized to extracellular exosome(Exo), cytoskeleton(Cyto), cell surface, endosome, 
blood macromolecule, endoplasmic reticulum (ER), mitochondrial, Golgi apparatus and 
nucleosome. Potential EV includes the proteins from EV, cytoskeleton, cell surface, and 
endosome as well as proteins that matched in Exocarta. Potential contaminants include 
blood macromolecule, endoplasmic reticulum (ER), mitochondrial, Golgi apparatus and 
nucleosome category. Undetermined category includes the proteins that could be 
identified either as potential EV and potential contaminants.  
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NGS Profiling of Plasma EVs Enriched by Pluronic Copolymer  
The initial let-7a qPCR assay suggested that the RNA inside plasma EVs enriched 
by F68 could be well preserved. To further identify what RNAs species that exist in the 
plasma EVs enriched by F68, total RNA sequencing and smRNA sequencing were 
performed respectively.  
Total RNA profile is summarized in Figure 2.4. The genes detected in the NGS 
were categorized according to the biotype from Ensemble GRCh38.85 RNA annotation 
in terms of RNA species count (Figure 2.4A) as well as relative abundance by FPKM 
(Fragment Per Kilo base of transcript Per Million mapped reads, Figure 2.4B). Among all 
RNA species detected in the plasma EV enriched by F68: ~58.5% are protein coding 
RNA species (including protein coding 52%, alternative splicing species(retained intron) 
~6.5%); About 5.7% of the transcripts match the non-sense mediated degradation 
category (NMD), consistent with previous study that showed RNA species subjected to 
RNA degradation were found in EVs116. All other species are different subtypes of non-
coding RNAs, including 10% transcripts without valid ORF; 4.3% are Long, intervening 
noncoding RNA (lincRNA), which also have been reported to be packaged into EVs6, 117; 
2% mtRNA, including mitochondria-origin tRNA and rRNA, which are also reported in 
previous researches116; Other non-coding RNA species, such as multiple antisense RNA, 
snRNA, snoRNA, Y_RNA that were reported to be packaged into EVs6, 116, 118 previously 
were also found in our study.     
In contrast, the relative abundance analysis showed that mt_tRNA was the most 
abundant RNA species from the plasma EV fraction enriched by F68, account for more 
than 80%, followed by protein coding transcripts (7.6%). Though quite some species of 
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NMD RNA were identified above, their levels are relative low in the EV fraction, only 
accounts for less the 0.08%; Y_RNA has also relative small amount of species number, 
but it accounts for more than 5% relative abundance of the total RNAs, consistent to the 
previous report that  considerable amount of Y_RNA was found in EVs116. 
Since the total RNA sequencing have limited capability in examining all short 
RNA fragments, smRNA sequencing was also performed by a ligation-based sequencing 
method119, whose optimal templates are 5’ phosphorylated RNAs, such as miRNA and 
those smRNA derived from tRNA (tRFs) and Y_RNA (RNY) but act like miRNA120-121. 
Variety of smRNA species were observed that mapped to miRNA, tRFs, RNY, piRNA as 
well and lincRNA with length range from 18 to 40 nucleotides. To evaluate if such 
smRNA profile could distinguish the enriched EVs from the corresponding plasma, a 
supervised-hierarchical clustering of the smRNA species was performed with the heat 
map shown in Figure 2.4C. Two smRNA clusters were formed, one show enriched and 
the other faded in the enriched EVs compared to the corresponding plasma profiles. In 
addition, relative quantitative measurement showed a bimodal distribution of smRNA in 
reference to plasma, with one set of smRNA features enriched from the plasma (Figure 
2.4D). 
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Figure 2.4 NGS Profiling of Plasma EVs Enriched by Pluronic Copolymer F68. Total 
RNA profiling was categorized by either RNA species number or their relative 
abundance according to their biotype:  A) RNA species number according to their 
biotypes, the frequency in the pie chart indicate the proportion of transcript species 
identified for each biotype; B) Frequency in the pie chart accounts for the combined 
relative expression levels in term of FPKM for each biotype. C) Heatmap of supervised 
hierarchical clustering of smRNA from plasma EV enriched by F68 and their 
corresponding plasma, from blue to red indicates smRNA expression level (log2 
normalized expression).  D) Density plot of smRNAs relative abundance in comparison 
to plasma in terms of fold changes. Fold changes were indicated in log2 scale, the arrow 
mark the smRNA set that enriched from plasma.  
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Comparing Plasma EVs Profiles from Advanced Breast Cancer and Non-Cancer Patients    
Our results proved that the proposed pluronic copolymer method was able to 
efficiently enrich plasma EV with less contamination of high abundance plasma protein. 
To explore its potential utility, plasma EVs from 20 breast cancers with advanced clinical 
stages (clinical stage III and IV) and 20 age-matched non-cancers were enriched by the 
F68 method and profiled (Table 2.1). The semi-quantitative MS profiles were then 
compared to find out whether protein signatures related to breast cancer at such clinical 
stage could be identified from these enriched plasma EVs. 
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Table 2.1 Demographic Information of Breast Cancer Patient and Controls 
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Total 2108 proteins were detected in both cancer and non-cancer groups. When 
categorized by their respective GO term as described above, over 300 proteins were 
identified directly related to EV, 185 proteins related to cytoskeleton, 76 related to cell 
surface proteins, 74 related to endosome and total 786 could be found in ExoCarta 
database (Figure 2.5B). Overall, 654 unique proteins that are “Potential EV” proteins 
features, 282 proteins could be either EV or free contaminant as “Undetermined” proteins 
while 146 proteins could be “Potential Contaminant” proteins from cellular organelles 
that are less likely associated with EV. Over four times of the potential EV proteins were 
identified compared to the potential non-EV contaminants, which was consistent to result 
above in the methodology characterization. 
In order to obtain the features most likely related to breast cancer EVs, proteomic 
profiling was performed on the four EVs generated from the breast cancer cell-lines 
MCF7, MDA-MB-468, MDA-MB-231 and T47D (Figure 2.5C). Total 3653, 5550, 3099 
and 4994 proteins were identified in respective cell line generated EVs. 872 proteins are 
shown to be shared features in all four kinds of EVs.  
One thing in common for all four breast cancer cell lines is that they have all 
shown aggressive, metastasis and invasive behavior in varieties of studies122. We 
hypothesized that there might be some common features related to such cancer cell 
aggression behavior. If such common features exist in cell line EVs, they might also exist 
in the breast cancer cells from patients. Ideally, they might also be detectable from the 
enriched plasma EVs. Therefore, features that in cell line EV would be most likely 
related to the cancer EVs from patient plasma. By overlapping between the features from 
cell line EVs and the features from patients’ enriched plasma EVs, it showed that 440 
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proteins to be shared features between EVs generated. These 440 features were detected 
in enriched plasma EVs, and then confirmed to be in the four breast cancer cells line EVs.  
Figure 2.5D shows the comparison between cancer and non-cancer groups of the 
2108 features detected in the patient samples. 217 features show statistically significant 
difference between cancer and non-cancer groups (p<0.05).  197 features show the 
relative abundance are significant higher in cancer group compared to non-cancer group 
by equal or more than 1.5 folds (p<0.05), while 6 of these features show relative 
abundance are significantly lower in the cancer group compared to non-cancer group by 
equal or less than 0.5 folds (p<0.05). More features on the side of elevated abundance 
were consistent to the expectation of EVs enrichment. 
General features that found in plasma EVs and high abundant plasma proteins 
were also compared between cancer and non-cancer groups (Figure 2.5Ea-e), as well as 
between plasma EV fractions and the corresponding neat plasma samples (Figure 2.5Ea-
e). As general EV marker, ACTB showed statistically significant between cancer and 
non-caner group (Figure 2.5Ea p<0.05). In contrast, VWF showed no statistically 
significant difference between the two groups (Figure 2.5Eb p>0.05). High abundant 
plasma proteins such as ALB, A2M and IgG showed no statistically significant difference 
between cancer and non-cancer group (Figure 2.5Ec-e, p>0.05), indicating the source of 
high abundant plasma protein contaminations in the enriched EV fraction were quite 
consistent across groups. At the same time, Figure 2.5Ef-g showed that the general EV 
marker, the relative abundance of ACTB and VWF were both significantly higher in the 
enriched EV fraction compared to the corresponding neat plasma. In contrast, all plasma 
high abundant proteins (ALB, A2M and IgG) showed magnitudes higher in neat plasma 
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sample compared to the corresponding enriched EV fraction, which was consistent to the 
previous result that the EVs from the patient plasma were enriched by the F68 copolymer 
with minimal high abundant plasma protein contaminations. Meanwhile, there was little 
correlation in the high abundant plasma proteins in the EV fractions with those from the 
corresponding neat plasma, suggesting trace of plasma leftover should not be the cause of 
such signal, especially for those proteins that was categorized as “Undetermined” above 
that showed potential in either as EV or plasma proteins category. 
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Figure 2.5 Clinical Comparisons between Advanced Breast Cancer and Non-Cancer. A) 
Age distribution in cancer and non-cancer group in Whiskers box plot; B) The unique 
proteins identified in the patient sample (protein detected at least in 10 samples in each 
group) were categorized to extracellular exosome, cytoskeleton, cell surface, endosome, 
blood macromolecule, endoplasmic reticulum (ER), mitochondrial, Golgi apparatus and 
nucleosome. “Potential EV”, “Potential Contaminant” and “Undetermined” protein 
categories were separated as described above by their respective GO term; C) Proteins 
overlapping between four breast cancer cell lines generated EVs and the clinical patient 
plasma sample EVs; D) Volcano plot of the cancer vs non-cancer plasma EV samples, 
the t-test p value (-log10) was plotted against the fold changes of the average relative 
abundance between cancer and non-cancer plasma EV samples; E) Relative abundance of 
proteins enriched from plasma EV comparison between cancer and non-cancer group by 
Whiskers box plot, a:ACTB, b:VWF, c:ALB, d:A2M and e:IgG. Comparison of relative 
protein abundance from enriched plasma EV (blue) to the neat plasma(red) in dot plot 
from individual patients, f:ACTB, g:VWF, h:ALB, i:A2M and j:IgG. Pearson correlation 
between plasma EV and neat plasma were also calculated. Y axis is the log10 
transformed relative abundance.  
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In order to assess the potential classification/prediction power by the proteomic 
profiles from the enriched plasma EVs, a Leave-One-Out (LOO) cross-validation model 
was built. The prediction performance in term of the area under curve (AUC) value was 
obtained. Figure 6A show the overall AUC performance is 0.7625 with optimal 
specificity of 0.9 and sensitivity about 0.6. To examine whether such performance was 
due to a random chance, AUC performance was calculated by randomly permuting the 
sample labels 10000 times. The distribution of AUC performance from the permutations 
is shown on Figure 2.6B. Compared to the permutation AUC performance, the AUC 
0.7625 obtained from the correct sample label is statistically significant (Figure 2.6B, 
p<0.05), indicating the classification performance between the original cancer/non-cancer 
group was not due to a random chance, suggesting the features from enriched plasma 
EVs was capable of differentiating the advanced breast cancer patient from non-cancer 
controls. 
60 features were found consistently contributed to the model in differentiating 
cancer from non-cancer sample. An unsupervised hierarchical clustering was performed 
to classify the current patient samples by those features. As shown in Figure 2.6C, two 
clusters were clearly formed, one with mostly cancer sample (16 cancers vs 3 non-
cancers) and the other is mostly non-cancer (17 non-cancers vs 4 cancers), with 
sensitivity of 80% and specificity of 85%, confirms the above feature selection process 
was able to screen features that separates advanced cancer patients from non-cancer 
controls.  
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Figure 2.6 Classification Performances and Feature Selection. A) Classification 
performance of the semi-quantitative mass spectrometry data was evaluated by a LOO 
cross-validation model based on random forest. The overall performance is AUC 0.7625; 
B) Classification performance from random permutations. Distribution of the AUC 
performance from all permutations was shown as blue, red vertical line marks the AUC 
performance of the correct sample label. The p value was estimated using the percentage 
of permutations with equal or larger AUC performance compared to the original AUC; 
C) Non-supervised hierarchical clustering of the patient samples by the features selected 
from the prediction model above. Two clusters were clearly formed in the patient 
samples, cluster 1 contains 16 cancers and 3 non-cancers (80% sensitivity), cluster 2 
contains 4 cancers and 17 non-cancers (85% specificity).   
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To further illustrate that the signal detected in the plasma EVs for the selected 
features was not from the trace of leftover plasma contaminations, Figure 2.7 shows more 
of those features with the most significant difference between advanced breast cancer and 
the non-cancer patients, as well as the comparison of their signals in plasma EVs to the 
corresponding neat plasma. Not only did these features show significantly higher relative 
abundance in the advanced breast cancer group compared to the control group (p<0.05), 
but they were also over expressed in the  enriched plasma relative to neat plasma. Little 
correlation between the signals in enriched plasma EVs and the neat plasma, indicating 
the selected features were most likely to be enriched by the proposed procedure instead 
from trace of the plasma leftover.  
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Figure 2.7 Features That Contributed in Breast Cancer Classification. Top features 
selected from the comparison (cancer vs non-cancer, plasma EVs vs neat plasma). 
Whisker Boxplot comparison between cancer/non-cancer; dot plots comparison of 
individual enriched plasma EV and their corresponding neat plasma (blue: plasma EV, 
red: neat plasma).   
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Discussion 
Secreted EV encompasses a very rapidly growing scientific field in biology and 
medicine. According to International Society for Extracellular Vesicles (ISEV), it is yet 
technically challenging to obtain a totally pure EV fraction free from non-vesicular 
components for functional studies. Though EVs are proved to contain proteins, lipid, 
mRNA and non-coding RNA species, the field of EV has not yet matured to the point 
that a list of “specific markers” could be given so that the EV population could be clearly 
separated from each subpopulation as well as the contaminants29. 
An ideal plasma EV enrichment method should be that the EV fraction is enriched 
with high efficiency while containing as less as possible of the plasma protein 
contaminations. In terms of the efficiency, reproducibility and simplicity, precipitation-
based methods are more competitive compared to UC or IP based methods. That in turn, 
also depends on whether the selectivity of the precipitation and compatibility the enriched 
fraction to downstream applications. There is no single platform or characterization yet, 
by its own, sufficient to indicate the enrichment of EV. Multiple platforms and 
characterization might be more appropriate in evaluating the quality of the enrichment. In 
our study, we showed that the Pluronic copolymer F68 was able to enrich the plasma EVs 
with membrane structure, ranging from 20nm to 100nm in size, contained highly 
enriched set of EV-related proteins as well as varieties of RNA species. At the same time, 
much less enrichment in high abundant plasma proteins contaminations was detected in 
the enriched EV fraction. The enriched EVs were also proven to have broad compatibility 
for variety of downstream applications including TEM, FL and MS without any 
additional procedures to remove the copolymer. According to the minimal experimental 
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requirements for definition of EVs, at least 3 proteins should be reported in at least semi-
quantitative manner in any EV preparation29. Here we reported not only the higher 
enrichment of EV related protein, including CD9, ACTB, HSP70 and VWF, but also 
lower the potential high abundant protein contaminants (ALB, A2M, and IgGs) from 
plasma by two semi-quantitative methods. Shotgun proteomic further found that the 
method enriched more potential EV proteins than others. However, since unique features 
were still found in different enrichment methods, the possibility that the existence of such 
EV subpopulation that might only be enriched by specific method/reagent, could not be 
excluded.  
In another remark, according to the minimal experimental requirements for 
definition of EVs, markers that are supposed to be absent or under-represented may also 
necessary to evaluate the purity of the enriched EVs29, semi-quantitative comparison for 
couple of such markers were shown in Figure 2.8A-C, including CYCS (mitochondria), 
CANX (ER) and HSP90B1 (ER). Compared to other methods, F68 precipitation was the 
only method that consistently showed significantly lower enrichment of these 
mitochondria/endoplasmic reticulum protein markers in comparison to the corresponding 
neat plasma as well as to the other precipitation-based methods. However, it is worth to 
note that the meaning of interpreting absence or under-represented marker that is already 
absence or under-represented in plasma might be limited and subjected for debate, 
partially because lack of a standard on what should be considered as normal for such 
markers in plasma sample as well as incomplete understanding of the cellular 
compartmental communications. 
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Figure 2.8 Markers Considered Not Related to EVs from Different Plasma EV 
Enrichment Protocols. Semi-quantitative mass spectrometry analysis of proteins expected 
to be absence or under-presented in EVs, comparison of relative abundance of CYCS, 
CANX and HSP90B1, * significant lower compared to original plasma (p<0.05); ** 
significant lower compared to Exoquick/TEI methods (p<0.05).   
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Almost half of the proteins that are highly enriched by F68 method (122 out of 
263) were not able to match the categories described in Figure 2.3C, further studies might 
be necessary to illustrate whether these proteins are cargos that are packaged by either 
specific or non-specific means into EVs other than through the EV biogenesis pathway. 
Interestingly, most of these proteins belong to three sub-categories, including integral 
components of membrane, cytoplasm (cytosol), and nucleus proteins. The integral 
components of membranes include those proteins that might be involved in interactions 
with the membrane bound receptor signaling cascades, such as CCR8, CYSLTR2, 
GPR151, ABCG5. A lot of proteins are also identified as cytoplasm/cytosol and nucleus 
proteins with RNA/DNA binding capability, including YTHDF1, CSRNP1, PHF21A, 
RBM42, ZFAT, TLE1, HMBOX1, AICDA, KLF17, which are involved in varieties of 
functions from potential translation regulation, tumor suppressor to transcription factor 
activity. The findings are consistent to the study that reveals transcriptional regulator 
proteins were highly abundant in EVs123, the potential biological implication of such 
factors being highly enriched in the plasma EVs might deserve more investigations.   
 Although it has been shown that variety of RNA species exist in EVs116, profiling 
of RNA/smRNA from plasma EVs has been challenging. The profile was highly 
dependent on the method used in preparing the EV fraction. This was further complicated 
by the fact that smRNAs are well-known to circulate in the bloodstream and other body 
fluids in a stable, cell-free status124, resulted in the RNA profiles may varies by different 
methods and may contains undistinguishable contaminants in various degrees. Despite 
that, with highly enriched EV related protein and much less enrichment for high abundant 
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plasma protein in the current method, supporting improvement could be achieved in the 
current study. 
In a broader view, the RNA/smRNA profiles for plasma EVs enriched by F68 are 
consistent to other PEG-based enrichment methods from other studies (either from 
Exoquick or from TEI kit preparations)116, 125. miRNA, piRNA, tRNA, tRFs, Y_RNA, 
RNY, MtRNA, protein coding RNA, rRNA, lincRNA as well as snRNA and snoRNA 
were all detectable. Interestingly, large amount reads were mapped to mtRNA. There 
might be two explanations: 1) small mitochondrial debris might still be co-precipitated 
with the copolymer, which is supported by the existence of small portion of particles with 
larger size, even in the UC cell line EV preparations; 2) alternatively, a recent study 
showed that mitochondria are also able to generate small vesicular carriers that transport 
mitochondrial contents to other intracellular organelles. One of the targets of such 
transportation from mitochondria was the late endosome, or multi-vesicular body, where 
the EVs were formed17, suggesting potential communication between mitochondrial and 
endosome, or maybe MVB as a result. This might be one of the reasons for such high 
level of mitochondrial RNA in the plasma EV fraction.  
 To explore the potential application for this enrichment method, proteomic 
profiling was performed and used to compare plasma EVs enriched from advanced breast 
cancer and non-cancer controls. The breast cancer plasma sample were all from advanced 
clinical stage (III and IV), the reasons of using such settings are in two folds: 1) 
According to the definition of breast cancer stages (https://www.cancer.net/cancer-
types/breast-cancer/stages), major character of clinical stage III and IV is that cancer of 
any size has spread to 4 to 9 axillary lymph nodes or has spread to the chest wall or 
  88 
caused swelling, or ulceration of the breast, as well as further spread to other organs. 
Symptoms like these might suggest that cancer cells at these stages are actively spreading 
to distal tissue and maybe constantly in contact with the blood stream, implying cancer 
cell generated EVs may be more likely expelled into the blood stream. Therefore, 
proteins related to cancer aggression behavior at such advanced stages might be more 
likely to be captured from plasma EVs; 2) by adopting such setting, features selected 
from the model were expected to be related to the cancer aggression, metastasis, invasion 
or other characters that are generally associated with such advanced stages. Therefore, it 
provided a clear direction for potential result interpretation.  
Feature selection process in the study also focused on those features that were 
shared between enriched plasma EVs and breast cancer cell line EVs. This is because the 
purity of the enriched EVs is yet to be perfect even the enrichment method had been 
improved. Therefore, without such screening, it might be difficult to ensure the 
authenticity for such association of the features to EVs. Secondly, EVs in plasma may 
come from variety of sources but not necessary related to breast cancer cells. By using 
the features that could be detected from EVs generated by breast cancer cell lines only, 
the chance of the selected features that are actually from breast cancer related sources 
could be significant increased. Combined with these two filters, the resulted features may 
have a better chance of actually associating with breast cancer at that stage.   
Characterization of the four different breast cancer cell lines  MCF7, MDA-MB-
231, MDA-MB-468 and T47D was previously reported122. Though genotypes, 
morphologies as well as growth rates might be different for these cell lines, one character 
in common for these cell lines is that they were all derived from cancer 
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metastasis/invasion sites126-129 and they are all able to show aggression, metastasis and 
invasion behavior in different models122, 130, implying certain common features might be 
involved in regulating such aggression/metastasis/invasion behavior. One of the 
expectations for the clinical comparison study was to find out whether such common 
features related to cancer aggression could be found in the plasma EV and whether these 
features could be used to differentiate the cancer patient from the non-cancer patients. 
In the LOO cross-validation model, 60 core features were selected. They are 
features that are detected in both patient plasma EVs and the breast cancer cell lines 
generated EVs.  These features were able to separate the advanced cancer sample 
population from non-cancer patient in both the cross-validation model and the un-
supervised hierarchical cluster method. Interestingly, according to the information from 
The Human Protein Atlas database131-133, as shown in Table 2.2, the expression of over 
70% of these features (43 out of 60) have been confirmed by immunohistochemistry on 
the breast cancer tissues, only 17 proteins are yet to be confirmed, partially because 
lacking of suitable antibodies, consistent to our expectation by screening the initial 
plasma EV features with features from EVs generated by breast cancer cell lines. 
Also according The Human Protein Atlas database, the prognostic performances 
of these 60 features were also analyzed by respective RNAseq dataset generated by 
TCGA134. The analysis was based on the FPKM value of each gene, patients were 
classified into two expression groups and the correlation between expression level and 
patient survival was examined by Kaplan-Meier survival estimators, and the survival 
outcomes of the two groups were compared by log-rank tests 
(https://www.proteinatlas.org/). Almost half of those proteins (28 out of 60) features 
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show significant prognostic values on varieties of cancers, implying their potential 
relevance to breast cancer.  
Also, through literature searching, 28 out of 60 features show potential 
association to breast cancer aggression/metastasis/invasion (Table 2.2) from previous 
studies. For example, CDC14A was shown to be recruited to the cell leading edge to 
regulate cell migration and adhesion in breast cancer cells135; CNOT2 was shown to 
promote proliferation and angiogenesis via VEGF signaling in breast cancer cells136;  
Downregulation of  ITGB3 integrin modulates cell adhesion and invasion by interrupting 
Erk/Ets1 network in triple-negative breast cancer137; Tumor but not stromal expression of 
ITGB3 is essential and required early bone-metastatic breast cancer138; High levels of 
KIAA0100 expression were associated with poor prognosis in patients with invasive 
ductal carcinomas of the breast139. Such large proportion of the final selected features 
shown related to cancer aggression, metastasis and invasion was consistent to our initial 
expectation. 
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Table 2.2 Summary of 60 Features Selected from the LOO Model. Prognostic potential 
by their RNA expression level in cancer tissue from TCGA database, analyzed by The 
Human Protein Atlas database (NA: not available); Protein expression of each protein 
from breast cancer tissues from The Human Protein Atlas database (NA: not available). 
The literature references of association of these proteins to breast cancer aggression, 
metastasis and invasion. The p value from comparing plasma EV samples from advanced 
breast cancer and non-cancer group. 
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Gene Name Prognostic Value in Cancer IHC expression breast cancer tissue 
References to 
Breast Cancer 
p vaule 
(t-test) 
ACTB Renal, Head and Neck Cancer Yes 140 0.002 
ACTC1 Head and Neck, Urothelial Cancer Yes 
141 0.001 
ANKRD62 NA NA  0.004 
APOE NA Yes 142 0.019 
ATR Pancreatic, Liver Cancer NA  0.004 
CDC14A NA Yes 135, 143-144 0.004 
CFAP44 Urothelial Cancer NA  0.005 
CHD2 NA Yes 145 0.009 
CHD7 Endometrial Cancer Yes 146 0.02 
CNOT2 Renal, Liver, Melanoma Cancer Yes 
136, 147 0.003 
EGFR Urothelial Cancer NA 148 0.003 
HRC NA NA  0.003 
ITGB3 NA NA 137-138, 149-150 0.017 
LRP1B NA Yes  0.002 
MTMR3 NA Yes 151 0.009 
NKAP Breast Cancer Yes 152-153 0.002 
ODF2 Liver, Prostate Cancer Yes  0.001 
POTEE NA Yes 154 0.008 
POTEKP NA NA  0.003 
PPIG Renal Cancer Yes  0.002 
PRSS3 Endometrial Cancer Yes 155-157 0.003 
REV3L NA Yes 158-159 0.002 
SCN2A NA NA 160 0.003 
SPTBN1 Renal Cancer Yes 161-162 0.003 
TMEM87A NA Yes  0.019 
XIRP2 NA Yes  0.013 
ZNF33B NA Yes  0.006 
ZNF804A NA Yes  0.002 
PRPF4B Urothelial, Liver Cancer Yes  0.006 
BAZ1B NA NA  0.004 
CCDC191 Urothelial Cancer Yes  0.013 
CNTLN NA Yes  0.011 
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KIAA0100 Liver Cancer Yes 139, 163 0.001 
NEB NA NA  0.024 
TRPM6 NA NA  0.017 
ZKSCAN5 Liver, Thyroid Cancer Yes  0.024 
ZC3H13 renal Cancer Yes  0.063 
DST NA Yes 164-166 0.008 
EGLN1/PHD2 Cervical Cancer Yes 167-169 0.026 
KDM5A NA NA 170-172 0.02 
NCAPD3 NA NA  0.011 
NEXN Colorectal Cancer NA  0.011 
SETD2 Renal, Melanoma Cancer Yes 173-174 0.022 
ADAM17 Urothelial Cancer Yes 175-177 0.043 
CACNA1B NA Yes 178 0.035 
GOLGA6L2 NA NA  0.018 
IQCA1L NA NA  0.024 
TTN NA Yes  0.02 
F5 Stomach Cancer Yes  0.011 
EIF3A NA Yes 179 0.019 
MYO6 Renal Cancer Yes 180-181 0.05 
CALD1 Renal, Melanoma Cancer Yes 182 0.023 
NRAP NA Yes  0.058 
CREBBP Renal Cancer Yes  0.023 
CCDC136 NA NA  0.017 
MSL2 Cervical Cancer Yes  0.015 
KMT2A NA Yes 183 0.056 
ZNF77 Lung, Endometrial, Cervical Cancer Yes  0.053 
USP33 NA Yes 184 0.044 
SORL1 Renal Cancer Yes  0.024 
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It is worth emphasizing that even though the EV fraction precipitated by the 
copolymer method was much cleaner, the possibility of contamination from certain 
amount plasma or other organelle debris could not be completely excluded, as they might 
be indistinguishable from EV in term of size as well as membrane properties. Indeed, our 
result showed the presence of a small percentage of larger vesicles and enrichment of 
some non-EV related organelle proteins. On the other hand, lack of universal EV unique 
marker might raise some questions regarding to the categorization accuracy, as proteins 
might locate in multiple organelles. For example, EVs may even contain DNA that bound 
by nucleus proteins16; mitochondrial-derived vesicles (MDVs) was also able to fused 
with the MVBs17; HSP60, a mitochondrial heat-shock protein, was found in tumor cell 
plasma membrane, EV membrane as well as in the Golgi apparatus18. Therefore, as more 
studies come out, more explicit definition would be expected. Despite of these concerns, 
the simple procedure, high enrichment, and much less high abundant plasma protein 
contamination in the current method might offer more advantages.  
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CHAPTER 3 
KIAA0100 MODULATES BREAST CANCER CELL AGGRESSION THROUGH 
INTERACTION WITH MICROTUBULE AND HEAT SHOCK PROTEINS 
 
Abstract 
KIAA0100 gene was isolated from human immature myeloid cell line cDNA 
library twenty year ago.  Recent studies have shown that its expression is elevated in 
breast cancer and associated with more aggressive cancer types as well as poor outcomes. 
However, its cellular and molecular function is yet to be understood. Here we showed 
that silencing KIAA0100 by siRNA in breast cancer cell line MDA-MB-231 significantly 
reduced the cancer cells aggression behavior, including cell aggregation, reattachment, 
cell metastasis and invasion. Most importantly, silencing the expression of KIAA0100 
sensitized the quiescent, suspended cancer cells to anoikis. Immunoprecipitation, mass 
spectrometry and immunofluorescence analysis revealed that KIAA0100 may play 
multiple roles, including stabilizing microtubule structure as a microtubule binding 
protein, and contributing to cancer cell anoikis resistance by its interaction with stress 
protein HSPA1A. Our study also implies that the interaction between KIAA0100 and 
HSPA1A may be targeted for new drug development to specifically induce anoikis cell 
death in cancer cell.  
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Introduction 
Human KIAA0100 protein belongs to the Human Unidentified Gene-Encoded 
(HUGE) database, which consists of over 2400 novel large human protein genes that 
have multiple domains potentially capable of binding many kinds of partners185. It was 
identified from a cDNA library in the Kazusa cDNA sequencing project in 1995186.  
In previous studies, it has been shown that among 71 cancer type-specific tags, 28 
were specific tags for breast carcinomas187; one tag of “GGTCCCCTAC” has been 
demonstrated to be highly expressed in the SAGE libraries of breast carcinomas and 
breast cancer cell lines compared to the libraries from normal mammary epithelium. The 
reliable UniGene cluster that matched to the tag of GGTCCCCTAC was identified to be 
Hs.151761, which was corresponding to the gene of KIAA0100163. In the most recent 
EST report, KIAA0100 was reported to have a total 448 EST sequences from a variety of 
human tissues, with 26 of the  ESTs confirmed to be in mammal grand tissue (NCBI 
Unique Gene:KIAA0100).  
Interestingly, data from multiple studies have shown that KIAA0100 might be 
related to breast cancer: in the non-cancerous human mammary breast epithelial cell line 
MCF10A transformed by v-Src, KIAA0100 protein was significantly up-regulated in 
response to the malignant transformation by proteomic profiling188. Genomic location of 
KIAA0100 (17q11) was also found to be within a close proximity to 17q12 chromosomal 
region. Amplification of this region was found in approximately 25% of breast tumors, 
which was associated with poor prognosis189, implying the expression of KIAA0100 may 
be affected if such event occurs; Also both ERRα and ER-α, were found to be recruited to 
the promoter region of KIAA0100 in the mouse model of ERBB2-initiated mammary 
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tumorigenesis190, implying the expression of KIAA0100 may be potentially up-regulated 
through these factor in breast cancer. High level of KIAA0100 expression was also 
shown to be associated with poor prognosis in patients with invasive ductal breast 
carcinomas139.  
Our recent data-mining from NCBI Gene Expression Omnibus (GEO) database 
also revealed a compelling expression pattern of KIAA0100 in breast cancer patients as 
well as in in-vivo tumor models: the expression level of KIAA0100 was significantly 
elevated in both basal-like and non-basal like breast cancer compared to normal controls 
191-192 (Figure 3.1A, GDS2250), suggesting its involvement might be necessary in both 
breast cancer types. In a mouse HER2 positive breast cancer model, the secondary tumor 
showed significantly higher expression of KIAA0100 compared to the primary tumor193 
(Figure 3.1B GDS4099), indicating its expression may be associated with the increasing 
cancer cells aggressive. Meanwhile, multiple bioinformatics tools have been employed to 
predict potential functions of KIAA0100 and show that it might be an anti-apoptotic 
factor related to carcinogenesis or progression186, 194. However, the molecular and cellular 
functions that KIAA0100 plays and how it contributes to cancer development and 
progression, especially in breast cancer cells, remain elusive. 
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Figure 3.1 Expression of KIAA0100 in GEO Datasets 
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In the previous chapter, plasma EV profiles comparison between advanced breast 
cancer and non-cancer patients showed that large portion of selected features were related 
to cancer aggression, metastasis and invasion. Considering that all current EV preparation 
methods are not perfect, the question becomes whether these features are really attributed 
to breast cancer development and aggressive behavior, and whether there is a link 
between these features and EVs. KIAA0100 was one of those features that showed 
significant higher level in the advanced cancer patient compared to the non-cancer 
controls. While most of those selected features have been extensively studied, the cellular 
and molecular functions of KIAA0100 have not yet been investigated, though multiple 
studies have shown its potential association to the breast cancer aggression. Therefore, 
functional study of KIAA0100 not only would be able to strengthen the conclusion in 
chapter 2, but also potentially may lead to the discovery of new drug targets to treat 
aggressive breast cancer. 
Cancer cell aggression can be exhibited in a variety of ways, including cell 
proliferation/growth195. However, other aggressive behavior, such as cell anchorage/re-
attachment196, cell adhesion/aggregation197-198, anoikis resistance52, a form of apoptosis 
after the cells’ detachment from the extracellular matrix (ECM), and 
metastasis/invasion199, all contribute in demonstrating the aggressive nature of the breast 
cancer cells.  In the current study, we adopted siRNA technology to knock down the 
expression of KIAA0100 in MDA-MB-231 cells, a highly aggressive triple negative 
breast cancer cell line122, 200, as a model to study its potential molecular and cellular roles 
associated with aggressive behavior of breast cancer cells. HEK293 over-expressing 
KIAA0100 recombinant protein was also employed as an additional cell-line model to 
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investigate its potential protein-protein interactions accounts for the underlying molecular 
mechanisms. 
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Materials and methods  
Cell Cultures 
MDA-MB-231 was maintained in L15 medium, supplemented with 10% FBS, 2 
mM L-glutamine, 1U/ml penicillin, and 1μg/ml streptomycin at 37°C and 0% CO2. 
HEK293 cells were maintained in DMEM with 2 mM L-glutamine, 1U/ml penicillin, and 
1μg/ml streptomycin and 10% of FBS with 5% CO2. pKIAA0100 (pKIA) expression 
vector with FLAG and Myc tag on its C-terminal was from Origene. HEK293 were 
transfected with pKIA by Transfectamine 3000 reagent (ThermoFisher) according to the 
manufactory’s instruction. Stable cell line HEK293/pKIA was established by screening 
the transfected cells with 300ug/ml Geneticin (ThermoFisher). For cell culture in 
suspension, the culture plates were coated with poly-HEMA as described before201.  
 
siRNA Transfection, Demecolcine Treatment 
Gene specific KIAA0100 siRNA (siRNA id: 219429) targeted exon 25, HSPA1A 
siRNA (siRNA id: 145248) targeted to exon 1, as well as the negative siRNA control that 
target no gene product in human sequences (AM4635) were from ThermoFisher. 
Transfection of the siRNA was performed by the RNAiMAX transfection reagent from 
ThermoFisher according to the manufactory’s instruction. Transfections were performed 
in either forward or reverse style. For forward transfection, cells were seeded on the 
culture plate and incubated overnight to let cells settle down and attached to the culture 
plate surface before transfection; for reverse transfection, transfection mixture was 
prepared and mixed with cells during seeding to the culture plate coated with poly-
HEMA to prevent cell from re-attaching the surface. 
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Demecolcine (Sigma) was dissolved in DMSO. HEK293 and HEK293/pKIA cells 
were seeded onto the 96 well tissue culture plates with 1, 10, 100, 1000ng/ml (2.7, 27, 
270, 2700nM) final concentration of Demecolcine. Control for 0ng/ml concentration was 
equal amount of DMSO instead. Cell viability were performed as described below at 0, 
24, 48 and 72 hours as described below and normalized to the 0ng/ml control at each time 
point as 100% viability. For MDA-MB-231 cells, treatments of Demecolcine were at 0, 
0.5, 5 and 50uM concentrations and viability were assessed at 24 and 48 hours after 
treatment.  
 
Cell Growth/Viability, Attachment/Anchorage and Invasion/Metastasis assay 
Cell proliferation/growth and viability were tested either by ViaCell instrument 
(Viacord) or multiTox-Fluor cell viability assay (Promega) according to the 
manufactory’s instruction; Cell attachment/anchorage assays were performed by seeding 
the floating cell culture onto the culture plate, 12 hours after the seeding, cells not able to 
attach/anchor to the plate surface were removed by gently washed with warm complete 
L15 medium, cell growth and viability were then tested as described; Cell 
invasion/Metastasis was examined by the CultreCoat 96 Well BME-Coated Cell Invasion 
Optimization Assay (R&D systems) according to the manufactory’s instruction.  
 
RT-qPCR, Western blot and Immunoprecipitation (IP) 
For RNA expression analysis, cells were lysis by Trizol-LS reagent 
(ThermoFisher). RNAs were then purified by the RNA minElute kit from Qiagen. 
Reverse transcription was performed according to the Superscript III RT kit manual from 
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ThermoFisher with poly-T primer. Taqman probe assay for KIAA0100 and β-actin were 
from ThermoFisher performed accordingly, relative expression abundances were 
analyzed by ''Ct method. For protein analysis, cells were also lysis by Cell Extraction 
buffer with protease inhibitor mixture (ThermoFisher), protein concentration was 
measured by microBCA assay (ThermoFisher). Equal amount of proteins was then 
separated on either Tris-Acetate or Bis-Tris SDS-PAGE and transfer to the PDVF 
membrane. The blot was then detected by anti-KIAA0100 antibody (ThermoFisher) and 
anti-β-Actin antibody (Abcam). 
For protein crosslinking, HEK293/pKIA cells were washed by PBS followed by 
incubating with 6mM of DTBP (ThermoFisher) in PBS for 5min. Cells were then lysed 
in NP40 cell lysis buffer (ThermoFisher).  Anti-FLAG monoclonal antibody (IgG1, 
Sigma) was used to capture the recombinant KIAA0100 protein; anti-HSPA1A 
monoclonal antibody (IgG1, Abcam) was used to capture native HSPA1A; anti-
Digoxigenin (DIG) monoclonal antibodies (IgG1, Abcam) were used as an isotype 
antibody control and bare beads were used as negative control. Equal amount of cell 
lysate was immune-precipitated by the respective antibodies by Dynabead protein-G 
immunoprecipitation kit (ThermoFisher) according to the manufacturer’s instruction. At 
the end of the immunoprecipitation, the beads were mixed with LDS buffer with reduced 
reagent and heated at 70qC for 5min. Protein samples were then separated on a 4-12% 
Bis-Tris SDS-PAGE PAGE gel and transfer to PDVF membrane. The blot was then 
probed by anti-Myc tag antibody (Abcam), anti-α-Tubulin antibody (Abcam), anti-
HSPA1A (Abcam), HSP90AB1 antibody (Abcam) respectively. The mouse monoclonal 
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antibody used in the immunoprecipitation was detected by anti-mouse-HRP antibody 
(Santa Cruz). 
 
Mass Spectrometry Analysis 
Protein samples were separated on 4-12% Bis-Tris PAGE gel and stained with 
Brilliant Blue (ThermoFisher); slices containing the protein bands of interested were 
excised. In-gel digestions by trypsin (ThermoFisher) were then performed. Samples were 
analyzed by nanoflow reverse phase liquid chromatography using a Dionex Ultimate 
3000 RSLCnano System (ThermoFisher) coupled in-line to a Q Exactive HF mass 
spectrometer (ThermoFisher). The nano LC system included an Acclaim PepMap 100 
C18 5μm 100A 300μm×5mm trap column and an EASY-Spray C18 2μm 100A 
50μm×150mm analytical column (ThermoFisher). Peptide samples were eluted with a 
two-step gradient of 2% to 30% B in 28 min then 30% to 45% B in 5 min, where B 
consisted of acetonitrile containing 0.1% formic acid.  Blank samples consisting of 0.1% 
formic acid in water were injected between each sample and eluted with the same 
gradient profile and times as the samples.  The LC system was interfaced with the mass 
spectrometry using an EASY-Spray electrospray ion source (ThermoFisher) and the 
samples were analyzed using positive ion spray voltage set to 2 KV, S-lens RF level at 
65, and heated capillary at 285°C. The Q Exactive HF was operated in the data-dependent 
acquisition mode for fragmentation. MS1 survey scans (m/z 400–1400) were acquired in 
the Orbitrap analyzer with a resolution of 120,000 at m/z 200, an accumulation target of 
3×106, and maximum fill time of 50ms. MS2 scans were collected using a resolution of 
30,000 at m/z 200, an accumulation target of 1×105, and maximum fill time of 100ms, 
  105 
with an isolation window of 1.5 m/z, normalized collision energy of 28, and charged state 
recognition between 2 and 7. 
ProteoWizard was used for peak-picking, filtering out peaks with intensity less 
the 100 and converting the file to mzML format. Protein search and identifications were 
performed using MS-GF+ search engine on homo sapiens (Uniprot TaxID=9606). Protein 
identification was set with parameter thresholds of peptide E-val of 0.01 and protein FDR 
of 0.01. 
 
Annexin V staining, Caspase 8, 3/7 Activity Assays 
Anoikis was detected by annexin V-FITC Apoptosis Detection Kit (Abcam) 
according to the manufactory’s instruction. The images were taken by a Zeiss Axio 
Imager 2 Fluorescence Microscope. For caspase activity measurement, cells were lysis by 
the caspase buffer (Promega), protein concentration were then measured by microBCA 
assay. Equal amount of protein (5ug) were used for measuring caspase 8, 3/7 activities 
according to the instructions. 
 
Immunofluorescence  
Cells were seeded on 8 well cell culture slides and incubated for designated time 
points and fixed with 4% formaldehyde for 10 minutes. The slides were then blocked by 
PBS buffer contains 5% of BSA. Anti-KIAA0100 c-terminal rabbit antibody 
(ThermoFisher) was co-labeled with α-anti-tubulin monoclonal antibody (ThermoFisher) 
or anti-HSPA1A monoclonal antibody (Abcam) respectively, following by anti-rabbit-
alexa488 and anti-mouse-alexa555 as secondary antibodies, or phalloidin-568 
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(ThermoFisher) for F-actin detection respectively. Slides were mounted by Prolong Gold 
anti-fade  with DAPI (ThermoFisher). Images were acquired by Zeiss Axio Imager 2 
Fluorescence Microscope or Leica TCS SP5 AOBS Spectral Confocal System. 
Statistical Analysis 
All the experiments were performed at least three times. Mean, SD, and t test 
were calculated either using Excel software (*, P < 0.05). Graphs were generated in 
Excel. 
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Results 
Silencing KIAA0100 Expression Does Not Affect the Anchorage-Dependent Cancer Cell 
Growth/Proliferation 
To assess the roles of KIAA0100 in breast cancer, its expression in breast cancer 
cell line MDA-MB-231 was first knocked-down by the siRNA in a forward transfection 
manner as indicated in Methods. Anchorage-dependent cell proliferation and growth 
were then examined as shown in Figure 3.2. The expression of KIAA0100 mRNA was 
effectively reduced more than 90% compared to mock control and the negative siRNA 
treated control cells within 24 hours and 48 hours after KIAA0100 siRNA treatment 
(Figure 3.2A). Consistently, the protein levels of KIAA0100 were also significantly 
decreased within 24 hours after the treatment, indicating the selected siRNA was very 
efficient in reducing the expression of both KIAA0100 mRNA and protein levels (Figure 
3.2B). However, there was no significant difference in the anchorage-dependent cell 
growth/proliferation between KIAA0100-silenced cells and the control cells for up to 5-
day of observation (Figure 3.2C), indicating that silencing the expression of KIAA0100 
had no effect on anchorage-dependent cancer cell proliferation/growth. This suggests 
KIAA0100 might not be directly involved in signal path for the cancer cell aggressive 
behavior in term of anchorage-dependent cell proliferation and growth. 
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Figure 3.2 Silencing KIAA0100 Expression Does Not Affect Cell Anchorage-dependent 
Proliferation/Growth.  MDA-MB-231 cells were first seeded on the culture plate and 
allowed to settle (attachment); cells were then transfected with KIAA0100 siRNA in a 
forward transfection manner. Efficiency of the siRNA was examined by qPCR and 
western blot at 24 and 48 hours after transfection. A) Relative KIAA0100 mRNA 
expression was analyzed by ΔΔCt analysis; mock control at 24hrs was used as reference 
group and the β-actin was used as reference gene. Y-axis is relative expression level 
indicated as fold changes in reference to the mock sample at 24hrs. Cells transfected with 
negative siRNA showed little reduction in KIAA0100 mRNA expression level compared 
to mock controls (p>0.05); KIAA0100 siRNA treatment significantly reduced the 
KIAA0100 mRNA expression level by over 90% in the first 24hrs and 48hrs (*p<0.05); 
B) KIAA0100 protein levels detected by Western blot. Consistent with the reduction in 
the mRNA level, protein level of KIAA0100 significantly decreased within 24 and 48 
hours, compared to the mock controls and cells treated with negative siRNA; C) Cell 
growth/proliferation were examined by multiTox-Fluor cell viability assay from day 0 to 
day 5, assay was performed every two days. No significant difference was observed in 
the cell proliferation/growth of the cells treated with KIAA0100 siRNA and the negative 
siRNA as well as the mock controls (p>0.05).  
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Scheme of Studying Cancer Cell Aggressive Behavior Other Than Anchorage-dependent 
Cell Growth and Proliferation 
Since silencing the expression of KIAA0100 failed to show any significant effect 
in cancer cells in terms of anchorage-dependent proliferation/growth, effects on 
anchorage-independent behavior of the breast cancer cells was then needed to be 
investigated. To this end, cancer cells aggregation in suspension, ability to re-
attachment/re-anchorage, anoikis resistance and invasion/metastasis upon KIAA0100 
knockdown were studied in the MDA-MB-231 cells. Figure 3.3 illustrates the experiment 
scheme used to evaluate these potential effects.  
MDA-MB-231 cells were maintained in poly-HEMA coated plates, which 
allowed them to mimic the behavior of cancer cells detaching from ECM and initiating 
metastasis. Expression of KIAA0100 in the suspended cells was then silenced by the 
siRNA in a reverse transfection manner. Morphology of the cells (aggregation) in 
suspension was observed using light-contrast microscopy; total cell number and viability 
in suspension was then determined by trypan blue based staining on a ViaCell counter 
(viability). Cells were then further studied for their ability to attach and migrate as 
follows. First, cells in suspension culture were seeded to the culture plate without poly-
HEMA at 24 and 48 hours after siRNA treatment; cells unable to re-attach back to the 
plate surface were then washed away while cells able to anchor back to the plate were 
assessed by the viability assay (attachment/anchorage). Second, 24 hours after siRNA 
treatment, the cells ability to migrate across the BME barrier was examined 
(invasion/metastasis). Additionally, cell death in the suspension culture due to the 
silencing of KIAA0100 was evaluated by caspase 8, 3/7 assay as well as annexin V 
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staining (anoikis). Cells samples were also taken for KIAA0100 protein and mRNA 
expression analysis. Therefore, cells aggregation/viability in suspension, anoikis 
resistance, ability of re-attaching, and capability of invasion was then assessed after 
KIAA0100 silencing without interference from the cell active growth phase. 
  
  112 
Figure 3.3 Scheme of Assessing Breast Cancer Cell’s Aggressive Behavior After 
Silencing of KIAA0100 
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Knocking-Down KIAA0100 Reduced Cancer Cell Aggregation 
Figure 3.4A shows the efficiency of silencing KIAA0100 in suspended cell 
culture in a reverse transfection manner. Relative expression levels of KIAA0100 as 
quantitated by RT-qPCR reduced by more than 90% compared to the mock cell control as 
well as the cells treated with the negative siRNA. Western blot showed protein levels of 
KIAA0100 were significantly reduced at 24 and 48 hours after the treatment compared to 
the mock and the negative siRNA treated control cells, confirming that there was no 
significant difference in the efficiency of the siRNA treatment between forward 
transfection scheme and the reverse transfection scheme.  
MDA-MB-231 cells are prone to forming loosely connected aggregates when 
maintained in suspension cultures202. Such cell aggregation has been shown to play an 
important role in cancer cell survival during ECM detachment and loss of anchorage203-
204. Consistent with this notion, control cells including mock and the negative siRNA 
treated MDA-MB-231 cells formed cell aggregates that were visible under the 
microscope as shown in Figure 3.4B. Though the cell aggregates appeared to be different 
sizes, in general cells were clumped in small spherical units and larger aggregates were 
formed by multiple units combined. Interestingly, silencing the expression of KIAA0100 
eliminated such cell aggregations within 24 hours of treatment and most of the cancer 
cells appeared as individual suspended cells. The disappearance of cell aggregation upon 
KIAA0100 siRNA treatment indicates KIAA0100 may play a role in maintaining cell-
cell contact and adhesion under the suspension culture condition. 
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Knocking-Down KIAA0100 Reduced Cancer Cell Viability 
Breast cancer cell lines, such as MCF7 and T47D are prone to forming very tight 
mammosphere in suspension. In contrast, cell aggregates formed by MDA-MB-231 in 
suspension culture were relatively loose. This suggests that the cell-cell adhesion in 
MDA-MB-231 cell aggregates may not be very strong. It has been shown that by gentle 
pipetting, the cell aggregates formed by MDA-MB-231 in suspension could be separated 
without any deleterious impact on the cells202. To take advantage of this, in 24 and 48 
hours after the KIAA0100 siRNA treatment, cells were separated by gentle pipetting and 
the total cell count and viability was examined through trypan blue staining on a Viacell 
device. Total cell number regardless of viability showed no significant difference at 24 
and 48 hours after the siRNA treatment in all samples (p>0.05, Figure 3.4 C). Though a 
slight decrease in total cell number was observed in all three samples at 48 hours, 
irrespective of the siRNA treatment indicating this effect was not specific to KIAA0100 
silenced cells. Cell viability percentage was relatively stable at around 90% at 24 hours 
after treatment for all samples. However, at 48 hours after treatment, cell viability in 
KIAA0100 silenced cells was significantly impacted as it decreased to less than 60%. In 
contrast, no significant difference was observed between the mock and negative siRNA 
treated control cells, as their viability remained relatively the same as that from the 
respective 24-hour time point at about 90%. Total cell numbers were at similar levels 
while only KIAA0100 silenced cells showed reduction in cell viability suggesting a direct 
effect of silencing the expression of KIAA0100 on the suspension cancer cells. 
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Figure 3.4 Knocking-down KIAA0100 Reduces Cell Aggregation and Viability in 
Suspension. MDA-MB-231 cells were reverse transfected with KIAA0100 siRNA and 
maintained in suspension culture plate coated with poly-HEMA. A) 24 hours and 48 
hours after transfection, both mRNA and protein levels of KIAA0100 in cell treated with 
KIAA0100 siRNA were examined by qPCR and western blot. Both mRNA and protein 
levels were significantly reduced compared to the cells treated with negative siRNA as 
well as the mock controls (*p<0.05); B) cell aggregation in suspension upon KIAA0100 
silencing was significantly reduced compared to the cells treated with negative siRNA 
and mock control; C) No significant difference in total cell number counts between cells 
treated with KIAA0100 siRNA and controls at 24 and 48 hours after the treatment by 
ViaCell (p>0.05); D) Cell Viability (in percentage) at 24 and 48 hours after treatment. No 
significant cell viability difference at 24 hours (p>0.05). However, silencing the 
expression of KIAA0100 resulted in significant drop in cell viability at 48 hours after 
treatment (*p<0.05). 
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Knocking-Down KIAA0100 Reduced Cancer Cell Invasion/Metastasis 
Cell invasion is fundamental to angiogenesis205, embryonic development206, 
immune responses207, and tumor cell metastasis208. MDA-MB-231 cells not only were 
derived from a metastatic site but have also been shown to be a highly invasive breast 
cancer cell line in multiple studies153, 209-210. To metastasis, cancer cells must detach from 
the original site, migrate, re-anchor and invade into distal tissue52. Figure 3.3 shows how 
cancer cells maintained in suspension could have the ability to re-anchor and 
invade/migrate across ECM and then be assessed by a BME assay. The effect of silencing 
KIAA0100 expression on the cancer cells can then be evaluated. To do so, 24 hours after 
the KIAA0100 siRNA treatment, aliquots of cells were collected and re-suspended in 
serum-free medium. Cell invasion/metastasis potential was examined using the cells 
ability to penetrate BME barrier in response to complete medium with 10% FBS.  
As previously described, the expression of KIAA0100 was significantly reduced 
at 24 hours after the siRNA treatment. However, total cell number and viability at this 
time point were not affected. Equal numbers of cells from each sample were then used for 
the BME assay. Figure 3.5A shows cells that were able to penetrate the BME barrier in 
mock control and negative siRNA transfected cells were at similar levels (p>0.05). In 
contrast, silencing the expression of KIAA0100 significantly reduced the number of cells 
that were able to migrate across the BME barrier, by more than 80%. In comparison to 
the control cells (p<0.05), this indicates that  the capability of re-anchoring and 
invading/migrating across the ECM matrix in the KIAA0100 silenced MDA-MB-231 
cancer cells in suspension was significantly reduced, suggesting KIAA0100 might play a 
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role in the epithelial to mesenchymal transition of breast cancer cells as well as their 
capability to colonize distant metastatic sites. 
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Figure 3.5 Knocking-Down KIAA0100 Reduces Cell Attachment, Metastasis and 
Invasion. A) Metastasis/Invasion potential was evaluated by the cells’ ability to penetrate 
the BME barrier. Cells able to penetrate the BME barrier were significantly reduced in 
KIAA0100 knock-down cells. There was approximately a 90% reduction compared to 
mock control and 80% compared to cells transfected with negative siRNA (*p<0.05); B) 
The number of cells able to attach onto the culture surface was examined by the cell 
viability assay. Significantly less cells were found to re-attach to the surface from 
KIAA0100 silenced sample compared to control cells (*p<0.05); C) Phase-contrast 
microscope image shows a reduced density of the KIAA0100 silenced cells compared to 
controls cells at 24 and 48 hours after treatment.  
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Knocking-Down KIAA0100 Reduced Cancer Cell Re-Attachment 
Anchorage dependence of cellular growth and survival prevents inappropriate cell 
growth or survival in ectopic environments and serves as a potential barrier to metastasis 
of cancer cells211. Cancer aggression manifests as the ability to detach from the original 
site, and then cancer cell’s ability to re-attach and start proliferation at a distant site. 
Cancer cells ability to re-attachment and invasion was investigated by silencing 
KIAA0100. The cancer cells ability to re-attach back to the culture surface was assessed. 
Equal numbers of cells in suspension culture were seeded to the culture plate without 
poly-HEMA 24 hours after treatment. Cells that were unable to re-attach back to the 
surface were washed away while cells that able to re-attach back to the plate were 
examined by a cell viability assay.  
As shown in Figure 3.5B, viable cells that were able to re-attach back to the 
culture plate decreased by more than 40% compared to control cells at 24 hours after 
treatment (p<0.05). At 48 hours after the treatment, the number of viable cells that were 
able to re-attach back on the culture plate reduced by more than 60% compared to control 
cells (p<0.05). Light-contrast microscope images showed a reduction of cell density upon 
KIAA0100 knock-down as compared to the controls under the microscope as shown in 
Figure 3.5C, indicating loss of KIAA0100 expression was able to reduce the cells’ ability 
to re-attach themselves back to the surface, suggesting that KIAA0100 may play a role in 
regulating the transition of cancer cells from suspension to anchorage.  
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Knocking-Down KIAA0100 Sensitized Cancer Cells to Anoikis  
Cells invasion and reattachment assays indicated that silencing the expression of 
KIAA0100 in breast cancer cell MDA-MB-231 in suspension hampered the ability of 
cells to re-attach back to the culture surface. At the same time, reduced cell viability in 
KIAA0100 silenced cells in suspension also implies KIAA0100 expression knock-down 
may invoke a cell death mechanism. Anoikis, a cell-detachment induced apoptosis, is one 
of the primary features required for cancer cells to become a malignant phenotype which 
supports tumor invasion and metastasis52. The untransformed mammary epithelial cell 
line MCF-10A underwent anoikis when detached and cultured in suspension condition211. 
In contrast, MDA-MB-231 has been shown to have significantly higher anoikis resistance 
compared to other less aggressive breast cancer cell lines upon detachment from the 
ECM, consistent with its aggressive invasion and metastasis212.  
To find out whether depletion of KIAA0100 could compromise MDA-MB-231 
cancer cells, anoikis resistance potential and cell death in suspension was evaluated. 
Anoikis was detected by Annexin V/PI staining 48 hours after the treatment of 
KIAA0100 siRNA and resulted in maximal protein depletion. As shown in Figure 3.6A, 
MDA-MB-231 cells in suspension showed no Annexin V staining, with only occasional 
dead cells shown with staining of PI in controls cells (white arrow pointed). This 
indicates negligible anoikis induction in control cells, which is consistent with the 
previous finding that MDA-MB-231 cells were highly resistant to anoikis212.  
In the initial stage of apoptosis/anoikis, cells translocate the membrane 
phosphatidylserine (PS) from the inner face of the plasma membrane to the cell surface. 
This was detected by staining with a fluorescent conjugate of annexin V and was showed 
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a ring shape.  In the late stage of apoptosis/anoikis, when the cell membrane structure is 
disrupted, apoptotic cells may appear double positive for Annexin V and PI staining. 
Moreover, apoptotic cells may be stained rapidly and strongly with PI and thus may not 
exhibit Annexin V staining at all213.  Accordingly, 48 hours after cells treated with 
KIAA0100 siRNA, MDA-MB-231 cells in suspension showed indications of both early 
and late stage of anoikis, particularly the late stage anoikis phenotype with halo Annexin 
V and PI being more dominant(Figure 3.6A).  
To confirm the anoikis pathway was activated, activities for caspase 8 and 3/7 
were examined. Caspase 8 was considered activated at the initial stage of anoikis and at 
the beginning of the caspase cascade, while caspase 3/7 was more as the effector caspase 
in later stage52 in the cascade. Figure 3.6B shows that both caspase 8 and caspase 3/7 
activity were significantly increased compared to control cells (p<0.05) at both 24 and 48 
hours after the treatment of KIAA0100 siRNA. Therefore, depletion of KIAA0100 in 
MDA-MB-231 cells in suspension initiate anoikis process was initiated. Specifically, 
silencing KIAA0100 induced cell anoikis but not general apoptosis since silencing 
expression of KIAA0100 on cells that firmly attached to the culture plate did not show a 
similar detrimental effect (Figure 3.2). 
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Figure 3.6 Knocking-Down KIAA0100 Induces Anoikis. A) Annexin V staining: anoikis 
of the cell in suspension were assessed by annexin V-FITC apoptosis assay.  Most of the 
mock control and negative siRNA transfected cells showed no visible annexin V-FITC 
other than the expected random cell death observed with PI (white arrow). Two types of 
staining pattern for anoikis were shown for cells transfected with KIAA0100 siRNA: 
early stage of anoikis - cells have lost membrane integrity will show red propidium iodide 
(PI) staining throughout the nuclei and a ring-like green staining annexin V-FITC on the 
plasma membrane; late stage of anoikis – cells stained with PI for the nuclei without 
annexin V staining with or without halo-green like annexin V-FITC staining. 
Apoptosis/Anoikis activation was examined by caspase 8, 3/7 activity assay: B) Caspase 
8 activity significantly increased in cells treated with KIAA0100 siRNA at both 24 and 
48 hours after transfection compared to mock control cells and cells treated with negative 
siRNA (*p<0.05); C) Caspase 3/7 activities in cells treated with KIAA0100 siRNA were 
significantly higher compared to mock control cells and cells treated with negative 
siRNA (*p<0.05). 
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Over-Expressed KIAA0100 Associates with Proteins from Cytoskeleton and Heat Shock 
Protein (HSP) Family 
Our results have shown that silencing the expression of KIAA0100 in MDA-MB-
231 breast cancer cells has a profound inhibitory effect on the breast cancer cells 
aggressive behavior, implying KIAA0100 may be involved in supporting the cell-cell 
adhesion, enhancing anoikis resistance and invasion. However, how it actually 
accomplishes these diverse roles remains unknown. In order to get deeper insight into the 
molecular mechanism of how KIAA0100 affects cancer cells, the open reading frame 
(ORF) of KIAA0100 was cloned with FLAG and Myc peptide tags added to the C-
terminal of the recombinant protein. The recombinant plasmid was then stably transfected 
into cell line HEK293 (as HEK293/pKIA). Over-expressing recombinant KIAA0100 
protein in HEK293 cells instead of breast cancer related cell lines is not ideal, but it is 
necessary due to the technical difficulty in transfecting large plasmid to multiple breast 
cancer cell lines, including MDA-MB-231.  
Cells over-expressing KIAA0100 (HEK293/pKIA) were viable with minimal 
morphologically differences compared to the original HEK293 (Figure 3.7A). Expression 
of recombinant KIAA0100 protein was confirmed by western blot probed by antibody 
against the Myc tag added to its C-terminal (Figure 3.7B). Immunofluorescence with 
KIAA0100 was performed by mixing HEK293/pKIA cells with the original HEK293 
cells (as KIAA0100 staining negative control). As shown in Figure 3.7C, the over-
expressed KIAA0100 recombinant proteins showed a distinguishable localization in the 
cytoplasm as thread-like networks in HEK293/pKIA cells. Such localization pattern was 
highly consistent with the microtubule network stained by the anti-TUBA antibody, 
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implying the recombinant KIAA0100 proteins might be associated with the microtubule 
network.  
Proteins associated with KIAA0100 might provide important clues on its potential 
molecular functions. To find out what proteins might be associated with KIAA0100, 
protein-protein interactions in HEK293/pKIA cells were first cross-linked by DTBP214, 
the recombinant KIAA0100 protein was then immune-captured by anti-FLAG antibody 
from the cell lysate. Captured proteins were then separated by SDS-PAGE and stained 
with coomassie blue. Compared to the control IPs, there are six distinguishable protein 
bands (Figure 6D, S1-S6) with molecular weight of >260KD, ~260KD, ~90-100 KD, 
~70KD, ~55KD and ~45KD. Protein bands of S1, S4 and S6 are unique to the sample 
that captured by the anti-FLAG antibody; Protein bands of S2 and S3 appeared from IP 
samples by both anti-FLAG and anti-DIG isotype antibody; however, the intensity of the 
bands was much stronger in IP by anti-FLAG antibody than the corresponding band from 
the IP sample captured by the anti-DIG antibody control.  Protein band S5 (Figure 3.7D, 
red arrow) in anti-FLAG IP matched the protein band in control IP sample captured by 
anti-DIG antibody, whose molecular weight matched the heavy chain of the capture 
antibody. At the same time, a very faint band (black arrow, S5) underneath that was 
unique to the anti-FLAG IP was also observed.  
Protein slices of S1 to S6 were then excised from the PAGE gel as shown in 
Figure 3.7D according to the area marked by the rectangles respectively, and then 
subjected to mass spectrometry analysis. The identified protein list from the mass 
spectrometry was then screened by the expected molecular weight shown by the 
corresponding SDS-PAGE slices. Top proteins that matched respective molecular weight 
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from individual protein slices and the number of peptides identified for those proteins are 
listed in Figure 3.7E: Slice S1 and S2 were shown to be KIAA0100 as expected with 40 
and 75 peptides identified; slice S3 was identified to be HSP90AB1 (HSP90) with 1 
peptide identified; slice S4 was identified to be HSPA1A (HSP70) with 19 peptides; band 
S5 and S6 was identified to be TUBA with 2 peptides and ACTB with 23 peptides 
respectively. Therefore, the identified proteins belong to two major family, cytoskeleton 
proteins and heat shock proteins.  
To verify the finding from the mass spectrometry analysis, western blot was then 
performed and probed by specific antibodies against the identified targets respectively. 
As shown in Figure 3.7F (left), KIAA0100 protein was clearly detected by the anti-Myc 
antibody from the IP sample captured by the anti-FLAG antibody at the positions of S1 
and S2, while no recombinant KIAA0100 was detected from IP captured by the antibody 
isotype and bare beads controls, confirming the IP captured with anti-FLAG antibody 
was very specific to the recombinant KIAA0100 proteins; The KIAA0100 recombinant 
protein was detected at the size around ~260KD, consistent to its calculated molecular 
weight. The signal from the recombinant protein was also detected at the S1 position 
(>260KD), which might be a result of larger protein complex formed by KIAA0100 with 
other proteins, or due to potential post-translational modification; Cytoskeleton protein 
TUBA and ACTB were detected at the corresponding position of band S5(black arrow) 
and S6 in sample captured by anti-FLAG IP while none of them was detected in the 
control IPs; protein corresponding to gel slice S4 was confirmed to be HSPA1A by the 
western blot. TUBA, ACTB and HSPA1A were confirmed without any non-specific 
capture from control IPs, suggesting that these proteins were most likely co-precipitated 
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with the recombinant KIAA0100 proteins. In contrast, the protein corresponding to slice 
S3 at ~90KD was confirmed to be HSP90AB1 by the western blot, but moderate non-
specific capture was also observed by IP with the isotype antibody. The IP input capture 
monoclonal antibodies were at similar level, suggesting the much higher HSP90AB1 
signal detected in comparison to the control may be partially due to protein co-
precipitation with KIAA0100.  
The potential interaction of KIAA0100 with HSPA1A was particularly notable 
due to its broad involvement in important cellular processes. Interestingly, HSPA1A was 
also detected by MS in the slice S1, which may be a protein complex formed with 
KIAA0100, further indicating its potential interaction with KIAA0100. To confirm its 
association with KIAA0100, IP western blots were also performed with an anti-HSPA1A 
antibody as capture antibody and probed with same set of antibodies as shown in the 
recombinant KIAA0100 IP. As shown in Figure 3.7F (right), recombinant KIAA0100 
and TUBA proteins co-precipitated with HSPA1A without non-specific capture in control 
IPs. In contrast, the co-precipitated HSP90AB1 signal was similar to the isotype control 
IP, therefore most likely HSP90AB1 was not involved in the interaction among 
KIAA0100, TUBA and HSPA1A. Though ACTB was also co-precipitated by HSPA1A 
antibody, the signal was relatively low compared to that from recombinant KIAA0100 IP, 
suggesting the interaction that mainly consists of KIAA0100, HSPA1A and TUBA and 
may be independent from the relatively minor association of KIAA0100 to HSP90AB1 
and ACTB. 
The initial KIAA0100 immunofluorescence in HEK293/pKIA cells in Figure 
3.7C shows hints that KIAA0100 might be connected to the microtubule network. 
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Immunoprecipitation was then used to confirm the association between KIAA0100 and 
the microtubule protein TUBA. To further verify this result, the individual 
HEK293/pKIA cells stained with KIAA0100 and TUBA were enlarged in Figure 3.7G. 
KIAA0100 proteins showed the thread-like network structures. Some but not all of the 
recombinant proteins were aligned to the same structures stained with the anti-TUBA 
antibody, which is consistent with the IP and earlier immunofluorescence results. At the 
same time, co-immunofluorescence was also performed with anti-KIAA0100 and 
phalloidin, a dye that specifically recognized the cell F-actin structure. As shown in 
Figure 3.7H, F-actin structures shown by phalloidin staining were mainly shown as fibers 
on the edge of the cell body with minimal pattern similarity and overlapping with the 
pattern of KIAA0100.  
Because the IP mass spectrometry and western blot results also strongly suggested 
potential the interaction between the recombinant KIAA0100 protein and the stress 
protein HSPA1A, their cellular localization was determined by IF, where HEK293/pKIA 
cells were co-labeled with KIAA0100 and HSPA1A antibodies. Consistent with the IP 
result, Figure 3.7I shows that KIAA0100 also partially co-localized with HSPA1A, 
indicating such closed contact between KIAA0100 and HSPA1A also exist.  
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Figure 3.7 Over-Expressing Recombinant KIAA0100 Proteins in HEK293 Cells. 
KIAA0100 over-expressing cell line HEK293/pKIA was established by transfecting 
KIAA0100 recombinant plasmid to HEK293 cells: A) Cell morphology comparison 
between HEK293 and HEK293/pKIA. 24 and 48 hours after seeding same number of 
cells to the culture plate; B) Western blot confirmed over-expression of the KIAA0100 
recombinant protein in HEK293/pKIA cells compared to the parent HEK293 cells; C) 
Immunofluorescence detection of the recombinant KIAA0100 and microtubule network 
(TUBA) in HEK293/pKIA cells*. Cells with white arrow did not expressing recombinant 
KIAA0100 and served as control for the recombinant KIAA0100 staining; D): 
Recombinant KIAA0100 was captured by anti-FLAG antibody from cell lysate; the 
captured proteins were separated on 4-12% SDS-PAGE and stained with coomassie blue. 
Six gel slices were excised as labeled S1 to S6 for mass spectrometry analysis; E) Top 
protein calls from mass spectrometry analysis that match the molecular weight according 
to the gel slice positions; F) Western blot was used to confirm the protein identified in the 
mass spectrometry analysis, IP with anti-FLAG tag antibody and anti-HSPA1A antibody 
compared to the corresponding controls with anti-DIG antibody as well as empty beads 
are presented; G) Immunofluorescence of recombinant KIAA0100 in HEK293/pKIA 
cells in a higher magnification, arrow point to the thread-like structure that both appears 
in the KIAA0100 staining and the TUBA staining*; H) Immunofluorescence detection 
recombinant KIAA0100 and F-actin filaments detected by phalloidin in HEK293/pKIA 
cells; I) Immunofluorescence of HEK293/pKIA cells stained with KIAA0100 and 
HSPA1A (arrow point to the potential co-localization spot). *In all immunofluorescence 
images above, KIAA0100 showed in green; other co-stained targets showed in red color. 
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Over-expressed recombinant KIAA0100 proteins showed microtubule-like 
network structures and interacted with TUBA. One explanation could be that KIAA0100 
may act as a microtubule binding protein MBP. If so, over-expressing recombinant 
KIAA0100 protein in HEK293/pKIA cells might be able to prevent microtubule targeting 
drugs, such as demecolcine from accessing the microtubule structure, in turn rendering 
the cells more tolerant to the microtubule-binding drugs.  
To test this hypothesis, HEK293/pKIA and the parent HEK293 cells were treated 
with microtubule depolymerizing drug demecolcine215 ranging from 1ng/ml to 1000ng/ml 
concentration, endpoint cell viabilities were compared at 72 hours (Figure 7A). Both cells 
responded to the demecolcine treatment in a dose-dependent manner,  but the cytotoxicity 
of demecolcine on HEK293/pKIA cells was significantly lower than the corresponding 
parent HEK293 cells: At 100ng/ml of demecolcine, the cell viability for HEK293 was at 
around 56% while viability for HEK293/pKIA above 70% (p<0.05); At 1000ng/ml of 
demecolcine, the cell viability for HEK293 was at around 50% while viability for 
HEK293/pKIA still stayed at above 70% (p<0.05). Cytotoxicity for both cell lines in 
response to treatment was also shown in a time-dependent manner. For concentration of 
1000ng/ml (Figure 3.8B), cells over-expressing KIAA0100 had a slower declining curve 
over a 72-hour period compared to the cells without over-expressing the protein. 
Cytotoxicity was also observed under the light contrast microscope as shown in Figure 
3.8CD. For the HEK293 cells, 72 hours after demecolcine treatment, most of the cells 
become round and lost cell anchorage from the surface while most of the HEK293/pKIA 
cells remained on the culture plate surface. The results indicate over-expressing 
KIAA0100 was able to decrease the demecolcine induced cytotoxicity in HEK293 cells, 
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suggesting the recombinant KIAA0100 proteins prevent the microtubule depolymerizing 
drug from accessing the microtubule structure.  
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Figure 3.8 Over-Expressing KIAA0100 Increases Tolerance to Microtubule Targeted 
Drug. A) HEK293 and HEK293/pKIA cells were seeded in 96 well plate with 
demecolcine concentration ranging from 1ng/ml to 1000ng/ml, cell viability was 
examined from 0 (DMSO only) to 72 hours. Cell viability for HEK293/pKIA at higher 
dose of demecolcine (100 and 1000ng/ml) were significantly higher than the 
corresponding HEK293 cells (*p<0.05); B) At 1000ng/ml demecolcine treatment, 
viability of both cells start to decrease at 48 hours after treatment, but HEK293/pKIA 
show significantly higher viability compared to HEK293 (*p<0.05); Phase contrast 
microscope image of C) HEK293 and D) HEK293/pKIA cells treated with 1000ng/ml 
demecolcine at 72 hours after treatment. Most HEK293 cells detached from the plate 
surface and appeared as round shape. In contrast, though some HEK293/pKIA cells also 
become round shape, most of the cell were still well attached to the plate surface and well 
spread. 
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KIAA0100 Co-localized with Microtubule Network and HSPA1A in MDA-MB-231 
 By using the KIAA0100 over-expressing HEK293 model cells, we were able to 
identify recombinant KIAA0100 proteins mainly associated with microtubule networks 
and HSPA1A. In order to verify whether the same interactions could exist in the breast 
cancer cell line MDA-MB-231, co-immunofluorescence was performed on MDA-MB-
231 cells and observed under the con-focal microscope. As shown in Figure 3.9A, unlike 
the recombinant KIAA0100 in HEK293/pKIA cells, the native KIAA0100 proteins in 
MDA-MB-231 cells showed speckle-like staining. However, the shape of the distribution 
is roughly consistent with the tubulin staining and is partially co-localized (yellow). In 
contrast, neither staining pattern similarity nor co-localization with F-actin staining could 
be observed (Figure 3.9B), consistent with the result from KIAA0100 over-expressing 
HEK293 cells. The co-localization of the KIAA0100 with HSPA1A in MDA-MB-231 
cells was also confirmed in Figure 3.9C, consistent with the above results from 
KIAA0100 over-expressing HEK293 cells. Our result confirmed that KIAA0100 proteins 
are mainly associated with microtubule networks and HSPA1A proteins in the breast 
cancer cells MDA-MB-231. 
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Figure 3.9 Immunofluorescence of KIAA0100 in MDA-MB-231 Cells. A) MDA-MB-
231 cells stained with of KIAA0100 and microtubules TUBA; B) MDA-MB-231 cells 
stained with KIAA0100 and Phalloidin (F-actin); C) MDA-MB-231 cells stained with 
KIAA0100 and HSPA1A. *in all figures, KIAA0100 showed as green, other targets 
showed in red color, arrow point to the yellow spot. 
  
  140   
  141 
Knocking-down HSPA1A Sensitizing MDA-MB-231 to Anoikis 
We have shown a strong association between KIAA0100 protein to microtubule 
networks and HSPA1A in KIAA0100 over-expressed HEK293 and breast cancer MDA-
MB-231 cells. Because microtubule networks and HSPA1A have both been reported to 
be involved in anoikis resistance, we then wondered which protein might be more 
responsible for the anoikis effect. MDA-MB-231 cells in suspension were treated with 
either siRNA to silence the expression of HSPA1A, or demecolcine to de-polymerize the 
microtubule networks. The respective effects were then observed and compared to the 
KIAA0100 silenced cells in above results. 
As shown in Figure 3.10A, mock and negative control siRNA treated control cells 
formed visible cell aggregates in suspension, but the aggregation dramatically dropped in 
cells treated with HSPA1A siRNA within 24 hours after the treatment and the loss of 
aggregation became more obvious at 48 hours after treatment. This phenomenon closely 
resembled the result was observed where diminished cell aggregation in KIAA0100 
silenced MDA-MB-231 cells. Consistent with the morphology changes, cell viabilities of 
HSPA1A silenced cells also dramatically dropped to about 70% at 24 hours and below 
60% at 48 hours after treatment while no significant changes in total cell number 
compared to controls was observed (Figure 3.10B and C). Similarly, depleting the 
expression of HSPA1A induced anoikis, which was detected by annexin V staining 
(Figure 3.10E). The decrease in cell viability coupled with an increase in anoikis 
occurred with KIAA0100 siRNA treatment of MDA-MB-231 cells. This suggests that 
KIAA0100 and HSPA1A might be involved in the same pathway of anoikis.  
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Treating cells with varying concentration of demecolcine (0.5, 5, 50µM) did not 
show a similar effect of losing cell aggregation and viability (Figure 3.11A and B) on the 
cells, indicating depolymerization of microtubules alone in the suspended MDA-MB-231 
cells was not enough to introduce an anoikis. This suggests that the association between 
KIAA0100 and HSPA1A drive anoikis, and not microtubule inhibitors. Silencing 
KIAA0100 resulted in loss of interaction partner to HSPA1A and may be the cause of 
activating the anoikis pathway. This further implies the interaction between KIAA0100 
and HSPA1A may account for the anoikis resistance for MDA-MB-231 cells. 
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Figure 3.10 Knocking-Down HSPA1A Resembles the Effect of Silencing the Expression 
of KIAA0100 in MDA-MB-231 Cells. A) MDA-MB-231 Cells were transfected with 
HSPA1A siRNA and cell morphologies were observed under microscopy at 24 and 48 
hours after the treatment. Mock and negative siRNA treated cells show significant 
aggregation in suspension culture at 24 and 48 hours, while HSPA1A siRNA treated cells 
lost cell aggregation from 24 hours after the treatment; B) Total Cell number in the 
suspension culture were similar at 24 and 48 hours between mock, negative siRNA 
treated cells and the HSPA1A siRNA treated cells; C) Viability of the HSPA1A treated 
cell dropped to about 70% at 24 hours and then below 60% at 48 hours; D) HSPA1A 
Silencing by the siRNA was confirmed by western blot analysis; E) annexin V/PI 
staining of MDA-MB-231 cells treated with HSPA1A siRNA, 24 hours after the 
treatment, arrows(white) point to PI nucleus staining with halo annexin V staining, 
arrows(yellow) point to PI nucleus staining with ring-shape annexin V staining. 
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Figure 3.11 Demecolcine Treatments Does Not Induced Anoikis in MDA-MB-231 Cells. 
A) Morphologies for MDA-MB-231 treated with 0.5, 5, 50uM of demecolcine at 24 and 
48 hours. There was no much morphologic difference in terms of cell aggregation 
between control DMSO treated cells and the cell treated with different concentration of 
demecolcine; B) Cell viability, both cells treated with DMSO and the cells treated with 
different concentrations of demecolcine show high cells viability at 24 and 48 hours after 
the treatment. 
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Discussion 
Breast tumorigenesis is a multi-step process starting from benign and atypical 
hyper proliferation, progressing into in situ carcinoma, invasive carcinomas, and 
culminating in metastatic disease216. The development and progression of breast cancer is 
a complex process including interaction of many genetic, epigenetic and environmental 
factors at different stages of cancer cells. These include proliferation/growth, 
anchorage/re-attachment, adhesion/aggregation, anoikis resistance, as well as 
metastasis/invasion. KIAA0100 has been found to be elevated in breast cancer tissues 
from multiple studies139, 163, 191-192 and in malignant transformed benign breast cancer 
cells188. Our study also showed that KIAA0100 protein was found in breast cancer cell 
lines MCF7, T47D and MDA-MB-231 and their respective EVs. The relative abundance 
of KIAA0100 in the enriched plasma EV fraction was shown to be elevated in advanced 
breast cancer patient compared to the non-cancer controls (Chapter 2), suggesting it 
might be related to breast cancer aggression.  
In the current study, the role of KIAA0100 in cancer aggression was investigated 
by adopting MDA-MB-231 cells - a highly aggressive breast cancer cell line122, 200 as a 
model. We found that while depleting the expression of KIAA0100 did not affect cell 
anchorage-dependent proliferation/growth, it did show a significant detrimental effect on 
the aggressive behavior in the anchorage-independent cells. The aggressive behavior of 
breast cancer cells in suspension, such as cell aggregation, re-attachment, migration and 
invasion were all affected to different extent upon silencing the expression of KIAA0100, 
suggesting KIAA0100 could be involved in a broad regulation network. Specifically, we 
found that silencing the expression of KIAA0100 render the MDA-MB-231 cells in 
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suspension sensitive to anoikis. We also provided evidence that KIAA0100 may be 
involved in anoikis resistance through its interaction with HSPA1A. At the same time 
KIAA0100 might also regulate other cancer aggression behavior through its interaction 
with microtubule networks.  
Silencing the expression of KIAA0100 reduced multiple cancer cell aggressive 
behaviors in MDA-MB-231 cells. However, which was the first one to be triggered, or 
whether they were all activated at the same time remains unknown, partially due to the 
fact that these seemingly separated processes are actually intertwined together and they 
may have mutual influence, which made it more difficult to isolate individual event 
experimentally. For instance, it has been shown that cell aggregation is important for 
anoikis resistance and promotes survival203-204, which in turn would increase the chance 
of viable cells to regain anchorage; on the other hand, if cells were under anoikis, it 
would be reasonable to assume that cells would not be able to aggregate as well as less 
likely to regain the anchorage. However, because MDA-MB-231 cells were reported to 
be anoikis resistant212 and its cell aggregates in suspension are relatively loose compared 
to other breast cancer cell lines202, suggesting that the aggregation dependent survival 
may not be the key contributor for its capability of anoikis resistance. The initiation of 
anoikis process but not the cell aggregation upon the silencing KIAA0100 might be the 
main driver for the loss of cell viability and resulted in the following diminished cell 
aggregation and cell reattachment. 
It is interesting that silencing the expression of KIAA0100 specifically induce 
anoikis, a programmed cell death process that is invoked upon cell detachment from 
extracellular matrix but not the common apoptosis for well anchored cells52. MDA-MB-
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231 cells that are firmly attached on the culture plate did not respond to the KIAA0100 
siRNA treatment for up to 5 days, while the same treatment on the cells in suspension 
showed a response within 24-48 hours post treatment. One potential explanation is that 
KIAA0100 may be particularly important to promote cell survival under stress condition 
caused by the losing of cell anchorage and it may contribute to the acquisition of anoikis 
resistance, an important step during cancer cell malignant transformation52. When a cell 
is not under stress, such function may not be that significant or may even be redundant. 
Our results showed that the interaction between KIAA0100 and HSPA1A, a stress 
protein that are well-known to be involved in promoting cell survival under stress 
condition, which is consistent with this interpretation217-219. 
Native KIAA0100 in breast cancer cell line MDA-MB-231 was localized in 
cytoplasm with a speckled pattern (Figure 3.9A), which is consistent with the KIAA0100 
staining patterns from Human Protein Atlas database, where KIAA0100 were detected in 
U-251MG (Glioblastoma), A431 (Epidermoid Carcinoma) and U2-OS (Osteosarcoma) 
cell lines220. Staining suggests the KIAA0100 is part of the microtubules network 
structure but not the action network. Interestingly, the over-expressed recombinant 
KIAA0100 proteins in HEK293 cells formed a clear thread-like network structure and 
showed partial co-localization with the microtubule network, implying the speckle-like 
distribution of native KIAA0100 proteins might be just protein spots that were distributed 
sporadically along the microtubule network. This was further supported by the 
immunoprecipitation which showed tubulin protein, the building block of the microtubule 
network, was co-immunoprecipitated with recombinant KIAA0100 proteins. 
Additionally, over-expressing KIAA0100 recombinant proteins in HEK293 cells 
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significantly increased the cells’ resistance to the microtubule depolymerizing drug 
demecolcine. The existence of similar interaction between native KIAA0100 and 
microtubule network was confirmed by immunofluorescence in the breast cancer cell line 
MDA-MB-231. This is consistent with the result from the over-expressing cell line model 
HEK293 even though it was not a breast cancer cell line, suggesting the interaction 
between KIAA0100 and microtubule network might be common across difference cell 
types.  
Microtubules are proven critical for anoikis resistance, aggregation, migration and 
invasion196-198, 215, 221-222. Our results suggested KIAA0100 might be functioning as a 
MBP, which have been shown to be a group of structurally and functionally diverse 
regulators of microtubule-mediated cellular processes223. MBPs have been reported to 
either stabilize/destabilize microtubules or move transport various cargoes along the 
microtubule networks223. MBPs have also been demonstrated to regulate the binding of 
microtubule-targeting drugs to microtubules; thereby modulating cancer cell sensitivity to 
these drugs223-225. Our results showed potentially close contact between KIAA0100 with 
microtubules was consistent to such description. On the other hand, whether KIAA0100 
is just bound to microtubules subunits or move along the network with cargoes is still left 
to be investigated. 
Interaction with microtubule network implies KIAA0100 may also have a role in 
regulating the cell spreading, mobility, metastasis and invasion198, 215, 226, which are the 
primary functions of microtubule network. According to the trypan blue cell viability 
assay, cell viabilities were similar between controls cells and the KIAA0100 silenced 
cells at 24 hours after treatment. Seeding cells at this time showed that about 50% of the 
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cells were able to re-attach back to the culture plate, which was roughly consistent to the 
cell viability at 48 hours after treatment due to the ~12 hours’ time gap needed for the re-
attachment assay. This suggests that at least part of the reason for the cells’ inability to 
re-attach to the culture surface was due to the loss of cell viability, possibly through 
activating the anoikis process. Because some cells were also seeded to evaluate their 
capability of invasion/metastasis potential, an interesting comparison was then 
demonstrated between the cell re-attachment rate and the migration/invasion rate upon 
depletion of KIAA0100: theoretically if sensitizing cells to Anoikis is the only effect 
from silencing the expression of KIAA0100, a roughly similar percentage of signal 
reduction in the BME metastasis-invasion assay would be expected. In contrast, the BME 
invasion result showed more than 80% reduction in signal from the KIAA0100-depleted 
cells compared to controls, much higher than the expected 50% of reduction, indicating 
that besides its role in anoikis, KIAA0100 may also have other functions that related to 
the capability of regaining anchorage as well as migration/invasion. The result implies 
that KIAA0100 might contribute to cell anchorage/migration/invasion by its interaction 
with the microtubule network. 
Multiple members in the HSP protein family were found potentially interacting 
with KIAA0100, in particular HSPA1A was confirmed by that fact that it was co-
precipitated and co-localized with KIAA0100 in HEK293/pKIA and MDA-MB-231 
cells. HSP protein family has long been shown to be involved in protein-chaperoning 
functions such as protein folding and refolding227-228. In addition, HSP proteins have also 
been widely reported to have stress-induced anti-apoptotic properties217 and they are 
actively involved in various processes as tumor cell proliferation, invasion, metastases 
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and death228.  Interestingly, it has been shown that HSPA1A is required for cancer cell 
survival under stress condition but not for cell proliferation and growth218. Due to such 
dual functionality, the question becomes whether the interaction between KIAA0100 and 
HSP proteins found in the current study was a result of a regular protein folding process 
through HSP’s chaperon function, or the possibility that KIAA0100 actually modulates 
Anoikis through of HSP proteins. Silencing the expression of HSPA1A showed a similar 
effect on the suspended MDA-MB-231 cells compared to the KIAA0100 silenced cells, 
in terms of losing cell aggregation and cell death caused by anoikis, suggesting that 
KIAA0100 and HSPA1A could be involved in the same signal pathway. 
KIAA0100 is a large protein with about 250KD in size. Naturally large proteins 
may contain multiple domains and serves as docking platform for other molecules185-186. 
Therefore, it may not be surprising that KIAA0100 is able to interact with multiple 
proteins that belong to a wide array of functional categories. Our immunoprecipitation 
experiments showed that KIAA0100 interacts with microtubules and HSPs, however, 
whether they interact with all at the same time as a complex or independently remains 
unknown. Potentially there are four interaction models that could be suggested from the 
IP results: 1) HSP and KIAA0100 are bound on same microtubule filament but in 
separated location; 2) HSP, KIAA0100 and microtubule bind to each other as a complex 
by different domains; 3) HSP interacts with KIAA0100, and KIAA0100 then bind to 
microtubules; 4) HSP binds to KIAA0100 and KIAA0100 binds to microtubules 
independently. There are two major domains on HSPA1A protein: The N-terminal 
nucleotide binding domain (NBD) is responsible for binding and hydrolyzing ATP; the 
C-terminal substrate-binding domain (SBD) binds to the client/substrate proteins229. 
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Interaction network of HSPA1A also has been explored extensively by both experimental 
and bioinformatics approaches (CORUM: P0DMV8; IntAct: HSPA1A; STRING: 
HSPA1A)230-232, but so far no study has demonstrated a direct interactions between 
HSPA1A and microtubules. Meanwhile, according to the data from The Human Protein 
Atlas, HSPA1A proteins are mainly localized to vesicles in the cytoplasm but not 
distribute along the microtubule networks (The Human Protein Atlas: HSPA1A). 
Silencing HSPA1A led to sensitization of the cells to anoikis, which is similar to that of 
silencing KIAA0100 while demecolcine treatment failed to do so. This evidence suggests 
that the interactions between KIAA0100 and microtubule and HSPs may be independent 
events. 
It has also been shown that HSPA1A is capable of binding to different 
phospholipids233 or even embedding itself within the lipid bilayer234. One of the 
phospholipids that has high affinity for HSPA1A is bis-(monoacylglycerol)-phosphate 
(BMP)235. The concentration of BMP in the late endosome is 15 mol % of the total lipid 
content of the organelle and can comprise as much as 70 mol % of the lipid composition 
of the intra-endosomal vesicles236-237, which is closely related to multi-vesicular bodies 
(MVB) and EVs generation20, 238. Indeed, HSPA1A was one of the most common 
proteins that found in EVs6, 29, 37, 239 as well as in the breast cancer cell line EVs used in 
Chapter 2. Therefore, it raised the possibility that KIAA0100 might be mediating the 
intra-vesicle transportation of HSPA1A proteins, MVBs or even EVs might be one of its 
potential destinations, which is consistent with the finding in the previous chapter that 
KIAA0100 was found in EVs generated from breast cancer cell lines as well as EVs 
enriched from plasma. Therefore, the interaction/co-localization between KIAA0100 and 
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HSPA1A in cell line studies suggests that there is a clear molecular path of associating 
KIAA0100 to EVs through its interaction with HSPA1A. This further supported the 
conclusions in Chapter 2 that the F68 co-polymer based plasma EV enrichment enriched 
plasma EVs and the features discovered from the clinical plasma EVs study (advance 
breast cancer vs non-cancer control) are closely associated with EVs.   
 Lastly, one interesting implication is that most of the cancer chemotherapy drugs 
are targeted to cancer cells with active cell cycles because most enzymes making DNA 
and RNA will stall at DNA damage. Non-cycling cells can take the time to repair the 
damage. DNA-damaging agents will primarily hit cells in the S-phase of the cell cycle 
and spindle poisons cells in mitosis. Hence, cells in the G0/G1 phase of the cell cycle 
have long been known to be relatively resistant to classical cytotoxic therapy 240. MDA-
MB-231 controls cells in suspension culture were not in an active proliferation status as 
indicated by negligible increase in total cell number from 24 to 48 hours after treatment 
and the cell numbers were still very close to the initial seeding cell number of 5x105 
(Figure 3.4C and Figure 3.10B). Therefore, it may not be surprising that treatment with 
demecolcine did not show any toxicity to the cells, partially because the demecolcine 
targets mitosis cells and not quiescent cells. This not only suggested that under the 
suspension condition, KIAA0100 contributes to the anoikis resistance through its 
interaction with HSPA1A, but also that KIAA0100 might be an attractive target aimed at 
the quiescent cancer cells because anoikis was initiated by silencing its expression alone. 
Though  HSPA1A related small molecules drugs have been developed241, such chemical 
may be toxic not only to cancer cells, but also to normal cells due to their inhibitory 
effects on normal cellular function like protein folding, autophagy, lysosomal function. 
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Because lack of toxicity on anchored cells by silencing KIAA0100 and the association 
between KIAA0100 and HSPA1A might be responsible for the anoikis resistance in 
suspended cells, specifically targeting to KIAA0100 or its interaction with HSPA1A 
might be able to sensitize the cancer cells that are in the process of metastasis to Anoikis 
with less cytotoxicity effect to normal cells. 
Unfortunately, most of the basic biochemical characterizations for KIAA0100 are 
not yet available, such as structure, domains, post-translational process/modification, 
protein-protein interactions as well as potential activity if there is any. Indeed, this 
protein is so unique in the human protein database that none has been found to have 
significant homology to it (NCBI BLAST); neither any significant conserved domain 
could be found from mammalian protein database. Though bioinformatics analysis 
suggests that KIAA0100 might contain domains like FMP27 and Apt1 (UniqProt: 
Q14667, analyzed by InterPro, Pfam and SMART), none of these domains originated 
from mammalian species, in contrast, those domains were rather from yeast and plant 
database, which might limit their functional interpretation in mammalian cells. Our 
finding suggested that there might be a microtubule or HSP protein binding domains on 
KIAA0100, which need to be further explored. 
In summary, we investigated the cellular and molecular functions of KIAA0100, a 
gene that is strongly related to breast cancer aggression. We showed that KIAA0100 
might modulate aggressive behaviors of breast cancer cell MDA-MB-231 in suspension, 
including cell aggregation, adhesion/attachment, and metastasis/invasion as well as 
anoikis resistance. Interaction between KIAA0100 and HSPA1A may be directly or 
indirectly responsible for imparting anoikis resistance to the breast cancer cell MDA-
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MB-231, thus making KIAA0100 a potential target for chemotherapeutic intervention. 
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CHAPTER 4 
PLASMA EXOSOME PROFILING OF CANCER PATIENTS BY A NEXT 
GENERATION SYSTEMS BIOLOGY APPROACH 
 
Abstract 
Technologies capable of characterizing the full breadth of cellular systems need to 
be able to measure millions of proteins, isoforms, and complexes simultaneously. We 
describe an approach that fulfils this criterion: Adaptive Dynamic Artificial Poly-ligand 
Targeting (ADAPT). ADAPT employs an enriched library of single-stranded 
oligodeoxynucleotides (ssODNs) to profile complex biological samples, therefore 
achieving an unprecedented coverage of system-wide, native biomolecules. In order to 
show its clinical utility, ssODNs libraries were enriched from plasma extracellular 
vesicles (EVs) from breast cancer patients and controls respectively. ssODNs that showed 
differentiation between breast cancer and controls were selected and then a ADAPT 
library with 2000 resynthesized ssODNs were used to profile a large scale clinical 
samples of total 500 subjects, including 206 breast cancer patients, 177 non-cancer 
patients, and 117 self-declared healthy controls. Feature selection, patient classification 
and prediction performance were then analyzed by a random forest-based model. Overall 
prediction performance of 0.73 in AUC was obtained when comparing biopsy-positive 
cancer patients to healthy donors, 0.64 when comparing to biopsy-negative patients. In 
addition, the cancer prediction performance was not associated with Bi-RAD breast 
composition categories. Our results suggested that ADAPT profiling was able to extract 
information from plasma EVs that associated with patients’ cancer status. 
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Introduction 
Extracellular vesicles (EV), which are secreted into circulation by many cell 
types, can provide a snapshot of cellular processes active in disease and healthy cells, 
allowing the EVs in circulation to serve as sentinels of the health of an individual. In 
cancer, EVs from neoplastic cells are involved in intercellular communication essential 
for several fundamental aspects of malignancy, including immune-evasion242, 
angiogenesis243, and metastasis13, 244. The molecular composition of EVs correlates with 
the cell-of-origin6, and alterations in membrane components, luminal contents, and 
abundance91 of EVs have been described in a variety of cancers245-248. Thus, EVs may be 
an informative biological substrate, reflecting the dynamic alterations that can occur 
during tumor progression. 
Libraries consisting of several trillion ssODNs encompass nearly infinite numbers 
of three-dimensional structures due to the vast complexity of DNA sequence space249-251. 
Selection/amplification schemes can be devised to scan this huge structural space for 
ssODNs that bind to simple or complex targets252-253. These qualifications enable parallel 
profiling of differences in molecular content across a wide range of biological sources 
without prior knowledge of binding partners254-255, but this potential has not been fully 
exploited to date. 
Here we described how libraries of ssODNs can be used to profile plasma EVs 
from women with and without breast cancer. We introduce “Adaptive Dynamic Artificial 
Poly-ligand Targeting (ADAPT)”, a novel approach for monitoring differences in the 
molecular content of plasma EVs in a massive parallel fashion without prior knowledge 
of the targets. 
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Material and Methods 
Cell Culture and EVs Isolation  
Cell culture: FBS was depleted of bovine EVs by centrifugation at 100,000g for 
16 h at 4°C. Vcap cells were cultured in DMEM supplemented with 10% depleted FBS, 2 
mM L-glutamine, 1 U/mL penicillin, and 1 µg/mL streptomycin at 37°C and 5% CO2. 
EVs were isolated from Vcap cell culture supernatant by sucrose density centrifugation. 
Briefly, supernatant was cleared of cells and cellular debris by sequential centrifugation 
at 400g for 10 min and 2000g for 20 min at 4°C. Cleared supernatant was concentrated 
by centrifugal filtration (Centricon Plus-70, 100 kDa NMWL), layered on a 30% sucrose 
cushion and centrifuged at 100,000g for 75 min at 4°C. Supernatant was removed and 
discarded without disrupting the cushion interface, which was then collected, diluted 6-
fold with PBS and centrifuged at 100,000g for 70 min at 4°C. The resulting EV pellet 
was re-suspended in PBS by pipetting and incubation overnight at 4°C, and then stored at 
-80°C. 
Ultracentrifugation: EVs were isolated from human plasma by direct 
ultracentrifugation. Pooled plasma from normal female donors was diluted 1:1 with PBS 
then centrifuged at 2000g for 30 min at 4 °C to eliminate contaminating cells, followed 
by 12,000g for 45 min at 4 °C to clear any remaining platelets and cellular debris. EVs 
were pelleted by centrifugation at 120,000g for 2 h at 4 °C. Pellets were washed twice by 
resuspension in PBS and subsequent centrifugation at 120,000g for 70 min at 4 °C. The 
final EV pellet was re-suspended and stored as described above. 
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Patients  
Bio-specimens utilized in this experiment were obtained under an IRB-approved 
Bio-repository Protocol (see the list of IRB committees below). All subjects were 
consented with an IRB approved consent form and per 21 CFR 50.20 guidelines. 
Informed consent was obtained from all subjects. All experimental procedures in this 
publication were reviewed by the Western Institutional Review  Board (WIRB) and 
deemed to fall under IRB Exemption per 45 CFR 46.101(b)(4). All experiments were 
approved by WIRB and performed in accordance with the Code of Federal guidelines and 
regulations. List of committees: Western IRB (Sponsor’s Central IRB). Additional Local 
IRBs consist of: CAMC/WVU Charleston IRB; Phoebe Putney Memorial Hospital 
(PPMH) IRB; MedCentral IRB; LVHN IRB; Margaret R. Pardee Memorial Hospital 
IRB; Community Healthcare System Central IRB; Hartford Healthcare IRB; Renown 
Regional Medical Center IRB; John Muir Health IRB; Jupiter Medical Center IRB; 
Middlesex Hospital IRB; Orlando Health/Orlando; Regional Healthcare System IRB; 
MPM-SAH IRB; St. Luke's Hospital and Health Network IRB; CCHC IRB; MCW/FH 
IRB; Bon Secours Richmond Health System IRB; Roper-St. Francis Healthcare IRB; 
CPHS; Greater Glasgow & Clyde Health Board. 
 
Demographics and Clinical Characteristics  
Patients’ information referred to the Appendix-C, Appendix-E, and Appendix-F.   
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Specimen Characteristics  
Blood plasma was collected at multiple collection sites using standardized 
protocol and the centrifuges provided by Caris Life Sciences. Blood was collected using 
standard venipuncture technique into four purple-top EDTA tubes, the tubes were spun in 
the Labofuge 200 for 10 min at 5300 RPM with proper balance. Plasma was then 
collected and aliquots were transferred into the cryovials, all cryovials were immediately 
placed into the -80°C freezer until use.  
 
Samples Combinations and Volume for the Following Assays  
SELEX: 1.2 ml 59/60 Breast Cancer Biopsy Positive/Negative samples (Negative 
sample includes 30 biopsy negative patient and 30 self-declared normal) were mixed as 
respective cancer/non-cancer pool. Each round of enrichment requires 300 µl of pooled 
plasma. For probing, 200 µl of plasma from individual 500 samples in 3 technical 
replicates were used.  
 
Library Design and Amplification  
ssODN library design as shown in Figure 4.1A, ssODNs library with 35bp 
random variable region flanked by primer-binding sites. The library was synthesized by 
Integrated DNA Technologies (IDT, USA) as “ultramer” (high-fidelity version of the 
synthesis) and purified by standard desalting. In order to avoid the low diversity problem 
that might happen when reading the sample index (i7) in the Illumina Hiseq platform, the 
library was synthesized in 4 separated parts with adding 0-3 bases right before the i7 
index sequence. 5’-phosphorylated forward primer 5’-TCG TCG GCA GCG TCA-3’ 
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(Tm: 62.6°C), and 5’-biotinylated reverse primer 5’-CTA GCA TGA CTG CAG TAC 
GT-3’ (Tm: 61.1°C) were used for library amplification by high fidelity Q5 DNA 
polymerase (NEB) with cycling condition: 98°C 30 s, followed by 10 cycles of 98°C 30 
s, 60°C for 30 s and 72°C 1 min, and final elongation at 72°C for 5 min. PCR product 
was purified by the NucleoSpin PCR clean-up kit (Macherey-Nagel) with NTI buffer 
according to the manufactory’s instruction. Purified dsDNA was quantified with a QuBit 
ds BR/HS assay kit (ThermoFisher). The dsDNA library was then mixed with Lambda 
Exonuclease (NEB) to degrade the strand with 5’-phosphorylation label at 37°C for 2 hrs. 
The enzyme was then inactivated at 80°C for 10 min. ssDNA was again purified by 
NucleoSpin columns with NTC buffer as instructed. Eluted ssDNA was quantified with 
the QuBit ssDNA assay kit (ThermoFisher). 
 
Library Enrichment  
Scheme of the library enrichment was shown in Figure 4.1B. Enrichments were 
performed for both cancer and non-cancer sample in separated routes. In both case, the 
initial amplified library (L0) were mixed with the cancer/non-cancer pool respectively; 
after incubation for 60min at ambient temperature, 20% PEG (Sigma-Aldrich) were 
added and mixed to final concentration of 6%. The samples were then inverted two times 
to mix, incubated for 15 min at 4qC, followed by centrifugation at 10,000g for 5 min at 
ambient temperature; the supernatant was then removed, the pellet was washed by 1.0 ml 
of 1X PBS with 3.0 mM MgCl2 and re-suspended in 100 µl H2O; the recovered libraries 
were then re-amplified, ssODN were then prepared and purified as described above.  
  165 
In the rest of the enrichment rounds, a scheme of positive selection, counter 
selection followed by another positive selection was followed for each round. In detail, 
the ssODNs amplified from the initial round of selection from cancer/non-cancer patient 
above were incubated with the same sample type plasma and repeat the selection as 
described above. By the end of the selection, ssODNs were recovered and put into the 
plasma sample with counter sample type as counter selection with same procedure. In 
counter selection, instead of collect the ssODNs associated with the EV pellet, ssODNs in 
the supernatant were collected and directly used to repeat a positive selection as input. 
The ssODNs recovered from this positive selection step were then amplified. The library 
enriched from cancer sample pool was denoted as L1 and library enriched from non-
cancer sample pool was denoted as L2. L1 and L2 were then mixed together and denoted 
as L3 and used for the next round of enrichment. Total three rounds of enrichment were 
performed as indicated in Figure 4.1B, the resulted final library gained approximately 106 
different unique sequences. 
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Figure 4.1 Design of the ssODN Library and General Enrichment Scheme. A) Design of 
the ssODN library. The primer highlighted in blue contains a sequence, complementary 
to the Illumina sequencing primer. The ssODN library was synthesized in a four parts 
with a staggered design, which differ from each other in length by +0, +1, +2, and +3 
nucleotides (green); B) Patterns of the forward strands of the index PCR product; C) 
ssODNs library enrichment scheme: a high-diversity molecule library (~1011) is mixed 
with blood plasma from biopsy-positive cancer sample (denoted by C) as well as with 
plasma from biopsy negative samples (denoted as non-Cancer, nC). In the 2nd step non-
bound ssODNs are removed with supernatant and bound molecules are collected in the 
EV pellet. In the 3rd step, ssODNs recovered from C are incubated with nC (and vice 
versa) and counter selection; non-binders ssODNs in the pellets are removed. The 
recovered ssODNs were used as input in in step 4, another positive selection same as 
step1 and the recovered ssODNs were amplified. Two separated libraries were obtained, 
L1 from cancer enrichment, L2 from non-cancer enrichment. L1 and L2 were then mixed 
to obtain the library of L3 and used for the next round. The enrichment process was 
repeated three times and the final L3 with diversity was estimated to be at ~106. 
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Protocol for Profiling Clinical Samples with Enriched or Synthetic Libraries   
Scheme profiling clinical sample is shown in Figure 4.2. Frozen plasma (1.0 ml) 
was thaw and treated with protease inhibitor (20X stock of protease inhibitor (Roche). 
Cells/debris were removed by centrifugation (10000g, 20 min, 4°C), and the supernatant 
was collected. 1.0 ml of 2X PBS (SH3025601, GE Healthcare) containing 6.0 mM MgCl2 
was added and thoroughly mixed. Dextran sulfate (APT-B006, Aptamer Sciences) were 
added to a final concentration of 0.01 mM, salmon sperm DNA (ThermoFisher) and 
tRNA (ThermoFisher) were added to a final 0.8ng/µl and mixed thoroughly. ssODNs 
aptamer probing library was added to a final concentration of 2.5pg/µl sample in 1X 
PBS, 3.0 mM MgCl2. The mixtures were then incubated for 1hr at ambient temperature 
with rotation followed by PEG EV precipitation at final concentration of 6% as described 
above. After re-suspended in H2O, the re-suspended sample was then directly amplified 
and sequenced by NGS. 
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Figure 4.2 ADAPT Profile Scheme. In the 1st step plasma samples of breast cancer 
patients are incubated with the profiling library L3. After incubation EVs are precipitated, 
supernatant is then removed (step 2). EV-associated oligonucleotides are subjected to 
next generation sequencing (step 3, NGS) to obtain a patient individual profile.  
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Next Generation Sequencing Library Preparation and HiSeq Sequencing Protocol 
One-step NGS prep protocol: libraries were amplified with 1 µM of both index 
primers as N7xx: CAA GCA GAA GAC GGC ATA CGG AT [i7] CTA GCA TGA 
CTG-CAG TAC GT and S5xx: AAT GAT ACG GCG ACC ACC GAG ATC TA AC 
[i5] TCG TCG GCA GCG TCA. PCRs were performed as the protocol described above. 
Index PCR products were then purified with AMPure beads (Beckman Coulter). The 
purified product was quantified with QuBit dsDNA kit (ThermoFisher), samples 
concentrations were normalized and then diluted to 14 nM before multiplexing. 
HiSeq2500 sequencing set up for Rapid run mode (single read): 5 µl of each 
sample (2 nM) was mixed to make particular multiplex, then 5 µl of the pool was mixed 
with 5 µl of 0.2 M NaOH and incubated for 5 min at RT. This solution was further 
diluted to 7 pM with chilled HT1 buffer, denatured at 96°C for 2 min, and snap-cooled in 
3:1 ice : water bath for 5 min. Sequencing was performed on the HiSeq 2500 (Illumina) 
TruSeq Rapid SR Cluster Kit - HS and sequencing kit TruSeq Rapid SBS Kit (50 cycle, 
enough for 74 cycles). 
 
NGS data processing  
After completion of sequencing, HiSeq Q score quality metrics were inspected to 
ensure the high accuracy of the base calling. Only runs with at least 85% of bases above 
Q30 (probability of correct base call is 99.9%) were considered. Runs with lower 
percentage were repeated. 
HiSeq sequencing data were converted to the “.fastq” file according to the 
specification of bcl2fastq package from Illumina and then de-multiplexed by a 
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customized pipeline. Read counts for individual unique sequences were then summarized 
for each individual sample. Individual sequence counts were then normalized to the 
average total read output from all samples as the representation of relative abundance 
(normalized count), which is further used for the statistical analysis. Total output reads 
refer to all NGS reads for particular sample while valid reads refer to sequences reads 
with only “ATCG” bases and without undetermined bases such as “N”. 
 
Statistical Analysis 
ANOVA Permutation test: Number of ANOVA F test significant aptamers was 
tested by 1000 permutations of the sample labels. A one-way ANOVA model was built 
for each aptamer using normalized count. P-value of significance was calculated as the 
probability of Aptamer sequence number with F-test less than 0.05 more than the correct 
label. 
Random Forest Models: Random Forest model analysis was performed in R 
environment. The probability for individual sample to be cancer was calculated by out-
of-bag (OOB) predictions. ROC curve was then plotted from the individual sample OOB 
predication. Prediction performances denoted by Area under the curve (AUC) were 
calculated. AUCs from sample label permutation for 1000 times were also calculated. 
The p-value for statistical significance was defined by the number of permutation AUC 
that is equal or more than the AUC from original label. 
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Results 
Library Enrichment Performance 
Aptamer libraries were enriched against EV fraction from cancer and non-cancer 
plasma pool, after three rounds enrichments of positive-counter-positive selections, the 
efficiencies of final library enrichment for L1 and L2 was assessed by average count per 
unique sequence as shown in Figure 4.3A. In the original library L0, count per sequence 
is below 5 counts per sequence, this is because the diversity in the original library was so 
high that is basically saturated the sequencing capacity, which reflected in a low count 
per sequence number. As the enrichments went on, diversity of the sequences was 
significantly reduced due to the selection pressure; ssODNs that bound to the EV fraction 
from plasma samples were able to be maintained and gained more advantages in PCR 
amplification while ssODNs that not bound to the EV fraction were most likely to be 
removed and became less likely to be amplified during PCR steps. As ssODNs diversity 
reduced but NGS outputs were at similar levels, numbers of count per sequence would be 
expected to increase. As expected, the count per ssODNs in L1 and L2 libraries were 
more than 10 folds higher than the corresponding L0 library, indicating the enrichment 
efficiency after the three rounds of enrichment, the ssODNs potentially bound to the EV 
fraction in the plasma have been enriched more than 10 folds on average. At the same 
time, as shown in Figure 4.3B, the average output of the NGS output for L0, L1 and L2 
library were at similar levels, demonstrated by both total output reads (T) and valid 
output reads (V).  
After obtaining enriched library L1 and L2 in each round of enrichment were then 
mixed together to gain library L3. The rationale behind this is that assuming L1 library 
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was enriched against specific targets in plasma EVs from cancer patient and L2 library 
was enriched specific targets against plasma EVs in non-cancer samples. When mixed, it 
would be expected that the ssODNs specifically associated with cancer plasma EVs 
would be more likely to be higher in cancer sample compared to non-cancer samples and 
vice versa.  The ssODN diversity of the final L3 library was close to 106 and the average 
count per sequence was greater than 50 (Appendix B).  
Profiles of relative abundance of the individual aptamer sequences could 
potentially contains signature pattern to that particular sample as well as pattern that 
might be specific to the sample status groups (cancer and non-cancer). After the 
enrichment, the ssODN sequences in the library were ranked according to their relative 
abundance. However, the quality of such library may not easy to be controlled due to the 
huge gaps in relative abundance for different sequences. In order to select appropriate 
ssODNs sequences and reconstruct a more stable library that could be used for the 
purpose of profiling different samples in large scale study, multiple small-scale profiling 
studies were performed by the enriched L3 library as probing library (Appendix-C for 
patient cohort; Appendix-D for individual sequences selected), including cancer vs non-
cancer as well as between different cohorts inside cancer group. ssODNs towards either 
side of the comparisons were selected respectively based on multiple criterions, including 
t test, fold changes as well as neutral sequences. Total 2000 sequences were selected and 
chemically synthesized. The new profiling library L2000 was then reconstituted with 
equal starting concentration of individual ssODNs.  
To evaluate whether the re-synthesized L2000 library retained comparable 
information from L3 library, same plasma samples were profiled by both L3 and L2000 
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library as shown in Figure 4.3C/D. In general, when comparing different technical 
replicates for the same sample, the technical variation of the individual profiles is 
expected to be low, therefore most of the ssODNs are expected to show similar relative 
abundance and the distribution of the relative abundance of the ssODNs is concentrated 
on the line of y=x (45q line) graphically. As expected, for the ssODNs profiles between 
technical replicates were very consistent. The variation of relative abundance of 
individual ssODNs from the profiles by either L3 or L2000 libraries were very low and 
display high correlation to the 45q line.  Correlations between the technical replicates 
were more than 99% for both L3 and L2000 libraries. This indicates within the same 
sample, the ssODNs profiles were very consistent. In contrast, when comparing different 
sample against each other, the sample variation would be expected much higher in 
assumption that specific of ssODN pattern in different samples. As showed in Figure 
4.3C/D (red), when comparing ssODN profiles from different samples by either L3 or 
L2000 library, much higher inter-sample variance was observed. Correlation between the 
different samples reduced from 99% in technical repeats to 90% in inter-sample 
comparison for L3 library, 99% to 80% for L2000 library respectively. Also, as shown in 
the figure, the relative abundance of ssODNs were also distributed more scattered (red) 
inter-sample comparison compared to that from technical replicates(blue), suggesting the 
potential information represented by the profiles of ssODNs  in the original L3 library 
was retained in the new synthesized, reconstituted L2000 from the selected ssODNs.  
Figure 4.3 Performance of Library Enrichment. A) Count per sequence comparison 
between the initial library(L0) and enriched library (L1 and L2); B) NGS output for the 
initial library (L0) and enriched library(L1 and L2) in term of total output (T) and valid 
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output(V);  C) Correlation between technical replicates and biological samples for L3. 
The scatter plot shows the distribution of normalized counts of aptamers recovered from 
ADAPT with the plasma aliquots of the same patient (blue dots, r > 0.99; intra sample: 
patient 27) or plasma samples from different patients (red dots, r = 0.90). Every 
individual dot represents a unique sequence with the count of that sequence 
corresponding to representation in different samples or technical replicates; D) 
Correlation between technical replicates and biological samples for L2000. Scatter plot 
shows distribution of normalized counts of aptamers recovered from ADAPT with the 
plasma aliquots of the same patient (blue dots, r > 0.99; intra sample: patient 27) or 
plasma samples from different patients (red dots, r = 0.80). Every individual dot 
represents a unique sequence with the count of that sequence corresponding to 
representation in different samples or technical replicates. 
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Clinical Utility of ADAPT Profiling System 
To evaluate the potential clinical utilities of L2000 library, whose sequence was 
selected from small amount of training samples, and whether the library were able to 
obtain profiles that could differentiate cancer patients from non-cancer controls other 
than the training samples, a large scale study with 500 patients, including 206 breast 
cancer patients (Appendix-E), 177 non-cancer patients (Appendix-F), and 117 self-
declared healthy controls were performed and the profiles from respective groups were 
compared.  
The 500 patient samples were profiled by the L2000 library in triplicates, relative 
abundance was calculated by normalizing individual sequence counts to the average 
output from the 2000 ssODN sequences total output among all samples instead of total 
counts indicated above (Appendix-G).   
To find out if there were any different patterns detected between the groups, one-
way ANOVA F-statistic comparison for each individual aptamer sequence between 
cancer, non-cancer and healthy controls was calculated. As shown in Figure 4.4A, there 
are 390 aptamer sequences showed statistically significant (p<0.05, red line), indicating 
for these 390 individual aptamer sequences, at least one group among cancer, non-cancer 
and health controls was found to be significantly different from the other two. If this is a 
true performance that might implicate that a specific pattern could exist in differentiating 
the different groups, otherwise, it might implicate the performance is a random effect. 
Therefore, in order to assess whether such specific number of ssODNs that reached 
statistical significance was a result of random effect, a permutation analysis was 
performed as shown in Figure 4.4A. Specifically, the sample labels (cancer, non-cancer 
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and healthy controls) were randomly assigned to sample for 1000 times, in each 
permutation, the one-way ANOVA F-statistic were re-calculated, the number of aptamer 
sequences that pass the significant level (p<0.05) were collected. If the F-statistic was 
from a random effect, it would expect similar or higher number of ssODN sequences that 
are able to pass the significant level in majority of the random permutations. In contrast, 
as shown in Figure 4.4A, most of the random permutation tests only showed less than 
100 sequences that pass the F-statistic significant level, much less than the 390 from the 
correct sample label performance. Number of permutation that have equal of higher 
Aptamer sequence that pass the F-statistic significant level is less than 50, or less than 5% 
of the total 1000 random permutations, indicating the number of ssODNs that could pass 
significant level in the F-statistic with correct sample label is statistically significant 
(p<0.05), suggesting such number of ssODNs passing the statistical significant level for 
the F-statistics was not a random effect, further implying specific patterns that 
represented by the ssODN relative abundance from different sample groups may exist. 
To further evaluate the ADAPT profile could differentiate cancer sample from all 
non-cancer samples (including non-caner and healthy controls) as well as its potential 
prediction performance, prediction models based on random forest (RF) were built. For 
each model, feature selection was carried out based on the significance of a particular 
ssODN sequence comparison between cancer and control samples from the training data, 
including t-test (p < 0.05), Wilcoxon rank-sum test (p < 0.05), Kolmogorov-Smirnov test 
(p < 0.05) or fold change (>1.2); features that passed these filters in the training set were 
then used to build the RF model; Out-Of-Box (OOB) was the calculated as the predicted 
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probability for particular sample to be cancer. All individual sample OOB prediction 
probabilities were then collected and used to calculate the overall AUC performance. 
As shown in Figure 4.4B, the overall performance AUC of cancer vs non-cancer 
samples was 0.66 (red line). Again, to exclude the probability that such AUC 
performance was a result of random effect, sample labels were then permutated 1000 
times, AUC performances from each permutation were re-calculated by the RF models as 
described above. If the prediction performance AUC of 0.66 was from a random effect, 
the chance of having AUC performance from randomly permutated datasets to have equal 
of even better AUC performance than the original label order should not be statistically 
significant ( p>0.05). In contrast, most of the AUC performance from the 1000 
permutations were less than 0.66 (Figure 4.4B, grey histogram). The number of AUC 
with equal or better than AUC 0.66 was less than 2 out of 1000 (p=0.002 < 0.05). 
Therefore, there was less than 5% of chance that a AUC performance of 0.66 could be 
obtained by a random chance, which was statistically significant to reject the null 
hypothesis that the current AUC of 0.66 was from a random effect, indicating the current 
prediction performance for the current dataset was unique and suggesting a specific 
information in the dataset was captured by the RF model, which differentiated the cancer 
sample from all other controls.  
RF model were also applied to differentiate cancer vs non-cancer and cancer vs. 
healthy controls. Predictive AUC values for each comparison were 0.64, 0.73 
respectively with permutation p-values of 0.024, 0.001 (Figure 4.4C, D). The above AUC 
for cancer vs all non-cancer controls was shown in Figure 4.4E. These analyses indicated 
that the specific prediction performance found between these groups in comparison were 
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not by a random effect, confirming that certain specific pattern or features were captured 
by the RF model so that cancer samples could be separated from non-cancer and healthy 
controls to some degree. 
Interestingly, there was a significant increase in the overall prediction 
performance for differentiating cancer samples from healthy donors in comparison to the 
performance in differentiating cancer sample from non-cancer controls (0.73 vs 0.64), 
implying that the L2000 library may be measuring molecules pattern that related to the 
abnormalities within the breast other than cancer status itself. To exclude such possibility, 
OOB predicted cancer probability for biopsy-positive cancer samples and biopsy-
negative non-cancer samples were then grouped according to their Bi-RAD composition 
categories256, an indicator of breast tissue density (low grade: Bi-RAD category A/B, 
high grade: Bi-RAD  category C/D).  As shown in Figure 4.4F, there is no significant 
difference in the cancer predicted probability (p>0.05) between Bi-RAD low grade and 
high-grade groups within the biopsy-positive samples; similarly, no significant different 
in the cancer predicted probability between Bi-RAD low grade and high-grade groups 
within the biopsy-negative samples (p>0.05). In contrast, significant different was found 
between the biopsy-positive cancer and the biopsy-negative controls within the same Bi-
RAD grade groups, indicating the L2000 ssODN profiles were able to differentiating the 
cancer from non-cancer sample regardless of their breast density status, confirming that 
the L2000 library was able to detect some intrinsic difference from the cancer status 
rather than some irrelevant physical condition of the breast.  
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Figure 4.4 Statistical Analysis of the Large-Scale Study. A) Number of sequence that 
pass of F-test significance (p<0.05) among cancer, non-cancer and healthy controls (red 
line), frequency distribution of number of sequence passes F-test significance from the 
1000 permutation. The performance of obtained that number of sequence that could pass 
the F-test significance is statistically significant (p<0.05). *P-val is the number of 
permutation with number of sequence passes the F-test significance equal of larger than 
the original correct label; B) Overall prediction performance AUC is 0.66 (red line, 
cancer vs others) and frequency distribution of the prediction performance AUC from 
1000 permutation tests (p=0.002 < 0.05). *p value is the number of permutation with 
equal of higher prediction performance AUC than the original correct label; C) ROC 
curve for cancer versus control samples with AUC = 0.66, p=0.002; D) ROC curve for 
cancer versus healthy donors with AUC = 0.73; p=0.001; E) ROC curve for cancer versus 
non-cancer with AUC = 0.64; p=0.024; F)  Prediction probability comparison between 
cancer (biopsy positive) and non-cancer (biopsy negative) grouped by Bi-RAD 
component categories (low category: A&B); high category: C&D), ***p<0.05.  
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Discussion 
 Mapping the protein universe is a daunting task. Charting the interactions of 
proteins in the human proteome, studying their function and how their expression 
changes in health and disease, may take decades. Compared with about 40,000 genes in 
the genome, the human proteome is predicted to top 1 million257. Traditional proteomics 
uses techniques such as two-dimensional gel electrophoresis or chromatography, 
combined with mass spectrometry, to separate and identify proteins on a large scale258. 
Tracking protein interactions and activity and determining functions at this scale is an 
even greater task, but is beginning to be tackled by protein arrays and multiplexed 
assays257. However, large scale protein array/chip technology also faces immense 
challenges. For example, one bottleneck that array/chip manufacturers face is that not 
enough antibodies generated against every human proteins as well as protein isoforms, 
especially antibodies with high affinity and specificity were even harder to obtain, which 
would put heavy limitation on the scales; another technical hurdle to producing a reliable 
protein arrays/chips is the protein stability and the corresponding shelf-life. Most protein 
arrays use antibodies as the immobilized capture probes. Such process of depositing 
antibodies onto a solid surface could potentially denature the antibody or affect its 
recognition properties. In addition, the shelf-life of the antibody products are also 
limited257, 259. 
Competing with antibodies will be various nucleic acid ligand-like molecules that 
have been termed aptamers, either RNA or DNA260. Nucleic acid aptamers can be 
selected in vitro based on repeated cycles of binding and PCR. A major advantage of this 
class of molecules is that it is very straightforward to carry out affinity maturation, 
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termed SELEX, in the process of the selection, allowing very high affinity ligands to be 
obtained261. Given that they are highly negatively charged molecules, it is likely that 
nucleic acid aptamers will work well with targets containing positive charge patches on 
their surface262. Traditional SELEX adopted a bottom-up approach as affinity maturation 
was in general focused on individual purified target first and then start to interpret the 
potential complex functions. Bottom-up SELEX approach faces multiple problems and 
limitations. Similar to the problem that are faced by protein/antibody-array, Bottom-up 
SELEX would not meet the demand of the increasing number of newly discovered novel 
proteins as well as isoforms in the coming future257 because the scale of isolation of such 
huge number of individual proteins is expected to be even more enormous and 
complicated than the human genome project. It is unlikely the development of aptamer 
for individual target would be able to catch up. Moreover, on the top of the enormous 
number of individual proteins, protein interactions that form protein complex and 
machinery further made the potential functional characterization even more complicated.   
Interestingly, recent studies showed that cell-based SELEX as well as in vivo 
SELEX were both able to obtain specific aptamers that targeting to tumor cell surface80-
84, and even able to identify brain-penetrating aptamers85, suggesting aptamer-based 
SELEX affinity maturation was not necessary restricted by the single pure target. With 
the increasing NGS sequencing capability, a top-down SELEX approach might be 
possible, which is more focus on generating an overall signature profile from complex 
samples as well as developing its potential utility first before targets are identified.   
Here we have demonstrated a top-down SELEX strategy, where the SELEX 
affinity maturation was performed using a complex sample and generated affinity 
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matured libraries.  Individual ssODN aptamers were then further selected according to 
the profiles generated by these affinity-matured libraries and combined as a new 
multiplexing detection system, termed “ADAPT”. ADAPT platform offers high 
multiplexing capability to generate an unbiased profiling of molecular signatures from 
complex samples. In the current study, DNA aptamer SELEX affinity maturation were 
performed on the plasma EV fraction, clinical application was explored by comparing 
ADAPT profiles from breast cancer and non-cancer patients as well as heathy control 
samples.  
ADAPT platform offers many advantages that offered by other profiling 
platforms, such as protein, antibody array as well as mass spectrometry and it is 
compatible to liquid biopsy, multiplexing with high-throughputs. At the same time 
ADAPT was able to avoid certain disadvantages from other systems, for example 
ADAPT requires no prior knowledge on the nature of intended targets, therefore sample 
complexity was not a major hurdle; DNA Aptamers were more stable and easier for 
storage than proteins like antibodies, therefore the shelf-life of the reagent may be 
improved significantly.  
Few top-down style aptamer-based molecular profiling approaches have been 
published to date.  The closest one is SOMAscan, a Bottom-up platform that utilized 
more than 1000 aptamers, which was selected on individual known specific targets263,  
has been adopted for the proteomic analysis of EVs from the prostate cancer cell line 
DU145264. In comparison, the potential multiplexing and information could be much 
higher in ADAPT platform. While ADAPT in its current form still demands for further 
improvement to bring it to a clinical standard, with more extensive libraries training and 
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quality improvement, information content and better diagnostic value would become 
available, which will provide better tool for the in-parallel massive analysis of complex 
samples and clinical utilities. 
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APPENDIX A 
DETAIL ANALYSIS OF EV BY FLOW CELL CYTOMETRY  
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Traditionally, FL analysis (single fluorescence label) involves gating a sample on 
the light scatter plot (scatter plot) followed by projection of the gated population to a 
histogram according to the fluorescence signal intensity. The detection of EV by FL has 
been very challenging, mainly because of the small sizes of EV particles, which is equal 
to or below the detection limit of the most of the machines currently available (>100nm 
for Apogee). At the same time, sizes of noise particles from reagents, such as PBS, 
antibody solution etc. also fall in the range under the machine’s detection limit and mixed 
with the EV particles, resulted in an inability to isolate EV particles from the noise 
particles based on their light scatter patterns.  
In order to solve such problem, we performed FL analysis with 4 different 
samples, including three positive controls: UC purified cell line EVs in PBS (Figure A1-
A), UC purified cell line EV in PBS and precipitated by F68 (Figure A1-B), UC purified 
cell line EV in plasma and enriched by F68 (Figure A1-C) and one sample of the native 
plasma EVs enriched by F68 (Figure A1-D). Each sample was analyzed with five 
negative controls including PBS, isotype-antibody solution, tetraspanin antibody solution, 
no antibody labeled sample control and isotype antibody-PE stained control. 
Figure A1-A shows a typical pure EV sample on the FL analysis as well as the 
other five negative controls. First the signal from large angle scatter (LALS, equivalent to 
side scatter in other equipment) and the small angle scatter (SALS, equivalent to forward 
scatter) are plotted on Figure A1-A row 1 (ignore the red/green lines and the yellow 
colors at this moment). The signal distributions from noise particles in PBS, isotype-
antibody solution, tetraspanin antibody solution were basically the same as samples with 
EV particles, including unstained EVs, isotype-PE stained EVs and tet antibody-PE 
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labeled EVs with SALS ranged from ~1.5 to 4 and LALS ranged from 0 to 4 in a log10 
scale. Consistent with difficulties of isolating the EV population by traditional light 
scatter plotting. In the PE labeled fluorescence event distribution histogram (Figure A1-A 
row 2), most of the control signals are very low compared to EV particles labeled with 
tet-PE antibody, or may even be undetectable on the graph (blue color: for all controls; 
green color: the EV sample stained with tet PE antibody, green histogram from EV 
sample stained with tet-PE antibody were applied in all figures from the negative controls 
samples in the back at the same scale to compare signal to noise level). This is mainly 
because the EV particle number is much more abundant than the noise particles. 
Therefore, lack of distinguishable pattern from light scatter plot prevents the analysis 
from isolating the desired EV particles from noise. This might be acceptable when the 
expected EVs particle amount is very large but create significant limitations for the 
sample with unknown or very low numbers of EVs, such as EVs enriched from plasma. 
To exam whether there is any other alternative non-fluorescence light scatter 
pattern that potentially could be used in assisting the separation between noise and true 
EVs particles, we found that other than the regular LALS/SALS, the integrated version of 
LALS and SALS were also collected (LALS-area and SALS-area) by the apogee device 
during sample analysis. LALS-area against SALS-area plots were then drawn as shown 
in Figure A1-A row 3, while SALS-area signal showed range between 0 to 200 for all the 
samples and controls without differentiation, we found that most of the noise particles 
from PBS, isotype antibody-PE solution, tet antibody-PE solution as well as non-labeled 
EV sample concentrated in an area with very narrow range of LALS-area values and 
distributed horizontally (<100, horizontal green line). In contrast, in the tetraspanin 
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antibody labeled EV sample, most of the particles showed increased signal of LALS-area, 
correlated with corresponding SALS-area signal and showed saturation of signal at about 
4000. Graphically it showed a concentrated bold line with an angle against horizontal 
noise population (Figure A1-A row 3, sample). The results showed that while traditional 
light scatter plot was not able to separate the EV particles from noise, regardless the 
antibody-bound status, once the EV particles were labeled with an antibody targeted to 
the surface marker, a distinguishable pattern was formed and separated this population 
from others on the LALS-area/SALS-area scatter plot.  This enabled us to separate the 
antibody-bound EVs from other noise particles as well as none-labeled EVs. Though this 
still does not directly distinguish the un-labeled EV population from noise, it might be 
very helpful for initial screening the particles according to the light scatter signals before 
the fluorescence signal analysis.     
Based on this finding, as shown in (Figure A1-A row 3), minimal (green line) and 
maximal (red line) values for SALS-area (Vertical green and red lines) and LALS-area 
(Vertical green and red lines) were set and applied to gate the samples as well as the 
negative controls. The selected particle populations from individual sample and controls 
were then projected back to the LALS-SALS light scatter plot in yellow color in Figure 
A1-A row 1. Such high density of yellow-marked population was shown only in the tet-
antibody-PE labeled EV sample but no other corresponding negative controls, indicating 
the population gated by LALS-area/SALS-area does help to filter out the noise and select 
the correct Tet-antibody bound population, which regular LALS-SALS light scatter plot 
was not able to achieve.  
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In order to further refine the population and make it more specific for the Tet-
antibody-labeled population, minimal and maximal SALS and LALS thresholds again 
were set manually according to range of the yellow area shown in Figure A1-A row 1 
sample (minimal: green lines; maximal red lines) to filter the population with additional 
SALS and LALS ranges (referred to as two-step gating below).  
After two-step gating, the selected population was then projected to the 
fluorescence events distribution histogram in Figure A1-A row 4 according to their 
fluorescence signal intensities. The event distribution histogram from EV samples labeled 
with Tet-antibody-PE was shown in green and appears in all other histograms from 
negative controls for comparison and the fluorescence event distribution histograms for 
individual negative controls were shown in blue in front of the green. While noise 
particle events were still visible in regular analysis histograms (Figure A1-A row 2), all 
noise fluorescence events after two-step gating were almost completely disappeared 
compared to the corresponding tet-antibody-PE labeled events (Figure A1-A row 4), 
indicating after the two-step gating, an EV population labeled with Tet-antibody-PE 
could be specifically selected.  
We found out by LALS-area/SALS-area light scatter signal plotting could isolate 
the EV population labeled with surface tetraspanin marker antibody, through two-step 
gating by LALS-area/SALS-area and LALS/SALS sequentially, a clean EV fluorescence 
labeled population could be selected. We then examined the sample precipitated by F68 
reagent, including cell line EVs in PBS precipitated by F68, plasma sample spiked with 
cell line EVs enriched by F68 and native plasma EVs enriched by F68 to see if a EV 
population bound by the tet-antibody could be isolated by the same analysis. 
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As shown in Figure A1-B, the same analysis layout was applied to the cell line 
EVs in PBS precipitated by F68. The result patterns are exactly the same as result from 
cell line EV control sample in Figure A1-A. This not only confirms the patterns observed 
from cell line EV control above, but also showed that the copolymer F68 was able to 
precipitate the cell line EVs without interfering its FL analysis.  
Figure A1-C further examines the sample that is one more step closer to the real 
situation with spiked cell line EVs diluted in plasma sample followed by and F68 
precipitation. Compared to the cell line EV control in Supplement Figure 1A and 1B, 
EVs enriched in the presence of plasma sample showed much wider LALS/SALS values 
in the regular light scatter plot (Figure A1-C row 1) and much higher noise in the 
fluorescence event distribution histogram, especially in the isotype antibody-PE labeled 
sample (Figure A1-C row 2). After two-step gating as shown above, a clean population 
without any noise contamination was isolated as shown in the fluorescence event 
distribution histogram for the gated population in Figure A1-C row 4. There are almost 
no noise events visible in blue, compared to the fluorescence event distribution histogram 
from Tet-antibody-PE labeled sample in green. The result further confirms that the EVs 
in plasma could be enriched by the F68 method; FL analysis based on the two-step gating 
could isolate such antibody-bound EV population. 
All three positive controls with spiked in cell line EVs show similar results, 
namely that  EV particles bound by the specific antibody could be isolated by the two-
step gating strategy compared to native plasma EV particles enriched by F68 were then 
analyzed to find out if similar population exists. As shown in Figure A1-D row 1 and 2, 
unlike the samples with cell line EV spiked, the native plasma EVs (regardless antibody-
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bound status) was not able to separate itself either from the noise in tradition light scatter 
plot or in the fluorescence event distribution histogram. The histogram was particularly 
noisy especially from isotype antibody-PE labeled samples, which was largely 
overlapped between noise and the tet-antibody-PE labeled sample. In contrast, on the 
LALS-area/SALS-area plot, two distinguishable populations as described above were 
again detected (Figure A1-D row 3). Though the population was much smaller compared 
to the cell line EVs, the expected pattern of two different populations was clearly 
appeared. Consistently, after two-step gating analysis, the fluorescence event distribution 
for selected population was shown in Figure A1-D row 4. A tet-antibody bound EV 
population was clear isolated compared the noise background from isotype-antibody 
bound events. The result further confirms that an EV population with tetraspanin 
expression from plasma could be enriched by copolymer F68 precipitation. 
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Appendix-A Figure 1B: 
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Appendix-A Figure 1C: 
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Appendix-A Figure 1D: 
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APPENDIX B 
NGS SUMMARY FOR LIBRARY ENRICHMENT  
  
  222 
Summary of the NGS sequencing reactions, quality matrix and etc. see respective 
excel worksheets. 
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APPENDIX C 
DEMOGRAPHICS FOR PATIENTS USED IN SMALL SCALE STUDIES  
  
  224 
List all the patient demographical information for all the small scale ADAPT 
studies. See the respective Excel sheet. 
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APPENDIX D 
INFO FOR THE SELECTED 2000 APTAMER SEQUENCES FOR ADAPT 
  
  226 
List all the ADAPT ssODNs from small scale study according to the listed criteria 
for final synthesis. 
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APPENDIX E 
CANCER PATIENT DEMOGRAPHICS IN LARGE SCALE STUDY  
  
  228 
Demographical information of cancer patient (biopsy-positive) in the large scale 
ADAPT study. 
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APPENDIX F 
NON-CANCER PATIENT DEMOGRAPHICS IN LARGE SCALE STUDY 
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Demographical information of cancer patient (biopsy-negative) in the large scale 
ADAPT study. 
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APPENDIX G 
DATA TABLE OF 500 LARGE SCALE ADAPT CLINICAL STUDY  
  
  232 
Normalized count for the large scale ADAPT study for individual samples. 
 
